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Abstract 
 
The ability of systemically administered bacteria to target and replicate to high 
numbers within solid tumours is well established. Tumour localising bacteria can be 
exploited as biological vehicles for the delivery of nucleic acid, protein or 
therapeutic payloads to tumour sites and present researchers with a highly targeted 
and safe vehicle for tumour imaging and cancer therapy. This work aimed to utilise 
bacteria to activate imaging probes or prodrugs specifically within target tissue in 
order to facilitate the development of novel imaging and therapeutic strategies. The 
vast majority of existing bacterial-mediated cancer therapy strategies rely on the use 
of bacteria that have been genetically modified (GM) to express genes of interest. 
While these approaches have been shown to be effective in a preclinical setting, GM 
presents extra regulatory hurdles in a clinical context. Also, many strains of bacteria 
are not genetically tractably and hence cannot currently be engineered to express 
genes of interest. For this reason, the development of imaging and therapeutic 
systems that utilise unengineered bacteria for the activation of probes or drugs 
represents a significant improvement on the current gold standard. Endogenously 
expressed bacterial enzymes that are not found in mammalian cells can be used for 
the targeted activation of imaging probes or prodrugs whose activation is only 
achieved in the presence of these enzymes. Exploitation of the intrinsic enzymatic 
activity of bacteria allows the use of a wider range of bacteria and presents a more 
clinically relevant system than those that are currently in use. The nitroreductase 
(NTR) enzymes, found only in bacteria, represent one such option. 
 Chapter 2 introduces the novel concept of utilising native bacterial NTRs for 
the targeted activation of the fluorophore CytoCy5S. Bacterial-mediated probe 
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activation allowed for non-invasive fluorescence imaging of in vivo bacteria in 
models of infection and cancer. 
 Chapter 3 extends the concept of using native bacterial enzymes to activate a 
novel luminescent, NTR activated probe. The use of luminescence based imaging 
improved the sensitivity of the system and provides researchers with a more 
accessible modality for preclinical imaging. It also represents an improvement over 
existing caged luciferin probe systems described to date. 
 Chapter 4 focuses on the employment of endogenous bacterial enzymes for 
use in a therapeutic setting. Native bacterial enzymatic activity (including NTR 
enzymes) was shown to be capable of activating multiple prodrugs, in isolation and 
in combination, and eliciting therapeutic responses in murine models of cancer. 
 Overall, the data presented in this thesis advance the fields of bacterial 
therapy and imaging and introduce novel strategies for disease diagnosis and 
treatment. These preclinical studies demonstrate potential for clinical translation in 
multiple fields of research and medicine. 
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prodrug therapy. Journal of Controlled Release, 170(1), 120-131. 
  
17 
 
Abstract 
 
The significant burden of resistance to conventional anticancer treatments in patients 
with advanced disease has prompted the need to explore alternative therapeutic 
strategies. The challenge for oncology researchers is to identify a therapy which is 
selective for tumours with limited toxicity to normal tissue. Bacteria have the unique 
potential to overcome traditional therapies‘ limitations by specifically targeting 
tumours. It has been shown that bacteria are naturally capable of homing to tumours 
when systemically administered, resulting in high levels of replication locally, either 
external to (non-invasive species) or within tumour cells (pathogens). Pre-clinical 
and clinical investigations involving bacterial vectors require relevant means of 
monitoring vector trafficking and levels over time, and development of bacterial-
specific real-time imaging modalities are key for successful development of clinical 
bacterial gene delivery. This introduction discusses the currently available imaging 
technologies and therapies associated with bacteria and the progress to date 
exploiting these for monitoring of bacterial activity in vivo.  
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Introduction 
 
Although the potential anti-cancer effects of post-operatively acquired bacterial 
infection have been evident for over 120 years and the presence of bacteria in 
excised tumours has been noted for over 60 years [1], it is only in more recent times 
that the tumour-specific growth of bacteria has been considered for therapeutic 
purposes. While the precise mechanism(s) behind preferential bacterial tumour 
colonisation remain poorly understood, this phenomenon must relate to unique 
tumour attributes that separate them from healthy tissues. Factors such as the 
irregular/leaky blood supply; local immune suppression; inflammation and unique 
nutrient supply (e.g. purines) in tumours have been proposed to play a role [2]. 
Bacterial entry into the tumour environment is proposed to be facilitated by the leaky 
vasculature within the tumour, where systemically circulating bacteria effectively 
leak out of blood vessels that are supplying the tumour. Cancer cells are 
characterised by an aberrantly accelerated metabolism and proliferation leading to an 
imbalance of oxygen supply and consumption which is a major causative factor of 
tumour hypoxia [3]. The regions of low oxygen that exist within solid tumours 
enhances the growth of anaerobic and facultatively anaerobic bacteria. In addition, 
these areas of low oxygen and high interstitial pressure are considered to be an 
immunological sanctuary, where bacterial clearance mechanisms are greatly 
inhibited [4]. Necrotic regions are also rich in nutrients favoured by bacteria (e.g. 
purines) due to tumour cell turnover. However, tumour selective bacterial 
colonisation now appears to be both bacterial species and tumour origin independent, 
since aerobic bacteria are also capable of colonising tumours, and even small 
tumours lacking an anaerobic centre are colonised (Figure 1).  
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Figure 1. Tumour characteristics associated with bacterial colonisation. (1) Leaky 
microvasculature: Bacteria circulating systemically through the vasculature come into 
contact with the tumour; (2) Lack of immune clearance: The inability of the immune system 
to mediate clearance of bacteria from immune-privileged tumour sites allows for uninhibited 
bacterial growth within the tumour. (3) Hypoxic microenvironment: Hypoxic/necrotic areas 
within tumour provide the necessary microenvironment for anaerobic bacterial proliferation, 
unavailable elsewhere in the body. (4) Abundant nutrients: Areas of necrosis also provide 
nutrients to promote bacterial growth.  
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Invasive bacteria can internalise and replicate within tumour cells, while non-
invasive bacteria grow externally to tumour cells, within the tumour micro-
environment [5]. The tumour selective growth of bacteria, as well as the relative ease 
with which certain species of bacteria can be genetically modified, has made them an 
attractive vehicle for the delivery of reporter genes, therapeutic genes or inhibitory 
RNA to a tumour for ameliorative or potentially diagnostic purposes. Protocols for 
the genetic modification of bacterial genomes and the transformation of plasmid 
DNA containing genes of interest into bacteria are becoming established for an 
increasing range of species. This allows for the creation of bacteria that i) directly 
express therapeutic genes, and/or ii) efficiently internalise into tumour cells with 
subsequent therapeutic nucleic acid release for tumour cell expression 
(―bactofection‖). The same bacterium can be engineered to co-express a reporter 
gene(s) that can be used for in vivo imaging of bacterial localisation and spread. 
Genetic manipulation of bacteria can also be used to create mutants with aberrant 
nutritional needs or that are attenuated and therefore non-pathogenic.  
Bactofection of mammalian cells applies to both active invasion of non-
phagocytic mammalian cells (e.g. tumour cells), and also ‗passive‘ uptake by 
phagocytic immune cells (DNA vaccination). Vaccination strategies involving 
bactofection of antigen presenting cells (APC) with defined tumour antigen genes 
using replication deficient mutants of Salmonella enterica Typhimurium and other 
strains have shown significant promise both preclinically and in clinical trials [6, 7]. 
After oral intake, such bacterial vector cells are phagocytosed by monocytes in the 
intestine, which differentiate and migrate to lymph nodes and the spleen. 
Subsequently, the attenuated strains (unable to replicate in hosts) lyse and release 
plasmid into the cytoplasm of monocytes, followed by expression of the desired 
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antigen and presentation to the immune system. This delivery platform has shown 
success in several preclinical tumour models employing various tumour antigens [8].  
 
In vivo Imaging 
 
The evolution of novel biological imaging techniques has played a major role in the 
development of modern medicine. Advances in the specificity and sensitivity of 
imaging devices has led to vast improvements in the diagnosis and treatment of 
disease as well as the development of drugs and the study of biological processes in 
vivo. The perpetual aim of in vivo imaging is to achieve increased sensitivity and 
resolution. A number of clinical molecular imaging strategies are available which are 
suited to preclinical studies of bacterial gene therapy, primarily Positron Emission 
Tomography (PET) and microPET. A more readily accessible technology available 
to standard research laboratories is Optical Imaging (OI) which is based on the 
detection and quantification of bioluminescent or fluorescent light from a subject, 
through use of a cooled charged coupled device (CCD) camera. The relevant merits 
and obstacles to these and other methodologies in the context of bacterial gene 
therapy of cancer are discussed hereafter. 
 
Optical Imaging 
 
Optical imaging is a highly sensitive, nontoxic technique based on the detection of 
visible light, produced by luciferase enzyme-catalysed reactions (bioluminescence) 
or by excitation of fluorescent molecules, using sensitive photon detectors. Although 
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the light emitted may be dim, it is detectable externally using sensitive photon 
detectors such as those based on cooled, or intensified CCD cameras, mounted 
within light-tight specimen chambers. The development of 
bioluminescent/fluorescent microorganisms allows for the real-time non-invasive 
detection of bacteria within intact living animals. As light passes through a range of 
tissue types it is possible to observe and quantify the spatial and temporal 
distribution of light production from within tumours or other tissue. Multiple time-
point imaging of the same animal throughout an experiment allows the progression 
of bacterial colonisation to be followed with accuracy, reducing the number of 
animals required to yield statistically meaningful data.  
 
Bioluminescence Imaging (BLI) 
 
Bioluminescence involves the release of light energy following a chemical reaction 
catalysed by a luciferase enzyme [9]. Luciferases generate visible light of a specific 
wavelength through the oxidation of their specific substrates. Unlike fluorescence, 
no external light source is necessary. Luciferase proteins have been isolated from a 
variety of insects, marine organisms and prokaryotes [10]. Some of the most 
common BLI systems employed for use in research are the luciferase derived from 
the North American firefly Photinus pyralis (FLuc), the sea pansy Renilla luciferase 
(RLuc), the marine copepod Gaussia princeps luciferase, (GLuc) and the bacterial 
luciferase gene cassette (lux) [8, 11-14]. 
Both RLuc and GLuc metabolise coelenterazine to produce visible light 
predominately in the blue-green spectrum which is not optimal for whole body 
imaging as light in this range is efficiently absorbed by living tissue [15]. Red-
23 
 
shifted RLuc variants have been developed which improve penetration of light in 
biological matrices [16]. The most significant disadvantage to the in vivo application 
of these reporters is the poor half-life of coelenterazine in animal systems; however, 
variants with improved longevity in animals are being developed [17]. To date GLuc 
has been successfully expressed in Mycobacterium smegmatis and used in whole 
animal imaging modalities [18]. S. Typhimurium engineered to express a variant 
of Rluc gene (RLuc8), under the control of the E. coli arabinose operon promoter 
(PBAD) have been imaged in murine tumours, with the added advantage of 
demonstrating ‗remote control‘ of bacterial gene expression [19].  
Notwithstanding the above luciferase/substrate combinations, the bacterial-
native lux system represents the mainstay of current in vivo bacterial OI (Figure 2) 
[20]. The luxAB genes isolated from Vibrio harveyi [21] and Photorhabdus 
luminescens (formerly Xenorhabdus luminescens), amongst others, have since been 
combined with all genes required for enzyme and substrate transcribed from a single 
cassette luxCDABE [22]. This non-invasive imaging system allows for qualitative 
and quantitative analysis of the localisation of bioluminescent bacteria in small 
animal models. It is important to note that bioluminescence from lux- and Luc-
expressing microorganisms is related to an organism's metabolic activity. This is due 
to the reliance of the luciferases on microbial metabolites, mainly FMNH2 and ATP, 
respectively. This is exemplified by the decrease in luminescence that has been 
observed when many lux-expressing bacterial species, such as Bifidobacterium [13], 
enter stationary phase during in vitro growth [23-25]. Bioluminescent bacteria have 
been used extensively to study a diverse range of biological processes such as 
infection [26], quorum sensing [27] and gene expression [28]. However, the 
employment of luciferase or lux tagged bacterial strains as gene delivery vehicles for 
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the treatment of cancer is an emerging field [29, 30]. A powerful potential diagnostic 
approach involves the use of genetically modified light-emitting bacteria to visualize 
their colonisation of tumours, thereby revealing the location of tumours based on 
light emission. 
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Figure 2. Bioluminescence imaging (BLI) of bacterial vectors and gene delivery. a) 
Bacterial vector bioluminescence. Lux-labelled (i) E. coli K12 MG1655 or (ii) B. breve 
UCC2003 were administered via tail vein to either athymic or BALB/c mice bearing 
subcutaneous FaDu hypopharyngeal carcinoma or CT26 colorectal carcinoma respectively. 
Lux signal was detected by 2D in vivo BLI specifically in tumours of mice 3–14 days post 
IV administration. 2D BLI is also useful for imaging DNA vaccine delivery using 
Salmonella as a vector in the gastrointestinal tract of mice. Trafficking of S. Typhimurium 
SL7207 in the initial 10h after gavage feeding was monitored using a bacterial lux 
expressing strain and BLI. A representative C57 BL/6 mouse gavage fed SL7207 is 
illustrated in (iii). A specific antitumour immune response was generated in a murine model 
of prostate cancer by oral administration of salmonellae containing a plasmid coding for 
murine prostate stem cell antigen (PSCA). b) Bacterial mediated transfer of plasmid DNA to 
tumour cells (bactofection) using Listeria monocytogenes. The ability to use L. 
monocytogenes to deliver genes to tumours in vivo was assessed using the eukaryotic cell-
specific CMV promoter to express FLuc reporter gene. 10
6
 L. monocytogenes/FLuc was 
intratumourally administered to athymic mice harbouring subcutaneous MCF-7 tumours. 
Mammalian cell expressed FLuc luminescence was observed specifically in tumours. 
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Fluorescence Imaging 
 
Another non-invasive imaging technique that has been successfully utilised to 
visualise bacterial vectors in cancer gene therapy is fluorescence imaging. In 
fluorescence imaging, an external light source excites a fluorophore [fluorescent 
protein (FP) or dye] and the transferred light energy is emitted at a different 
wavelength when the fluorophore returns back to its ground state. The excitation of 
the fluorophores by filtered light of a defined wavelength results in the emission of a 
fluorescent signal. This low energy, shifted wavelength light signal can be identified 
and quantified both in vitro and in vivo without the requirement for cell/animal 
sacrifice. The high level of autofluorescence and visible light absorption associated 
with in vivo imaging of fluorophores in the green spectrum greatly limits the tissue 
depth from which a clear fluorescent signal can be obtained [31, 32]. However, the 
development of near-infrared (NIR) probes has allowed for the in vivo analysis of 
fluorescence to become practical [33]. NIR probes reduce the level of background 
signal by increasing the signal-to-noise ratio and therefore facilitates fluorescent 
imaging at greater depths [34].  
For a fluorescent marker to be successfully used for optical imaging it has to 
fulfil several criteria including suitable excitation and emission wavelengths, 
photostability, brightness and maturation speed [35-37]. Historically, the most 
commonly used fluorescent probe for the detection of bacterial vectors is the green 
fluorescent protein (GFP) or its derivatives. GFP is an isolate from the jellyfish 
Aequorea victoria. A number of studies have described imaging of GFP-expressing 
bacteria in live bacterial-infected animals [38-40]. Such studies use fluorescent 
imaging for monitoring the infection progression over time and illustrate the spatial–
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temporal behaviour of the process. Bacteria expressing the GFP variants are 
sufficiently bright as to be clearly visible from outside the infected animal and the 
increasing levels recorded using a CCD camera. An auxotrophic strain of S. 
Typhimurium A1 expressing GFP which caused nuclear destruction in vitro and 
tumour inhibition and regression of xenografts has been visualized in vivo by whole-
body imaging [39]. The sensitivity of GFP fluorescence, in conjunction with the R. 
reniformis luciferase (RUC), has been exploited to study E. coli, S. Typhimurium 
and Vibrio cholera colonisation of tumours in live animals [41]. The sensitivity of 
GFP imaging was also used to facilitate the identification of metastasised tumours 
where strong fluorescence demonstrates intratumoural growth of bacteria at primary 
and secondary tumour sites [42]. Fluorescence imaging is also valuable for fine-
detail post-mortem histological study of bacterial localisation [43]. To date, almost 
all the published reports of fluorescent imaging for bacteria utilise GFP, despite its 
unsuitable excitation and emission wavelengths for tissue penetration. However, the 
relative explosion in the number of red-shifted FPs (and therefore more suitable for 
in vivo imaging) developed in recent years should see this exciting field begin to 
flourish. 
 
Instrumentation for OI 
 
The minute amount of light emitted by optical reporters is detected using a CCD 
camera which is generally kept cooled to -90C or below [44]. Depending on the 
imaging strategy, optical filters can select for both excitation and emission 
wavelengths as required. Although filters are primarily used for fluorescence 
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imaging, they can also distinguish between luminescent reporter signals and for 
determining the depth of a luminescent source within a subject. Both 2D and more 
recently 3D OI tomography instrumentation and software (e.g. IVIS Spectrum – 
Perkin Elmer; PhotonIMAGER - Biospace Lab) are available that provide 
quantitative information with improved spatial resolution [45]. An overview of 
currently available instrumentation is reviewed elsewhere [46]. Overall, the 
development of more affordable or more powerful instrumentation, in combination 
with other imaging methods such as X-ray and micro-CT is rapidly advancing the OI 
field [47]. 
 
Engineering bacteria to express reporter genes 
 
A caveat to the exploitation of bacterial reporter systems is the recalcitrance of 
certain species to genetic manipulation. The engineering technology currently 
available for tagging of different species has dictated what bacterial strains have 
been reported in the context of OI to date. The suitability of OI for bacterial studies 
is dependent on the ability to genetically modify the bacterial strain in question to 
stably carry and express the reporter gene (e.g. lux or a FP gene), and also the 
activity of the reporter system in that strain. Even in currently genetically tractable 
strains, the activity of the lux system varies dramatically between bacterial species 
[20]. Some considerations for improving bacterial reporter gene expression are 
discussed below.  
Stable gene expression: The integration of reporter genes in a bacterial genome is 
preferable over episomal plasmid-based expression to ensure stable and homogenous 
expression levels. Importantly, this also provides the opportunity to remove the need 
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for antibiotic selection generally required to maintain plasmids which would be 
unavailable in vivo, and represents an important regulatory consideration in terms of 
clinical application. Alternative methods of maintaining episomal plasmids in the 
absence of antibiotic selection have also been developed. For example, strains of E. 
coli rendered metabolically dependent on diaminopimelic acid (DPI) have been 
generated, permitting maintenance of plasmids featuring DPI-producing genes as 
plasmid loss leads to bacterial cell death [48, 49]. Transposon [23, 50], transducing 
bacteriophages [19], temperature sensitive vectors [51] and bacteriophage integrase 
systems [52-54] have been developed to integrate genes into the chromosomes of 
selected bacteria. However, it is important to stress that the maintenance and 
expression of high levels of recombinant DNA may place an unwelcome metabolic 
burden on microorganisms. Indeed, a number of researchers have described 
attenuation in lux- and GFP-expressing strains [24, 55-57]. 
Maximizing reporter expression: Bacterial reporter gene expression is exquisitely 
dependent on transcriptional and translational signals. The choice of promoter is vital 
for optimizing reporter levels and should be assessed on an individual strain basis. 
The codon usage of the particular organism of interest is also an important 
consideration. The sequence of the lux genes is AT-rich (>69%) and as a result they 
are not always expressed efficiently in high-GC bacteria such as Streptomyces 
coelicolor. A synthetic lux operon lacking TTA codons was constructed and 
validated for S. coelicolor [58]. Furthermore, codon optimizing the firefly luciferase 
for M. tuberculosis resulted in a 30-fold increase in signal [54]. However, codon 
optimization may have unforeseen effects; the lux operon codon optimized for M. 
tuberculosis was found to be non-functional [54] reported to be as a result of 
secondary DNA structures which impede translation. 
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Increasing cofactor availability: For bacteria expressing the lux operon, it is possible 
that the availability of aldehyde and FMNH2 are limiting factors. The insertion of an 
extra promoter in front of luxCDE to boost substrate synthesis resulted in a six-fold 
higher lux signal in M. smegmatis [54] and S. aureus [59]. In yeast, co-expression 
of luxAB together with an frp gene which encodes an NADPH–FMN oxidoreductase 
from V. harveyi, led to a 100-fold increase in luminescence [60]. This strategy has 
also been applied to bacteria and the frp from V. harveyi was cloned in reporter gene 
constructs for use in S. aureus. However, in this case, inclusion of frp was 
detrimental and resulted in no transformants [59] potentially due to the generation of 
superoxide (O2
−
) from the auto-oxidation of flavoproteins [59].  
 
Dual bioluminescent/fluorescent labelling of microorganisms 
 
In genetically accessible strains of bacteria, the dual labelling of strains with both 
fluorescent and bioluminescent reporter genes combines the strengths of both 
systems and reduces the effect of individual cofactor requirements of fluorescent 
proteins and luciferases. Tagging strains with a luciferase in tandem with GFP has 
allowed the discrimination between microbial counts (by fluorescence) and 
metabolic activity (by bioluminescence) [61-63]. Furthermore, fluorescence labelling 
allows samples to be analysed by fluorescence microscopy and flow cytometry in 
addition to OI. Importantly, this means that more data can be gathered using fewer 
experimental animals while also bridging the gulf between the macroscopic and 
microscopic levels of resolution, that is, individual microorganisms at one end of the 
imaging spectrum and the detection of mass populations in specific niches in the 
living animal at the other [64]. 
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Applications of OI Reporter Genes 
 
Early demonstrations of the tumour targeting capabilities of lux expressing bacteria 
not only provided clear evidence for selective in vivo growth and replication of 
bacteria within tumours, but also importantly showed that whole body imaging of 
animals colonised by bioluminescent bacteria could be a useful method in the study 
of bacterial gene therapy of cancer. A model organism, E. coli K12 MG1655, has 
been demonstrated to specifically colonise a wide array of tumour xenografts, 
including metastases, following IV administration [48, 49]. This has also been 
supported by findings with other bacterial species such as bifidobacteria [13]. The 
use of co-imaging techniques to simultaneously visualise luciferase and lux signals 
in vivo has been used to great effect to demonstrate the clustered growth pattern of 
lux expressing bacteria in different tumour models [43]. The administration of lux-
tagged commensal bacteria to mice harbouring luciferase tagged tumours facilitates 
the generation of 3D diffuse optical tomography displaying the exact distribution of 
the bacteria within the tumour mass, in relation to viable tumour regions and 
vascular supply [through computed tomography (CT) imaging]. While non-invasive 
bacteria such as B. breve and E. coli MG1655 are not amenable to strategies 
requiring transfection of tumour cells, their ability to selectively grow within the 
tumour microenvironment makes them ideal candidates for ‗cellular therapy‘ of 
cancer, i.e. bacterial production of therapeutics within the tumour stroma. 
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OI alternative approaches - Bacterial-specific probes 
 
Gene-based reporter technology is not applicable to all bacterial strains. The 
development of a suitable genetic reporter construct can involve substantial resource 
commitments, and differences in subsequent reporter gene expression between 
strains hinders applications. Therefore a number of groups have explored alternative 
strategies using synthetic probes in combination with OI to image bacteria in vivo 
[65]. Identification of substrates or metabolites specific to bacteria and not 
mammalian cells permits exploitation for imaging through addition of an imaging 
moiety. 
Near-infrared probes: The use of an injectable NIR probe consisting of a bacterial 
affinity group conjugated to an NIR dye is recently demonstrating success [66, 67]. 
Maltodextrin-based optical imaging probes have been shown to successfully detect 
small numbers of bacteria in vivo with very high specificity and selectivity due to the 
fact that maltodextrin transporter is unique to bacteria [68]. A further advantage to 
this strategy is that the lumen of intestinal tissues and the skin are not permeable to 
glucose oligomers, and therefore MDPs delivered systemically should not be 
internalized by the resident bacterial microflora. Similarly, bis-zinc(II)-dicolylamide 
ligands have high affinity for the anionic phospholipids and other molecules residing 
in bacteria [67]. Xenolight RediJect probe sold by Perkin Elmer is a NIR fluorescent 
agent for in vivo detection of bacteria targeting the anionic phospholipids of bacterial 
cell membranes. The potential to adapt these technologies to image bacteria 
colonising tumours is exciting; however this approach may only be applicable to 
subcutaneous surface tumours. Imaging of bacteria in deeper tissues with higher 
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background fluorescence requires colonisation numbers of 10
8
 or more in a defined 
space.  
Quantum Dots: In recent years, quantum dots (QDs) have received some attention as 
probes for OI, especially in cancer research. QDs are small fluorescent nanocrystals 
made of inorganic semiconductor materials. They are extremely photostable 
following excitation by an exogenous light source and posess wide excitation and 
narrow emission spectra. Their emission wavelength depends on their size and they 
can be manufactured to suit the requirement. However, for bacterial gene therapy 
applications the size of the QD can inhibit binding of the probe to its target on the 
bacterial surface [69]. Although autofluorescence is decreased with NIR emission 
wavelengths, tissue absorption and scattering still impede the amount of excitation 
light that reaches the fluorophore. To address this ‗self-illuminating‘ QDs have been 
developed which couple QDs with the Renilla luciferase [70]. By completely 
eliminating the need for excitation light, this very elegant approach could be refined 
by combining different luciferases with QDs of different wavelengths [64]. 
Caged luciferin probes: An emerging form of bioluminescence imaging that 
employs the use of activatable luminescent probes referred to as ―caged luciferin 
probes‖ represent a variant of the standard luciferase-luciferin system that is most 
commonly utilised for BLI. These caged probes allow for more targeted production 
of the luminescent signal and hence increased ability to determine the spatial 
localisation of the light signal. The caged probe consists of D-luciferin conjugated to 
a caging moiety that can be removed by target cells (such as bacteria) to liberate D-
luciferin which, in the presence of luciferase, leads to photon generation and 
emission of a quantifiable light signal [71]. Such a probe has been used to detect 
luciferase expressing bacteria in vivo in models of infection and tumour colonisation 
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[72]. This probe was designed to be uncaged by bacterial nitroreductase (NTR) 
enzymes leading to the production of a luminescent signal at the site of infection. 
 Overall, such strategies represent an exciting avenue for imaging bacteria 
within all tissue types which is ideally suited to cancer gene therapy-related 
applications. 
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Alternative modalities to OI 
 
Photoacoustic Imaging 
 
Photoacoustic imaging (PAI), also known as optoacoustic imaging is an imaging 
modality based on the photoacoustic effect. Excitation of a target molecule or tissue 
is achieved using pulsed lasers. The absorbed energy from the pulsed laser is 
converted to heat, thereby causing the excited molecule or tissue to transiently 
expand. This thermal expansion results in the emission of ultrasonic waves which 
can be detected by ultrasonic transducers before conversion to a 2D or 3D image. 
While BLI, FLI and PAI all rely on optical excitation of a target molecule, the 
detection of a sound wave is unique to PAI and is in contrast to BLI or FLI which 
both rely on detection of emitted light from the excited molecule for image 
acquisition and signal dissemination. While many endogenous molecules such as 
haemoglobin produce an intrinsic photoacoustic signal, the modality can also be 
exploited to detect photoacoustic signals from specific exogenous contrast agents 
[73, 74]. 
 
Positron Emission Tomography (PET) 
 
While fluorescent and luciferase based imaging is effective in small animal models, 
these imaging techniques have not, as yet, been adapted for routine clinical use. It is 
in this respect that PET is seen as a vital imaging modality in the translation of 
cancer gene therapy from the lab to the clinic [75]. PET exploits the emission of 
pairs of γ-rays from positron emitting radionuclides to create quantitative, 3D 
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images, of in vivo biological processes [76]. Molecular probes labelled with 
positron-emitting isotopes are used to detect biologically active molecules, as a result 
of the target-dependent sequestration of the systemically administered positron-
emitting probes [77]. While one of the most commonly utilised PET probes 
fluorodeoxygluxose labelled with fluorine
18
, also known as [
18
F] FDG, has 
previously been used as a radiotracer to image bacteria in vivo, it is the use of 
thymidine kinase (TK) substrates that has been appropriated to greatest effect in 
bacterial gene therapy studies. These TK substrates become trapped within tumour 
cells that have been colonised by bacteria allowing for quantitation of intra-tumoural 
bacteria as well as visualisation of the tumour in vivo. Two substrates of the herpes 
simplex virus 1 TK (HSV-TK) reporter gene that have been reportedly used 
successfully to image tumour targeting bacteria are [
124I] 2‘-fluoro-1-β-D-arabino-
furanosyl-5-iodo-uracil ([
124
I]FIAU) [78] and [
18
F]-2‘-Fluoro-2‘ deoxy-1β-D-
arabionofuranosyl-5-ethyl-uracil ([
18
F]FEAU) [79]. Using these radionuclides it had 
been possible to quantitatively confirm targeting of E. coli Nissle 1917 [79] and the 
S. Typhimurium [78] to tumour sites within mice.  
 
Magnetic Resonance Imaging 
 
Magnetic resonance imaging (MRI) has a number of important advantages over 
other non-invasive imaging modalities, described in detail by Waerzeggers et al [80] 
but are summarised as follows; (i) it has relatively high three-dimensional spatial 
resolution when compared with PET (ii) it has very good sample penetration in 
multiple imaging planes, (iii) it has the ability to measure more than one 
physiological parameter using different radiofrequency pulse sequences, (iv) it has 
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no risk of ionizing radiation and (v) it is already widely used in the clinic [81]. A 
drawback is its low sensitivity: approximately micromolar concentrations of an 
imaging probe can be detected within a given voxel (10
−3–10−5 mol/L) which is three 
to six orders of magnitude lower than the sensitivity of optical imaging for detection 
of fluorochromes in vivo [82]. 
Benoit et al. (2009) exploited the innate physiology of magnetotactic bacteria 
to target tumours in mice and provide positive contrast for visualization using MRI. 
The ability of Magnetospirillum magneticum AMB-1 to confer positive MRI 
contrast was determined both in vitro and in vivo [83]. The strain was administered 
to tumour bearing mice either intratumourally or intravenously and tumour targeting 
was confirmed using a multiple of approaches including 64Cu-labeled bacteria. 
Significantly M. magneticum with small magnetite particles generate T1-weighted 
positive contrast, enhancing in vivo visualization by MRI. Ferritins are ubiquitous 
iron storage proteins and recent studies have shown that human ferritin can be used 
as a reporter of gene expression for MRI [84]. Bacteria also encode three classes of 
ferritin-type molecules which Hill et al. (2011) have recently investigated for their 
potential as MRI reporter genes [85]. Tumour specific induction of bacterioferritin-
expression in colonised murine tumours resulted in contrast changes within the 
bacteria-colonised tumours. However, such research on MR imaging genes is still in 
its infancy and with the exception of the previously discussed studies, its ability to 
complement bacterial gene therapy imaging is currently limited. 
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Bacterial-Mediated Tumour Therapy 
 
The attractiveness of bacteria as vectors for cancer gene therapy is evidenced by the 
growing number and range of studies that have employed bacteria as gene delivery 
vectors. To date, the genera of bacteria that have been exploited as vehicles for 
delivery to tumours include Salmonella, Escherichia, Listeria, Clostridium and 
Bifidobacterium [14, 38, 43, 86-91]. These bacteria can be delivered to the tumour 
via multiple routes such as intratumoural injection (IT), intravenous injection (IV) or 
in certain instances orally. Preclinical studies have shown the ability of different 
bacterial strains to locally produce therapeutic agents and mediate highly effective 
and specific therapeutic responses [5]. A wide range of gene therapy strategies exist, 
aiming at inducing malignant cell death either directly (e.g. using ‗suicide‘ genes) or 
indirectly, such as cancer immunotherapy approaches based on killing tumour cells 
through intervention of various effector cells of the immune system [6]. Invasive 
bacteria can enter cancer cells and deposit genes within them for host cell 
expression. In the case of non-invasive bacteria, strains can be engineered to secrete 
therapeutic proteins locally within the tumour environment, external to tumour cells 
[91]. This approach is suitable for indirectly acting therapeutic strategies such as 
anti-angiogenesis and immune therapy (Figure 3).  
 Live bacteria were first associated with cancers almost two centuries ago 
when tumour regression was observed in patients who contracted gas gangrene [92] 
caused by C. perfringens [93]. Clostridia are obligate anaerobic bacteria which 
proliferate preferentially in regions of solid tumours resulting in tumour regression 
but also acute toxicity. The application of non-pathogenic Clostridium strains has 
generally not provided efficient clinical tumour therapy to date. For example, in 
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clinical studies, C. butyricum M-55 induced ‗liquefaction‘ (oncolysis) of gliomas at 
the well oxygenated outer rim of tumours but lead to regrowth in all patients [94]. 
However, a recent study utilising an attenuated strain of Clostridium, C. novyi-NT, 
was shown to effectively lyse tumour cells in canine models and also in a single 
human patient. This encouraging result, while limited to a single patient, indicates 
the potential for the efficacious use of bacteria, and in particular Clostridium, in 
tumour therapy [95]. Unfortunately, the paucity of molecular tools for this genus has 
also hindered success at further adapting the species for gene delivery. 
 Genetically engineered strains of Salmonella have also been proposed for 
tumour selective therapy. In contrast to Clostridia, Salmonella are Gram-negative 
motile bacteria that have potential to grow in both oxygenated and hypoxic tumour 
areas. S. Typhimurium has been genetically engineered to produce a variety of 
therapeutic agents, with success in animal models, accomplishing relatively tumour-
specific therapeutic gene expression, reviewed by Chorobik et al. [96]. Despite the 
preferential tumour colonisation following the administration of attenuated 
Salmonella to tumour-bearing animals normal tissues are also colonised transiently 
and to a lesser extent [91]. A safety-attenuated strain of S. Typhimurium designated 
VNP20029 has been examined in several clinical trials [97]. The pre-clinical success 
of Salmonella has not, however, translated into human studies, and clinical trials 
have demonstrated tumour colonisation in only a low proportion of patient tumours 
[98]. This is most likely as a result of the maximum tolerable dose exceeding the 
therapeutic dose, resulting in a poor therapeutic window. The only established, 
licenced cancer therapy employing bacteria is Bacillus Calmette-Guérin (BCG), an 
attenuated Mycobacterium bovis strain which was successfully used by Morales, 
Eidinger and Bruce in 1976 for the treatment of superficial bladder cancer [99]. BCG 
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has become the treatment of choice for high risk, superficial bladder cancer in most 
countries, with an increasing rate of treating approximately one million patients per 
year [100]. The BCG vaccine is a form of immunotherapy that stimulates a local 
immune response leading to a therapeutic response to the tumour. 
 While the benefits of using bacteria as vectors for cancer gene therapy are 
abundantly clear, there are some disadvantages associated with their use in cancer 
treatment. As with all vector strategies, balance between efficacy and safety is key. 
In terms of safety, despite the use of safety-attenuated bacterial strains in gene 
therapy studies employing pathogenic species, the possibility of inducing an 
immune-mediated toxic response in the host following bacterial administration 
remains a concern. Therefore, interest in prokaryote-based approaches to cancer 
therapy has re-emerged with the discovery of non-pathogenic strains that specifically 
and preferentially target solid tumours. This method has drawn further attention with 
the development of techniques to genetically modify the bacteria, thereby enabling 
the expression of anti-cancer therapeutic genes in these hosts [101]. Numerous 
publications provide convincing evidence that genera of bacteria including 
Bifidobacterium and Escherichia have potential in cancer therapy [43, 86, 87, 91, 
102-105]. This vector class compares favourably with other vectors in terms of key 
attributes such as safety, ease of manipulation, and production. While non-
pathogenic bacteria have yet to enter clinical trial in the context of tumour targeting 
vectors, existing knowledge strongly indicates their suitability as a vector system for 
clinical use.  
The inconclusive outcomes to date from bacterial therapy strategies in Phase 
I/II clinical trials has hindered the progression of this concept [94, 106]. For gene 
therapy in general, a paucity of technologies to monitor events post vector 
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administration to patients represents a block in clinical progression [107]. Indeed, in 
response to the first gene therapy death, the NIH Recombinant DNA Advisory 
Committee (RAC) called for better assays to monitor gene delivery [108]. As the 
field of bacterial gene therapy develops, it is becoming clear that the ability to image 
bacteria in vivo following administration is essential. Therefore, in order to 
determine the location and spread of bacteria within the treated host, the bacteria 
must be amenable to one of the rapidly evolving modes of imaging that are available 
to researchers today. Unlike other vector strategies, humans feature a ‗background‘ 
of indigenous bacteria (GIT, oral and genital cavities, skin), and therefore, high 
specificity for the vector of interest is required, be it from introduced reporter genes, 
or strain-specific probes. 
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Figure 3. Bacterial imaging and therapy. Schematic illustrating strategies for in vivo 
bacterial imaging or tumour therapy. 
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Exploiting endogenous bacterial activity for imaging 
 
A major limitation currently exists regarding the availability of plasmids and tools 
for engineering of a wide range of bacterial genera (both Gram positive and Gram 
negative) to enable tagging with reporter genes. The development of imaging 
techniques and therapies that rely solely on the endogenous activities of bacteria 
present fewer regulatory hurdles than vectors featuring genetic modifications. The 
endogenous bacterial TK activity of several strains including E. coli, C. novyi, S. 
aureus, and Enterococcus faecalis has been exploited to monitor their location and 
tumour targeting activity [109]. The bacteria can be selectively imaged in 
experimentally-infected mice using exogenously administered [
125
I]FIAU, a 
nucleoside analogue substrate for microbial TK that is taken up by rapidly 
proliferating cancer cells at an accelerated rate compared to non-cancer cells [110]. 
The TK enzyme phosphorylates FIAU, leading to accumulation within the bacteria. 
Since FIAU is a poor substrate for mammalian TK, the radiotracer selectively labels 
bacteria. The bacteria can therefore be imaged in situ using PET or single photon 
emission computed tomography (SPECT) in conjunction with CT. Since radio-
pharmaceutical based imaging provides a comprehensive 3D assessment of the 
whole tumour it correlates well with colonisation levels. 
 A strategy termed sequential reporter-enzyme luminescence has been 
described recently, which combines luciferase-expressing bacteria with a β-
lactamase-cleavable substrate [111]. Bluco is a ‗caged‘ luciferin, which is released 
by bacterial β-lactamase hydrolysis for reacting with luciferase [112]. Tumour 
targeting bacteria such as certain strains of Salmonella or E. coli [113] endogenously 
produce the enzyme β-lactamase which may be sufficient to cleave the β-lactam ring 
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in Bluco and liberate D-luciferin. Free D-luciferin could then be oxidised by FLuc to 
produce light for in vivo detection of tumours and metastasis. Successful use of 
Bluco for in vivo tumour visualisation could pave the way for therapies utilising 
endogenous bacterial enzymes to cleave pro-drugs specifically within tumours 
thereby avoiding concerns associated with genetically modified organisms.  
  
Bacterial Directed Enzyme Prodrug Therapy 
 
An exciting approach to increasing the efficacy of a bacterial vector and reducing its 
therapeutic dosage has been to use BDEPT. This involves ‗arming‘ bacteria with a 
gene coding for a prodrug converting enzyme (that has no human homologue, or/and 
has more favourable enzyme kinetics than any human isozyme) and using them to 
deliver the enzyme to the locality of the tumour. BDEPT is a two-step therapy 
(Figure 4). In the first step, the armed vector is administered to the patient and 
targets specifically to the site of the tumour where the enzyme is expressed. In the 
second step, once the levels of enzyme expression are optimal, a prodrug is 
administered and is converted to a cytotoxic drug by the expressed enzyme strictly at 
the tumour site. This results in tumour-selective cytotoxicity. 
 BDEPT has a number of homologous therapeutic strategies: Antibody 
Directed Enzyme Prodrug Therapy (ADEPT) was first conceived more than 20 years 
ago [114] [115] [116]. It involves targeting tumour antigens extracellularly with a 
monoclonal antibody that is chemically conjugated to a purified prodrug converting 
enzyme. A number of ADEPT systems are under investigation [117] some of which 
have advanced to clinical trials [118]. Viral Directed Enzyme Prodrug Therapy 
(VDEPT) [119-121] has shown promise in pre-clinical [122] and clinical trials [123]. 
45 
 
Other similar therapies include Polymer Directed Enzyme Prodrug Therapy 
(PDEPT) [124], Ligand Directed Enzyme Prodrug Therapy [125], Melanocyte 
Directed Enzyme Prodrug Therapy (MDEPT) [126] and Prodrug Monotherapy 
[127]. The broad term Gene Directed Enzyme Prodrug Therapy (GDEPT) covers all 
strategies which involve tumour cell gene expression of prodrug converting enzymes 
(for a review on the background and principles of both GDEPT and its prodrugs see 
[128] and [129]). One of the most described GDEPT systems has been the Herpes 
Simplex Virus thymidine kinase (HSV-tk)/nucleoside analogue combination and 
dates back to the 80's [130]. Delivery of the gene coding for HSV-tk in vivo has been 
achieved using many vectors e.g.; retroviruses [131], adenoviruses [132] and 
liposomes [133]. 
 The Cytosine Deaminase enzyme (CD) is found in many bacteria and fungi 
but not in mammalian cells. It catalyses the deamination of cytosine to uracil but can 
also convert the antifungal agent 5-flurocytosine (5-FC) to the popular antitumour 
drug 5-flurouracil (5-FU). The latter is further metabolised by mammalian enzymes 
to RNA and DNA synthesis inhibitors. Initial BDEPT studies utilized Clostridium 
beijerinckii NCIMB 805 and E. coli CD (codA). CD could be expressed from shuttle 
vectors designed to work in Gram-positive bacteria. CD activity was measured in 
both supernatant and cell lysates and was sufficient to inhibit the growth of an EMT6 
murine carcinoma cell line in vitro. Subsequently, Clostridium sporogenes was used 
to deliver CD activity to WAG/Rij rats bearing rhabdomyosarcoma [134]. 
Clostridium acetobutylicum could also target and deliver active CD to similar 
tumours. To further increase the effectiveness of BDEPT with this vector, vascular 
collapse was induced by combretastatin A4 phosphate which resulted in increased 
CD activity in tumours versus normal tissue (presumably by increasing the hypoxic 
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area of the tumour and allowing for more consistent targeting of clostridia spores 
[135]). In therapy experiments Liu et al [136] demonstrated that Clostridium 
sporogenes expressing CD could deliver CD to tumours exclusively. Following 
intravenous administration of 5-FC, tumour regression was observed in experimental 
models. However, no follow up studies on this particular system have ever been 
published since.  
At a similar period, CD expression was being investigated in 
Bifidobacterium longum [137]. Active CD delivery to tumours was confirmed with 
VNP20047 [138] and later with Bifidobacterium breve I538w [139]. In separate 
studies, intratumoural and intravenous injections of B. longum expressing CD in rats 
resulted in a preferential proliferation within hypoxic areas of the tumours and 
efficient conversion of 5-FC to 5-FU. Tumour cell death was evaluated 
histologically using the TUNEL assay and revealed that the majority of the tumour 
cells were apoptotic at or near the sites of bacterial colonisation. A significant 
tumour mass regression was also documented [140]. Similar levels of efficacy were 
shown with Bifidobacterium infantis in melanoma tumours [141]. To improve 
BDEPT with B. longum in conjunction with CD; an E. coli CD mutant (D314A) 
initially identified by Mahan and co-workers [142] was utilised. Growth studies in 
vitro showed that during log phase, B. longum-CD (D314A) was about 10 fold more 
potent than B. longum expressing wild type CD [143]. Increased potency was 
maintained in late log phase and stationary phase making B. longum-CD (D314A) a 
good candidate vector for pre-clinical studies. 
Impressive BDEPT results have also been achieved by Salmonella 
expressing E. coli CD. King and co-workers [144] demonstrated in murine 
experimental tumours that Salmonella harbouring CD resulted in high colony 
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forming units (CFU) in tumours (1x109 over normal tissue 1x106) following IV 
administration. An 88%-96% tumour regression was achieved in mice treated with 
Salmonella -CD and 5-FC as opposed to 38%-79% achieved with Salmonella -CD in 
the absence of the prodrug. 5-FC alone did not show any effect on the tumour. These 
results prompted a small clinical trial (pilot study) involving 3 patients with head 
and neck cancer. Intratumoural injections of Salmonella -CD resulted in persistence 
of bacteria in two of three patients for 15 days however at low levels (1x105 CFU/g 
of tumour). Salmonella -CD was able to convert 5-FC to 5-FU at the tumour site in 
both patients. No significant 5-FC conversions were measured elsewhere. Despite 
this, no tumour regression was observed in any patient and the trial was discontinued 
[106]. In relation to this, there was a study done to assess the efficacy of 5-FC 
conversion by CD in tumour bearing mice [145]. Mice were treated with Salmonella 
-CD and 5-FC and 5-FC to 5-FU conversion within the tumours was measured by 
19F-MRS (magnetic resonance spectroscopy) and chromatography. Paradoxically, 
although all tumours in the groups had comparable enzyme expression levels and 
CD activity, some tumours failed to convert 5-FC to 5-FU and did not respond to 
treatment. Tumour bacterial colonisation levels as well as histological examination 
of tumour hypoxia were found to be similar in both treatment ―responders‖ and 
―non-responders‖. However, this study did not report tumour structural vascularity 
studies or show microscopy images of bacterial distribution within the tumours. 
Further research into this phenomenon should broaden our understanding of prodrug 
activation in tumours by bacteria and could aid BDEPT improvements in the future. 
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Figure 4. BDEPT schematic. In the first step of the therapy, bacteria carrying a BDEPT 
enzyme (e.g. CD) are administered to the patient and target to the site of the tumour where 
they establish extracellular colonies or directly invade the tumour cells and deliver the gene 
by bactofection. In the second step, a non-toxic prodrug is administered systemically and is 
converted to a cytotoxic agent (e.g. DNA cross linking agent) strictly at the tumour site by 
the expressed BDEPT enzyme. In addition to direct cytotoxicity, for both extracellular 
bacteria and bactofection strategies, the active drug is taken up by tumour cells in the 
vicinity (bystander cytotoxic effect) which leads to tumour regression. Taken from [146] 
  
  
49 
 
Advantages of BDEPT as a therapeutic strategy 
 
In BDEPT and other prodrug converting strategies, the drug is generated in situ 
following tumour targeting. This gives a number of advantages over conventional 
therapies. First, tumour selectivity is achieved as the prodrug is strictly converted 
within the tumour, reducing side effects in other organs. Second, an amplifying 
effect is achieved, which results from the ability of a single therapeutic enzyme 
molecule to activate many prodrug molecules. This results in high concentrations of 
active drug at the tumour site (which is higher than can be achieved with classical 
chemotherapy). Third, a bystander effect is accomplished. This is defined as the 
ability of bacterial cells expressing the enzyme to stimulate the killing of 
neighbouring tumour cells that do not express the enzyme. Therefore, bacteria can be 
clustered in colonies in the tumour stroma and do not need to invade cancer cells for 
successful eradication/regression of the tumour to occur. The bystander effect is 
integral to all prodrug-converting therapies and is key to their efficacy [129, 147].  
BDEPT also has further benefits over its related therapies. For example, 
ADEPT is challenged by tumour antigen heterogeneity and antigen expression 
levels. VDEPT requires a productive viral infection for successful transgene 
expression that is dependent on both intracellular and extracellular proteins. 
Furthermore, retroviral genomic integration is not always stable and may result in 
spontaneous loss of the therapeutic gene. GDEPT may suffer from gene expression 
issues in general. A sufficient level of therapeutic gene/transgene expression is 
required for an effective prodrug conversion which is dependent on many molecular 
variables. In cases where the transgene is of bacterial origin, it is possible for its 
activity to be hampered by eukaryotic post-translational modifications, e.g N-linked 
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glycosylation of carboxypeptidase 2 [148]. In BDEPT, bacterial targeting relies on 
the physical rather than the biochemical nature of the tumour; non-pathogenic 
bacteria can be employed which are intrinsically nontoxic to the host; there exists a 
wealth of bacterial molecular biology technology with relatively few hurdles to 
bacterial gene expression; any possible transgene toxicity in human normal tissue 
(that could arise due to vector mistargeting) is avoided as the bacteria harbour the 
gene; serum components cannot inhibit the enzyme as it is protected by bacterial 
membranes and a cell wall; in the bacterial cell, there is a pool of cofactors such as 
NADH or NADPH available to therapeutic enzymes that require a reducing 
environment; and finally, bacteria, unlike viruses, can be scaled up for clinical use 
with relative ease.  
One important difference between BDEPT and other bacterial therapies that 
employ constitutively toxic genes; (e.g. Salmonella expressing pro-apoptotic 
cytokine Fas ligand [149]) is that in BDEPT, toxicity is controlled and induced 
strictly following prodrug administration whereas the other types of bacterial 
therapies can be toxic following injection in the patient. Systemic toxicity can be 
induced rapidly, especially if the bacteria secrete the therapeutic protein. 
Furthermore, bacteria which carry therapeutic genes controlled by eukaryotic 
promoters can also pose problems if the vector mistargets to healthy cells, resulting 
in off target toxicity. Ideally, BDEPT could be integrated with imaging techniques in 
order for the clinician to be able to evaluate targeting and decide beforehand if it is 
appropriate to administer the prodrug.  
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Bacterial therapeutic gene expression technology 
 
There are a number of ways to express prodrug-converting enzymes in tumours with 
bacteria. One way involves cloning the gene of choice in a plasmid under a bacterial 
promoter (which can be inducible e.g.[150, 151]) that can direct high levels of 
protein expression. In our laboratory, the gene coding for CPG2 as well as other gene 
constructs have been expressed successfully in Salmonella strains using a cassette 
(found in commercially available plasmid pTrc99A) consisting of the hybrid trc 
promoter, the LacZ Shine Dalgarno sequence and the E. coli rrnB operon T1 
terminator. Others have also used various commercially available plasmids for their 
work with Gram-negative vectors. However, Gram-negative expression systems 
don‘t work well in Gram-positive bacteria such as Clostridia or Bifidobacteria as 
they have different requirements. Therefore, researchers have developed their own 
shuttle vectors for use in Bifidobacteria [143] and Clostridia [152]. These shuttle 
vectors contain compatible origins of replication to the host‘s replication machinery 
as well as endogenous promoters in order to direct high gene expression levels. 
Further, researchers may also opt to optimise codon usage of foreign genes inserted 
into those plasmids to achieve better expression [153].  
Alternatively, instead of artificial expression systems, plasmid free bacteria 
which express enzymes from their natural promoters can be used (e.g. Endogenous 
E.coli genes; cytosine deaminase (CD) codA, nitroreductase (NR) nfsA and nfsB and 
purine nucleoside phosphorylase (PNP) deoD). However when using this strategy, 
the gene expression level and enzymatic activity within the bacteria must be 
sufficient for an efficient prodrug conversion to occur in order for them to be 
‗effective agents‘.  
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Finally, during therapy, we have observed that in the absence of antibiotic 
selection pressure, the plasmid may be lost also resulting in the loss of the 
therapeutic gene (see also Min [154]). Strategies to bypass this problem do exist. For 
strains where suitable genetic technology is available, gene constructs can be 
integrated into the bacterial genome, or an antibiotic resistance-free ‗balanced lethal 
system‘ [155] could be employed [156], which is also clinically preferable.  
Tumour cell transfection of the BDEPT gene represents an alternative 
approach, and involves cloning the gene of interest in a mammalian plasmid under a 
mammalian promoter like the cytomegalovirus promoter [157] and using bacteria as 
in vivo gene transduction agents, much like viral vectors, in order to transduce 
individual tumour cells. This method is termed bactofection and is becoming popular 
as means to deliver toxic genes to tumours [14]. It is also widely used in bacterial 
vaccination strategies against cancer [8] (this topic is beyond the scope of this 
article; see [158] and [159] for an extensive review). Its drawback is that in the case 
of any unforeseeable emergency it is impossible to shut down gene expression as 
transduced mammalian cells actively producing the therapeutic protein will not 
respond to antibiotics. It also suffers from similar issues as GDEPT (see above). 
Delivering transgenes inside tumour cells by bactofection makes this strategy a 
hybrid between BDEPT and GDEPT. 
 
Combined imaging and therapy 
 
Magnetic resonance spectroscopy (MRS) complements MRI as a non-invasive 
means for the characterization of tissue. MRS has been used for quantitative non-
invasive imaging of tumours expressing cytosine deaminase as a combined reporter 
53 
 
and therapeutic gene [160]. Stegman et al. (1999) exploited cDNA encoding for 
yeast cytosine deaminase in combination with the 5-fluorocytosine (5-FC) prodrug. 
The yCD-catalyzed conversion of 5-FC to the chemotherapeutic agent (5-FU) was 
quantified in vivo using 
19
F MRS. Similar prodrug therapy approaches using 
bacterial expressed CD exist in the literature [161] and its derivative TAPET-CD 
(which expresses the E. coli CD) have been investigated in Phase 1 clinical trials in 
cancer patients. Pre-clinical studies with the commensal Bifidobacterium have also 
been conducted. The “Bifidobacterial Selective Targeting” BEST [86, 162] strategy 
exploits B. longum 105-A containing pBLES100-S-eCD, a plasmid containing a CD 
under the control of the hup gene promoter of B. longum [137]. B. longum 
selectively produces CD in hypoxic mammary tumour tissues in rats, converts 5-FC 
into 5-FU in vivo [139, 140, 143]. This system could be significantly improved by 
combination with MR imaging technology. 
 Thymidine Kinase is another example of a gene therapy approach which 
combines both therapeutic and reporter activity simultaneously. The most commonly 
used TK for gene therapy studies is HSK-TK in combination with an 
acycloguanosine such as ganciclovir which has been tested in a series of pre-clinical 
and clinical trials in a wide range of cancer types [163, 164]. The potential exists to 
improve this study by combining it with multi-modality imaging techniques such as 
SPECT, PET or MRI. Combined application of the imaging modalities and imaging 
probes will maximise the diagnostic and therapeutic potential of bacterial gene 
therapy and achieve a targeted regime for cancer therapy with minimal off-target 
effects. 
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Figure 5. Dual imaging of tumour and bacterial bioluminescence. (i) 3D 
Bioluminescence co-registration. An athymic mouse bearing a subcutaneous FLuc 
expressing HCT116 tumour 7 days post IV administration of 10
5
 B. breve UCC2003 
pluxMC3. Tumour FLuc = orange, Bacterial lux = green. Both bacterial lux and tumour 
FLuc were imaged sequentially. An Atlas mouse skeleton is shown for spatial reference. (ii) 
A still from a movie illustrating tomographic detail of source signal distribution of B. breve 
pluxMC3 10 days post IV administration to mice bearing HCT116 FLuc (orange) expressing 
tumours. B. breve lux is observed in multiple disparate ‗clusters‘ within the tumour.  
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Conclusions and future perspectives 
 
A growing number of studies have reported the successful targeting and treatment of 
murine tumours by bacteria. However, numerous challenges remain before these 
vectors can be routinely applied in the clinic, including identifying the targeting 
mechanism as well as addressing concerns regarding toxicity and genetic instability. 
The potential for the vector to cause toxicity in the host as well as the genetic 
instability of any exogenous genes will need to be addressed on an individual strain 
basis but may be circumvented through the use of non-pathogenic strains or 
exploiting endogenous genes for prodrug activation. The challenge of successful 
targeting of the bacterial vector to the tumour is a complex issue. The ideal 
application of the vector would target not only the primary tumour but also 
metastases at distal sites without affecting healthy tissue. In order to demonstrate this 
targeting, the ability to image the vector in patients is essential.  
Each imaging modality has inherent strengths and weaknesses, with none 
fulfilling all purposes. Nuclear medicine imaging modalities such as PET are highly 
sensitive but suffer from poor spatial resolution [81]. MRI has the highest image 
resolution, but sensitivity is less than nuclear techniques [9]. FP detection has shown 
some success at preclinical levels however high background levels and poor tissue 
penetration of both excitation and emission waves restrict efficacy. BLI reporting 
systems display fewer drawbacks and autoluminescence is almost non-existent 
permitting much higher sensitivity and specificity than fluorescence in vivo. 
However, there are some obvious limitations to OI such as light scattering and 
spatial resolution which is depth dependent [165]. 3D optical tomography systems 
have improved the resolution and the increasing availability of defined bandwidth 
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filters for capturing photonic signals, and improvements in spectral unmixing 
algorithms to differentiate between signals with different emission spectra, opens up 
exciting new avenues for bacterial imaging in vivo. However the OI technology is 
currently limited to small animals or surface tumours.   
 The inherent disadvantages associated with each modality means none are 
perfectly suited to advance the concept of bacterial gene therapy of cancer alone. 
However, the potential to co-register optical-imaging data with other technologies 
such as MRI, PET or even SPECT, X-ray and CT is an exciting development. A 
variety of factors determine the choice of specific imaging system, some of them are 
the imaging requirements (single or repeated), the proposed use (animal or human) 
and spatial requirements (tissue depth). Combination imaging should allow each 
modality to bring its unique advantages to the fore, while providing complementary 
information. The ability to monitor bacterial colonisation dynamics by optical 
imaging or exploiting endogenous/exogenous genes in combination with an imaging 
technology while simultaneously recording the resultant changes in host physiology 
and anatomy using other imaging modalities, will considerably enhance our 
understanding of the complexities of this process in vivo and can be applied to 
multiple fields of research including the detection of infectious disease. 
  
57 
 
References 
 
1. Abelmann, H., Cancer as I see it. New York Philosophical Library, New 
York, NY, 1951. 
2. Yu, Y.A., Q. Zhang, and A.A. Szalay, Establishment and characterization of 
conditions required for tumor colonization by intravenously delivered 
bacteria. Biotechnol Bioeng, 2008. 100(3): p. 567-78. 
3. Harada, H., et al., The Akt/mTOR pathway assures the synthesis of HIF-
1alpha protein in a glucose- and reoxygenation-dependent manner in 
irradiated tumors. J Biol Chem, 2009. 284(8): p. 5332-42. 
4. Pawelek, J.M., K.B. Low, and D. Bermudes, Bacteria as tumour-targeting 
vectors. Lancet Oncol, 2003. 4(9): p. 548-56. 
5. Baban, C.K., et al., Bacteria as vectors for gene therapy of cancer. Bioeng 
Bugs, 2010. 1(6): p. 385-94. 
6. Tangney, M., et al., Gene therapy for prostate cancer. Postgrad Med, 2010. 
122(3): p. 166-80. 
7. Ahmad, S., et al., Prostate stem cell antigen DNA vaccination breaks 
tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther, 
2009. 17(6): p. 1101-8. 
8. Ahmad, S., et al., Induction of effective antitumor response after mucosal 
bacterial vector mediated DNA vaccination with endogenous prostate cancer 
specific antigen. J Urol, 2011. 186(2): p. 687-93. 
9. Chuang, K. and T. Cheng, Noninvasive Imaging of Reporter Gene 
Expression and Distribution In Vivo. Fooyin J Health Sci, 2010. 2(1): p. 1-
11. 
10. Michelini, E., et al., Luminescent probes and visualization of 
bioluminescence. Methods Mol Biol, 2009. 574: p. 1-13. 
11. Morrissey, D., G.C. O'Sullivan, and M. Tangney, Tumour targeting with 
systemically administered bacteria. Curr Gene Ther, 2010. 10(1): p. 3-14. 
12. Tangney, M. and C.G. Gahan, Listeria monocytogenes as a vector for anti-
cancer therapies. Curr Gene Ther, 2010. 10(1): p. 46-55. 
13. Cronin, M., et al., Orally administered bifidobacteria as vehicles for delivery 
of agents to systemic tumors. Mol Ther, 2010. 18(7): p. 1397-407. 
58 
 
14. van Pijkeren, J.P., et al., A novel Listeria monocytogenes-based DNA delivery 
system for cancer gene therapy. Hum Gene Ther, 2010. 21(4): p. 405-16. 
15. Prescher, J.A. and C.H. Contag, Guided by the light: visualizing 
biomolecular processes in living animals with bioluminescence. Curr Opin 
Chem Biol. 14(1): p. 80-9. 
16. Loening, A.M., A.M. Wu, and S.S. Gambhir, Red-shifted Renilla reniformis 
luciferase variants for imaging in living subjects. Nat Methods, 2007. 4(8): p. 
641-3. 
17. Levi, J., et al., Bisdeoxycoelenterazine derivatives for improvement of 
bioluminescence resonance energy transfer assays. J Am Chem Soc, 2007. 
129(39): p. 11900-1. 
18. Wiles, S., et al., Alternative luciferase for monitoring bacterial cells under 
adverse conditions. Applied and environmental microbiology, 2005. 71(7): p. 
3427-3432. 
19. Nguyen, V.H., et al., Genetically engineered Salmonella typhimurium as an 
imageable therapeutic probe for cancer. Cancer Res, 2010. 70(1): p. 18-23. 
20. Gahan, C.G., The bacterial lux reporter system: applications in bacterial 
localisation studies. Curr Gene Ther, 2012. 12(1): p. 12-9. 
21. Belas, R., et al., Bacterial bioluminescence: isolation and expression of the 
luciferase genes from Vibrio harveyi. Science, 1982. 218(4574): p. 791-3. 
22. Riedel, C.U., et al., Improved luciferase tagging system for Listeria 
monocytogenes allows real-time monitoring in vivo and in vitro. Appl 
Environ Microbiol, 2007. 73(9): p. 3091-4. 
23. Francis, K.P., et al., Visualizing pneumococcal infections in the lungs of live 
mice using bioluminescent Streptococcus pneumoniae transformed with a 
novel gram-positive lux transposon. Infect Immun, 2001. 69(5): p. 3350-8. 
24. Hardy, J., et al., Extracellular replication of Listeria monocytogenes in the 
murine gall bladder. Science, 2004. 303(5659): p. 851-3. 
25. Wiles, S., et al., Organ specificity, colonization and clearance dynamics in 
vivo following oral challenges with the murine pathogen Citrobacter 
rodentium. Cell Microbiol, 2004. 6(10): p. 963-72. 
26. Davis, R.W.I.V., et al., In Vivo Tracking of Streptococcal Infections of 
Subcutaneous Origin in a Murine Model. Molecular Imaging and Biology, 
2015: p. 1-9. 
59 
 
27. Nealson, K.H., Autoinduction of bacterial luciferase. Occurrence, 
mechanism and significance. Arch Microbiol, 1977. 112(1): p. 73-9. 
28. Bhaumik, S. and S. Gambhir, Optical imaging of Renilla luciferase reporter 
gene expression in living mice. Proceedings of the National Academy of 
Sciences, 2002. 99(1): p. 377. 
29. Baban, C.K., et al., Bacteria as vectors for gene therapy of cancer. 
BioEngineered Bugs, 2010. 1(12). 
30. Chen JQ, Z.Y., Wang W, Jiang SN, Li XY, The engineered Salmonella 
typhimurium inhibits tumorigenesis in advanced glioma. EXPERIMENTAL 
THERAPEUTICS AND TARGETED THERAPIES, 2015. 2015:8: p. 
2555—2563. 
31. Min, J.J., V.H. Nguyen, and S.S. Gambhir, Molecular Imaging of Biological 
Gene Delivery Vehicles for Targeted Cancer Therapy: Beyond Viral Vectors. 
Nuclear Medicine and Molecular Imaging, 2010. 44(1): p. 15-24. 
32. Beckmann, N., et al., In vivo mouse imaging and spectroscopy in drug 
discovery. NMR in Biomedicine, 2007. 20(3): p. 154-185. 
33. Hilderbrand, S.A. and R. Weissleder, Near-infrared fluorescence: 
application to in vivo molecular imaging. Current Opinion in Chemical 
Biology, 2010. 14(1): p. 71-79. 
34. Bokobza, L., Near infrared spectroscopy. Journal of Near Infrared 
Spectroscopy, 1998. 6: p. 3-18. 
35. Zhao, M., et al., Spatial-temporal imaging of bacterial infection and 
antibiotic response in intact animals. Proc Natl Acad Sci U S A, 2001. 
98(17): p. 9814-8. 
36. Mehta, S.R., et al., Real-time in vivo green fluorescent protein imaging of a 
murine leishmaniasis model as a new tool for Leishmania vaccine and drug 
discovery. Clin Vaccine Immunol, 2008. 15(12): p. 1764-70. 
37. Kong, Y., et al., Application of optical imaging to study of extrapulmonary 
spread by tuberculosis. Tuberculosis (Edinb), 2009. 89 Suppl 1: p. S15-7. 
38. Zhao, M., et al., Tumor-targeting bacterial therapy with amino acid 
auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci 
U S A, 2005. 102(3): p. 755-60. 
60 
 
39. Hayashi, K., et al., Cancer metastasis directly eradicated by targeted therapy 
with a modified Salmonella typhimurium. J Cell Biochem, 2009. 106(6): p. 
992-8. 
40. Miwa, S., et al., Tumor-targeting Salmonella typhimurium A1-R prevents 
experimental human breast cancer bone metastasis in nude mice. Oncotarget, 
2014. 5(16): p. 7119. 
41. Yu, Y.A., et al., Visualization of tumors and metastases in live animals with 
bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol, 
2004. 22(3): p. 313-20. 
42. Wang, Y.W., et al., Renilla luciferase-Aequorea GFP (Ruc-GFP) fusion 
protein, a novel dual reporter for real-time imaging of gene expression in 
cell cultures and in live animals. Molecular Genetics and Genomics, 2002. 
268(2): p. 160-168. 
43. Cronin, M., et al., High resolution in vivo bioluminescent imaging for the 
study of bacterial tumour targeting. PLoS One, 2012. 7(1): p. e30940. 
44. Snoeks, T.J., C.W. Lowik, and E.L. Kaijzel, 'In vivo' optical approaches to 
angiogenesis imaging. Angiogenesis, 2010. 13(2): p. 135-47. 
45. Zhang, Q., et al., Quantitative bioluminescence tomography guided by diffuse 
optical tomography. Opt Express, 2008. 16(3): p. 1481-6. 
46. Leblond, F., et al., Pre-clinical whole-body fluorescence imaging: Review of 
instruments, methods and applications. J Photochem Photobiol B, 2010. 
98(1): p. 77-94. 
47. Tangney, M. and K.P. Francis, In vivo optical imaging in gene & cell 
therapy. Curr Gene Ther, 2012. 12(1): p. 2-11. 
48. Min, J.J., et al., Noninvasive real-time imaging of tumors and metastases 
using tumor-targeting light-emitting Escherichia coli. Molecular Imaging 
and Biology, 2008. 10(1): p. 54-61. 
49. Min, J.J., et al., Quantitative bioluminescence imaging of tumor-targeting 
bacteria in living animals. Nat Protoc, 2008. 3(4): p. 629-36. 
50. Winson, M.K., et al., Engineering the luxCDABE genes from Photorhabdus 
luminescens to provide a bioluminescent reporter for constitutive and 
promoter probe plasmids and mini-Tn5 constructs. FEMS Microbiol Lett, 
1998. 163(2): p. 193-202. 
61 
 
51. Riedel, C.U., et al., Construction of p16Slux, a novel vector for improved 
bioluminescent labeling of gram-negative bacteria. Appl Environ Microbiol, 
2007. 73(21): p. 7092-5. 
52. Bron, P.A., et al., Novel luciferase reporter system for in vitro and organ-
specific monitoring of differential gene expression in Listeria 
monocytogenes. Appl Environ Microbiol, 2006. 72(4): p. 2876-84. 
53. Steinhuber, A., et al., Bioluminescence imaging to study the promoter activity 
of hla of Staphylococcus aureus in vitro and in vivo. Int J Med Microbiol, 
2008. 298(7-8): p. 599-605. 
54. Andreu, N., et al., Optimisation of bioluminescent reporters for use with 
mycobacteria. PLoS One, 2010. 5(5): p. e10777. 
55. Rocchetta, H.L., et al., Validation of a noninvasive, real-time imaging 
technology using bioluminescent Escherichia coli in the neutropenic mouse 
thigh model of infection. Antimicrob Agents Chemother, 2001. 45(1): p. 129-
37. 
56. Bumann, D., Examination of Salmonella gene expression in an infected 
mammalian host using the green fluorescent protein and two-colour flow 
cytometry. Mol Microbiol, 2002. 43(5): p. 1269-83. 
57. Sanz, P., et al., Detection of Bacillus anthracis spore germination in vivo by 
bioluminescence imaging. Infect Immun, 2008. 76(3): p. 1036-47. 
58. Craney, A., et al., A synthetic luxCDABE gene cluster optimized for 
expression in high-GC bacteria. Nucleic Acids Res, 2007. 35(6): p. e46. 
59. Mesak, L.R., G. Yim, and J. Davies, Improved lux reporters for use in 
Staphylococcus aureus. Plasmid, 2009. 61(3): p. 182-7. 
60. Gupta, R.K., et al., Expression of the Photorhabdus luminescens lux genes 
(luxA, B, C, D, and E) in Saccharomyces cerevisiae. FEMS Yeast Res, 2003. 
4(3): p. 305-13. 
61. Unge, A., et al., Simultaneous monitoring of cell number and metabolic 
activity of specific bacterial populations with a dual gfp-luxAB marker 
system. Appl Environ Microbiol, 1999. 65(2): p. 813-21. 
62. Qazi, S.N., et al., Development of gfp Vectors for Expression in Listeria 
monocytogenes and Other Low G+C Gram Positive Bacteria. Microb Ecol, 
2001. 41(4): p. 301-309. 
62 
 
63. Tamagnini, I., et al., Generation and comparison of bioluminescent and 
fluorescent Bacillus licheniformis. Curr Microbiol, 2008. 57(3): p. 245-50. 
64. Andreu, N., A. Zelmer, and S. Wiles, Noninvasive biophotonic imaging for 
studies of infectious disease. FEMS Microbiol Rev, 2011. 35(2): p. 360-94. 
65. van Oosten, M., et al., Targeted imaging of bacterial infections: advances, 
hurdles and hopes. FEMS Microbiology Reviews, 2015. 
66. Leevy, W.M., et al., Optical imaging of bacterial infection in living mice 
using a fluorescent near-infrared molecular probe. J Am Chem Soc, 2006. 
128(51): p. 16476-7. 
67. Leevy, W.M., et al., Noninvasive optical imaging of staphylococcus aureus 
bacterial infection in living mice using a Bis-dipicolylamine-Zinc(II) affinity 
group conjugated to a near-infrared fluorophore. Bioconjug Chem, 2008. 
19(3): p. 686-92. 
68. Ning, X., et al., Maltodextrin-based imaging probes detect bacteria in vivo 
with high sensitivity and specificity. Nat Mater, 2011. 10(8): p. 602-7. 
69. Leevy, W.M., et al., Quantum dot probes for bacteria distinguish 
Escherichia coli mutants and permit in vivo imaging. Chem Commun 
(Camb), 2008(20): p. 2331-3. 
70. Loening, A.M., et al., Consensus guided mutagenesis of Renilla luciferase 
yields enhanced stability and light output. Protein Eng Des Sel, 2006. 19(9): 
p. 391-400. 
71. Porterfield, W.B., et al., A “Caged” Luciferin for Imaging Cell–Cell 
Contacts. Journal of the American Chemical Society, 2015. 137(27): p. 8656-
8659. 
72. Vorobyeva, A.G., et al., Development of a Bioluminescent Nitroreductase 
Probe for Preclinical Imaging. PloS one, 2015. 10(6). 
73. Kim, H.-S., et al., In vivo imaging of hemoglobin and melanin variations 
using photoacoustic tomography. Journal of Nuclear Medicine, 2015. 
56(supplement 3): p. 1206. 
74. Krumholz, A., et al., Multicontrast photoacoustic in vivo imaging using near-
infrared fluorescent proteins. Scientific reports, 2014. 4. 
75. Tjuvajev, J.G., et al., Imaging Adenoviral-mediated Herpes Virus Thymidine 
Kinase Gene Transfer and Expression In Vivo. Cancer Research, 1999. 
59(20): p. 5186-5193. 
63 
 
76. Bengel, F.M., et al., Cardiac Positron Emission Tomography. Journal of the 
American College of Cardiology, 2009. 54(1): p. 1-15. 
77. Collins, S.A., et al., PET Imaging for Gene & Cell Therapy. Curr Gene Ther, 
2012. 12(1): p. 20-32. 
78. Soghomonyan, S.A., et al., Positron emission tomography (PET) imaging of 
tumor-localized Salmonella expressing HSV1-TK. Cancer Gene Therapy, 
2004. 12(1): p. 101-108. 
79. Brader, P., et al., Escherichia coli Nissle 1917 facilitates tumor detection by 
positron emission tomography and optical imaging. Clinical Cancer 
Research, 2008. 14(8): p. 2295-2302. 
80. Waerzeggers, Y., et al., Methods to monitor gene therapy with molecular 
imaging. Methods, 2009. 48(2): p. 146-160. 
81. Waerzeggers, Y., et al., Methods to monitor gene therapy with molecular 
imaging. Methods, 2009. 48(2): p. 146-60. 
82. Weissleder, R. and U. Mahmood, Molecular imaging. Radiology, 2001. 
219(2): p. 316-33. 
83. Benoit, M.R., et al., Visualizing implanted tumors in mice with magnetic 
resonance imaging using magnetotactic bacteria. Clin Cancer Res, 2009. 
15(16): p. 5170-7. 
84. Gossuin, Y., R.N. Muller, and P. Gillis, Relaxation induced by ferritin: a 
better understanding for an improved MRI iron quantification. NMR 
Biomed, 2004. 17(7): p. 427-32. 
85. Hill, P.J., et al., Magnetic resonance imaging of tumors colonized with 
bacterial ferritin-expressing Escherichia coli. PLoS One, 2011. 6(10): p. 
e25409. 
86. Fujimori, M., [Anaerobic bacteria as a gene delivery system for breast 
cancer therapy]. Nippon Rinsho, 2008. 66(6): p. 1211-8. 
87. Zhou, S., M. Zhang, and J. Wang, Tumor-targeted delivery of TAT-Apoptin 
fusion gene using Escherichia coli Nissle 1917 to colorectal cancer. Med 
Hypotheses, 2011. 76(4): p. 533-4. 
88. Tangney, M., J.P. van Pijkeren, and C.G. Gahan, The use of Listeria 
monocytogenes as a DNA delivery vector for cancer gene therapy. Bioeng 
Bugs, 2010. 1(4): p. 284-7. 
64 
 
89. Walther, W., et al., Novel Clostridium perfringens enterotoxin suicide gene 
therapy for selective treatment of claudin-3- and -4-overexpressing tumors. 
Gene Ther, 2011. 
90. Theys, J., et al., Clostridium as a tumor-specific delivery system of 
therapeutic proteins. Cancer Detect Prev, 2001. 25(6): p. 548-57. 
91. Tangney, M., Gene therapy for cancer: dairy bacteria as delivery vectors. 
Discov Med, 2010. 10(52): p. 195-200. 
92. Minton, N.P., Clostridia in cancer therapy. Nat Rev Microbiol, 2003. 1(3): p. 
237-42. 
93. Hall, S.S., A commotion in the blood : life, death, and the immune system. 
1997, London: Little, Brown, 1998. xiv,544p., [8]p. of plates. 
94. Heppner, F. and J.R. Mose, The liquefaction (oncolysis) of malignant gliomas 
by a non pathogenic Clostridium. Acta Neurochir (Wien), 1978. 42(1-2): p. 
123-5. 
95. Roberts, N.J., et al., Intratumoral injection of Clostridium novyi-NT spores 
induces antitumor responses. Science Translational Medicine, 2014. 6(249): 
p. 249ra111-249ra111. 
96. Chorobik, P. and J. Marcinkiewicz, Therapeutic vaccines based on 
genetically modified Salmonella: a novel strategy in cancer immunotherapy. 
Pol Arch Med Wewn, 2011. 121(12): p. 461-6. 
97. Cunningham, C. and J. Nemunaitis, A phase I trial of genetically modified 
Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, 
VNP20029) administered by intratumoral injection in combination with 5-
fluorocytosine for patients with advanced or metastatic cancer. Protocol no: 
CL-017. Version: April 9, 2001. Hum Gene Ther, 2001. 12(12): p. 1594-6. 
98. Toso, J.F., et al., Phase I study of the intravenous administration of 
attenuated Salmonella typhimurium to patients with metastatic melanoma. J 
Clin Oncol, 2002. 20(1): p. 142-52. 
99. Morales, A., D. Eidinger, and A.W. Bruce, Intracavitary Bacillus Calmette-
Guerin in the treatment of superficial bladder tumors. J Urol, 1976. 116(2): 
p. 180-3. 
100. Sylvester, R.J., Bacillus Calmette-Guerin treatment of non-muscle invasive 
bladder cancer. Int J Urol, 2011. 18(2): p. 113-20. 
65 
 
101. Patyar, S., et al., Bacteria in cancer therapy: a novel experimental strategy. J 
Biomed Sci, 2010. 17(1): p. 21. 
102. Cronin, M., et al., Progress in genomics, metabolism and biotechnology of 
bifidobacteria. Int J Food Microbiol, 2011. 149(1): p. 4-18. 
103. Zhu, L.P., et al., Therapeutic efficacy of Bifidobacterium longum-mediated 
human granulocyte colony-stimulating factor and/or endostatin combined 
with cyclophosphamide in mouse-transplanted tumors. Cancer Sci, 2009. 
100(10): p. 1986-90. 
104. Tang, W., et al., A novel Bifidobacterium infantis-mediated TK/GCV suicide 
gene therapy system exhibits antitumor activity in a rat model of bladder 
cancer. J Exp Clin Cancer Res, 2009. 28: p. 155. 
105. Brader, P., et al., Escherichia coli Nissle 1917 facilitates tumor detection by 
positron emission tomography and optical imaging. Clin Cancer Res, 2008. 
14(8): p. 2295-302. 
106. Nemunaitis, J., et al., Pilot trial of genetically modified, attenuated 
Salmonella expressing the E. coli cytosine deaminase gene in refractory 
cancer patients. Cancer Gene Ther, 2003. 10(10): p. 737-44. 
107. Tangney, M., Editorial: in vivo imaging & gene therapy. Curr Gene Ther, 
2012. 12(1): p. 1. 
108. Hollon, T., Researchers and regulators reflect on first gene therapy death. 
Nat Med, 2000. 6(1): p. 6. 
109. Bettegowda, C., et al., Imaging bacterial infections with radiolabeled 1-(2'-
deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouracil. Proc Natl Acad Sci 
U S A, 2005. 102(4): p. 1145-50. 
110. Davis, S.L., et al., Bacterial thymidine kinase as a non-invasive imaging 
reporter for Mycobacterium tuberculosis in live animals. PLoS One, 2009. 
4(7): p. e6297. 
111. Kong, Y., et al., Whole-body imaging of infection using bioluminescence. 
Curr Protoc Microbiol, 2011. Chapter 2: p. Unit 2C 4. 
112. Yao, H., M.K. So, and J. Rao, A bioluminogenic substrate for in vivo imaging 
of beta-lactamase activity. Angew Chem Int Ed Engl, 2007. 46(37): p. 7031-
4. 
66 
 
113. Bradford, P.A., et al., SHV-7, a novel cefotaxime-hydrolyzing beta-lactamase, 
identified in Escherichia coli isolates from hospitalized nursing home 
patients. Antimicrobial agents and chemotherapy, 1995. 39(4): p. 899-905. 
114. Bagshawe, K.D., Antibody directed enzymes revive anti-cancer prodrugs 
concept. Br J Cancer, 1987. 56(5): p. 531-2. 
115. Bagshawe, K.D., et al., A cytotoxic agent can be generated selectively at 
cancer sites. Br J Cancer, 1988. 58(6): p. 700-3. 
116. Bagshawe, K.D., Antibody-directed enzyme/prodrug therapy (ADEPT). 
Biochem Soc Trans, 1990. 18(5): p. 750-2. 
117. Tietze, L.F. and K. Schmuck, Prodrugs for targeted tumor therapies: recent 
developments in ADEPT, GDEPT and PMT. Curr Pharm Des, 2011. 17(32): 
p. 3527-47. 
118. Francis, R.J., et al., A phase I trial of antibody directed enzyme prodrug 
therapy (ADEPT) in patients with advanced colorectal carcinoma or other 
CEA producing tumours. Br J Cancer, 2002. 87(6): p. 600-7. 
119. Lukashev, A.N., et al., Late expression of nitroreductase in an oncolytic 
adenovirus sensitizes colon cancer cells to the prodrug CB1954. Hum Gene 
Ther, 2005. 16(12): p. 1473-83. 
120. Schepelmann, S. and C.J. Springer, Viral vectors for gene-directed enzyme 
prodrug therapy. Curr Gene Ther, 2006. 6(6): p. 647-70. 
121. Tychopoulos, M., et al., A virus-directed enzyme prodrug therapy (VDEPT) 
strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 
reductase fusion protein. Cancer Gene Ther, 2005. 12(5): p. 497-508. 
122. Schepelmann, S., et al., Suicide gene therapy of human colon carcinoma 
xenografts using an armed oncolytic adenovirus expressing carboxypeptidase 
G2. Cancer Res, 2007. 67(10): p. 4949-55. 
123. Patel, P., et al., A phase I/II clinical trial in localized prostate cancer of an 
adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. 
Mol Ther, 2009. 17(7): p. 1292-9. 
124. Satchi-Fainaro, R., et al., PDEPT: polymer-directed enzyme prodrug therapy. 
2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a 
model combination. Bioconjug Chem, 2003. 14(4): p. 797-804. 
67 
 
125. Spooner, R.A., et al., A novel vascular endothelial growth factor-directed 
therapy that selectively activates cytotoxic prodrugs. Br J Cancer, 2003. 
88(10): p. 1622-30. 
126. Knaggs, S., et al., New prodrugs derived from 6-aminodopamine and 4-
aminophenol as candidates for melanocyte-directed enzyme prodrug therapy 
(MDEPT). Org Biomol Chem, 2005. 3(21): p. 4002-10. 
127. Tietze, L.F., et al., Duocarmycin-based prodrugs for cancer prodrug 
monotherapy. Bioorg Med Chem, 2008. 16(12): p. 6312-8. 
128. Springer, C.J. and I. Niculescu-Duvaz, Prodrug-activating systems in suicide 
gene therapy. J Clin Invest, 2000. 105(9): p. 1161-7. 
129. Niculescu-Duvaz, I., et al., Gene-directed enzyme prodrug therapy. 
Bioconjug Chem, 1998. 9(1): p. 4-22. 
130. Moolten, F.L., Tumor chemosensitivity conferred by inserted herpes 
thymidine kinase genes: paradigm for a prospective cancer control strategy. 
Cancer Res, 1986. 46(10): p. 5276-81. 
131. Finzi, L., et al., Improved retroviral suicide gene transfer in colon cancer cell 
lines after cell synchronization with methotrexate. J Exp Clin Cancer Res, 
2011. 30: p. 92. 
132. Abate-Daga, D., et al., Oncolytic adenoviruses armed with thymidine kinase 
can be traced by PET imaging and show potent antitumoural effects by 
ganciclovir dosing. PLoS One, 2011. 6(10): p. e26142. 
133. Suzuki, S., et al., Liposome-mediated gene therapy using HSV-
TK/ganciclovir under the control of human PSA promoter in prostate cancer 
cells. Urol Int, 2001. 67(3): p. 216-23. 
134. Nuyts, S., et al., Increasing specificity of anti-tumor therapy: cytotoxic 
protein delivery by non-pathogenic clostridia under regulation of radio-
induced promoters. Anticancer Res, 2001. 21(2A): p. 857-61. 
135. Theys, J., et al., Specific targeting of cytosine deaminase to solid tumors by 
engineered Clostridium acetobutylicum. Cancer Gene Ther, 2001. 8(4): p. 
294-7. 
136. Liu, S.C., et al., Anticancer efficacy of systemically delivered anaerobic 
bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene 
Ther, 2002. 9(4): p. 291-6. 
68 
 
137. Nakamura, T., et al., Cloned cytosine deaminase gene expression of 
Bifidobacterium longum and application to enzyme/pro-drug therapy of 
hypoxic solid tumors. Biosci Biotechnol Biochem, 2002. 66(11): p. 2362-6. 
138. Mei, S., et al., Optimization of tumor-targeted gene delivery by engineered 
attenuated Salmonella typhimurium. Anticancer Res, 2002. 22(6A): p. 3261-
6. 
139. Hidaka, A., et al., Exogenous cytosine deaminase gene expression in 
Bifidobacterium breve I-53-8w for tumor-targeting enzyme/prodrug therapy. 
Biosci Biotechnol Biochem, 2007. 71(12): p. 2921-6. 
140. Sasaki, T., et al., Genetically engineered Bifidobacterium longum for tumor-
targeting enzyme-prodrug therapy of autochthonous mammary tumors in 
rats. Cancer Sci, 2006. 97(7): p. 649-57. 
141. Yi, C., et al., Antitumor effect of cytosine deaminase/5-fluorocytosine suicide 
gene therapy system mediated by Bifidobacterium infantis on melanoma. 
Acta Pharmacol Sin, 2005. 26(5): p. 629-34. 
142. Mahan, S.D., et al., Alanine-scanning mutagenesis reveals a cytosine 
deaminase mutant with altered substrate preference. Biochemistry, 2004. 
43(28): p. 8957-64. 
143. Hamaji, Y., et al., Strong enhancement of recombinant cytosine deaminase 
activity in Bifidobacterium longum for tumor-targeting enzyme/prodrug 
therapy. Biosci Biotechnol Biochem, 2007. 71(4): p. 874-83. 
144. King, I., et al., Tumor-targeted salmonella expressing Cytosine deaminase as 
an anticancer agent. Hum Gene Ther, 2002. 13(10): p. 1225-33. 
145. Dubois, L., et al., Efficacy of gene therapy-delivered cytosine deaminase is 
determined by enzymatic activity but not expression. Br J Cancer, 2007. 
96(5): p. 758-61. 
146. Lehouritis, P., C. Springer, and M. Tangney, Bacterial-directed enzyme 
prodrug therapy. J Control Release, 2013. 170(1): p. 120-31. 
147. Huber, B.E., et al., Metabolism of 5-fluorocytosine to 5-fluorouracil in 
human colorectal tumor cells transduced with the cytosine deaminase gene: 
significant antitumor effects when only a small percentage of tumor cells 
express cytosine deaminase. Proc Natl Acad Sci U S A, 1994. 91(17): p. 
8302-6. 
69 
 
148. Marais, R., et al., A cell surface tethered enzyme improves efficiency in gene-
directed enzyme prodrug therapy. Nat Biotechnol, 1997. 15(13): p. 1373-7. 
149. Loeffler, M., et al., Inhibition of tumor growth using salmonella expressing 
Fas ligand. J Natl Cancer Inst, 2008. 100(15): p. 1113-6. 
150. Royo, J.L., et al., In vivo gene regulation in Salmonella spp. by a salicylate-
dependent control circuit. Nat Methods, 2007. 4(11): p. 937-42. 
151. Loessner, H., et al., Drug-inducible remote control of gene expression by 
probiotic Escherichia coli Nissle 1917 in intestine, tumor and gall bladder of 
mice. Microbes Infect, 2009. 11(14-15): p. 1097-105. 
152. Minton, N.P., et al., Chemotherapeutic tumour targeting using clostridial 
spores. FEMS Microbiol Rev, 1995. 17(3): p. 357-64. 
153. Liu, S.C., et al., Optimized clostridium-directed enzyme prodrug therapy 
improves the antitumor activity of the novel DNA cross-linking agent PR-
104. Cancer Res, 2008. 68(19): p. 7995-8003. 
154. Min, J.J., et al., Noninvasive real-time imaging of tumors and metastases 
using tumor-targeting light-emitting Escherichia coli. Mol Imaging Biol, 
2008. 10(1): p. 54-61. 
155. Galan, J.E., K. Nakayama, and R. Curtiss, 3rd, Cloning and characterization 
of the asd gene of Salmonella typhimurium: use in stable maintenance of 
recombinant plasmids in Salmonella vaccine strains. Gene, 1990. 94(1): p. 
29-35. 
156. Friedlos, F., et al., Attenuated Salmonella targets prodrug activating enzyme 
carboxypeptidase G2 to mouse melanoma and human breast and colon 
carcinomas for effective suicide gene therapy. Clin Cancer Res, 2008. 
14(13): p. 4259-66. 
157. Fu, W., et al., Synergistic antitumor efficacy of suicide/ePNP gene and 6-
methylpurine 2'-deoxyriboside via Salmonella against murine tumors. Cancer 
Gene Ther, 2008. 15(7): p. 474-84. 
158. Singh, R. and A. Wallecha, Cancer immunotherapy using recombinant 
Listeria monocytogenes: transition from bench to clinic. Hum Vaccin, 2011. 
7(5): p. 497-505. 
159. Paterson, Y., P.D. Guirnalda, and L.M. Wood, Listeria and Salmonella 
bacterial vectors of tumor-associated antigens for cancer immunotherapy. 
Semin Immunol, 2010. 22(3): p. 183-9. 
70 
 
160. Stegman, L.D., et al., Noninvasive quantitation of cytosine deaminase 
transgene expression in human tumor xenografts with in vivo magnetic 
resonance spectroscopy. Proc Natl Acad Sci U S A, 1999. 96(17): p. 9821-6. 
161. Fox, M.E., et al., Anaerobic bacteria as a delivery system for cancer gene 
therapy: in vitro activation of 5-fluorocytosine by genetically engineered 
clostridia. Gene therapy, 1996. 3(2): p. 173-178. 
162. Fujimori, M., Genetically engineered bifidobacterium as a drug delivery 
system for systemic therapy of metastatic breast cancer patients. Breast 
Cancer, 2006. 13(1): p. 27-31. 
163. Shen, Y. and J. Nemunaitis, Herpes simplex virus 1 (HSV-1) for cancer 
treatment. Cancer Gene Ther, 2006. 13(11): p. 975-92. 
164. Pawelek, J.M., K.B. Low, and D. Bermudes, Tumor-targeted Salmonella as a 
novel anticancer vector. Cancer Res, 1997. 57(20): p. 4537-44. 
165. Massoud, T.F., A. Singh, and S.S. Gambhir, Noninvasive molecular 
neuroimaging using reporter genes: part I, principles revisited. AJNR Am J 
Neuroradiol, 2008. 29(2): p. 229-34. 
 
71 
 
Chapter 2: Development of a novel 
probe-based strategy for in vivo imaging 
of non-GM bacteria. 
 
Sections from this chapter have been published as 
Stanton, M., Cronin, M., Lehouritis, P., & Tangney, M. (2015). In Vivo Bacterial 
Imaging without Engineering; A Novel Probe-Based Strategy Facilitated by 
Endogenous Nitroreductase Enzymes. Current gene therapy, 15(3), 277-288. 
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Abstract 
 
The viability and usefulness of bacteria as vectors for gene therapy is becoming 
increasingly recognised. This is primarily due to a number of intrinsic properties of 
bacteria such as their ability to carry large genetic or protein loads, their tumour 
targeting capabilities and the availability of well-established genetic engineering 
tools for a range of common lab strains. However, a number of issues relating to the 
use of bacteria as vectors for gene therapy need to be addressed in order for the field 
to progress. Amongst these is the need for the development of non-invasive 
detection/imaging systems for bacteria within a living host. The ability to track 
bacteria within a live host over time provides researchers developing bacteria as gene 
delivery vehicles and other disciplines with an invaluable tool. In vivo optical 
imaging has advanced preclinical research greatly, and typically involves 
engineering of bacteria with genetic expression constructs for luminescence (e.g. the 
lux operon) or fluorescent proteins (GFP etc.). This requirement for genetic 
modification can be restrictive, where engineering is not experimentally appropriate 
or technologically feasible (e.g. due to lack of suitable engineering tools). This 
chapter describes a novel strategy exploiting endogenous bacterial enzymatic activity 
to specifically activate an exogenously administered fluorescent imaging probe. The 
red shifted, quenched fluorophore CytoCy5S is reduced to a fluorescent form by 
bacterial-specific nitroreductase (NTR) enzymes. NTR enzymes are present in a 
wide range of bacterial genera and absent in mammalian systems, permitting highly 
specific detection of Gram-negative and Gram–positive bacteria in vivo. In this 
study, dose-responsive bacterial-specific signals were observed in vitro from all 
genera examined – E. coli, Salmonella, Listeria, Bifidobacterium and Clostridium 
73 
 
difficile. Examination of an NTR knockout (NTR KO) strain validated the enzyme 
specificity of the probe. In vivo whole-body imaging permitted specific, dose-
responsive monitoring of bacteria over time in various infection models, and no 
toxicity to bacteria or host was observed. This study demonstrates the concept of 
exploiting innate NTR activity as a reporting strategy for wild-type bacteria using 
optical imaging, while the concept may also be extended to NTR-specific probes for 
use with other imaging modalities. 
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Study Aim 
 
The aim of this study was to develop a novel imaging strategy for the in vivo 
detection of non-genetically modified (GM) bacteria. Nitroreductases are a family of 
enzymes found in bacteria that are not present in mammalian cells and hence may be 
capable of the bacteria targeted reduction of the quenched fluorophore CytoCy5s 
leading to the emission of an imageable fluorescent signal in vivo. This fluorescent 
signal may then be used to detect the localization of non-GM bacteria within a live 
host. 
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Introduction 
 
Bacteria represent an attractive and viable alternative to viruses as gene therapy 
vectors. Bacteria are capable of carrying large genetic or protein loads and also 
possess a reservoir of enzymes and proteins that are not found in mammalian cells or 
tissue. These bacteria specific products can be exploited to confine activation of 
imaging probes or prodrugs to bacteria infected tissue and hence minimise off-target 
effects. GMP has been established for bacteria and the availability of invasive and 
non-invasive strains allows researchers to choose whether  a payload is delivered 
externally or internally to target cells. This work aims to develop a non-invasive 
imaging system for the detection of live bacteria within a host in a number of 
infection settings. This system can be used to monitor multiple forms of bacteria 
such as Gram-positive and Gram-negative strains as well as invasive and commensal 
bacteria. The development of such a system is of interest and importance to the field 
of bacterial gene therapy as a whole but also to researchers from a number of other 
fields such as infectious disease and cancer.  
The benefits provided to researchers in translational fields by the increasing 
availability of preclinical imaging technologies are multi-fold [1] [2], while at a 
clinical level, the European Centre for Disease Prevention and Control and the 
European Medicines Agency have recently highlighted the critical need to develop 
novel screening techniques and methods for the early detection of infectious diseases 
[3]. The accessibility of multiple preclinical imaging modalities such as micro 
Positron Emission Tomography (µPET), micro Magnetic Resonance Imaging 
(µMRI) and Optical Imaging (OI) has led to the development of an ever increasing 
array of probes and reporter systems to facilitate non-invasive imaging in vivo [4]. 
Preclinical imaging systems allow for longitudinal studies of small animals and 
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contribute to a considerable reduction in the number of animals required for studies. 
Optical imaging has become the most utilised preclinical in vivo imaging modality in 
academic and industrial research laboratories due to its relative cost-effectiveness, 
ease of use, and high-throughput potential [5] [6, 7].  
Optical imaging is a non-invasive imaging technique that relies on the 
detection of either native light emitted by a molecule or of light emitted from a 
molecule following excitation by an exogenous light source such as a laser. The 
emitted light can be detected and quantified using specialised software. Optical 
imaging of bacterial luminescence afforded by the lux operon is currently the 
mainstay of preclinical in vivo imaging in this space. The luxCDABE operon isolated 
from Vibrio harveyi and other species has facilitated the generation of 
bioluminescent strains in different bacterial genera [8]. However, the degree of 
genetic tractability of a given bacterial strain limits its use, due to the large size of 
the operon (approaching 6 Kb) and the requirement for stably integrated constructs, 
ideally, to permit accurate longitudinal monitoring. Furthermore, light emission from 
lux varies dramatically between species due to variations in co-factor availability 
(FMNH2 and molecular oxygen) [9], in addition to the level of expression afforded 
by different gene-expression systems (copy number and promoter variables). 
Eukaryotic luminescence genes have also been introduced to certain bacteria in an 
attempt to overcome such problems, such as beetle luciferases [10, 11]. Strains have 
also been engineered to express fluorescent proteins [12]. While genetic engineering 
tools for bacterial strains which are traditionally difficult to engineer are becoming 
available for some species, highly sophisticated technology permitting genomic 
integration of large heterologous sequences such as the lux operon are still 
unavailable for many species of interest. Furthermore, it is frequently not feasible to 
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engineer strains in studies involving mixed or undefined populations of bacteria 
(microbiome research etc.).  
If the full potential of bacteria as vectors for gene therapy is to be exploited it 
is imperative that advances in the field of preclinical imaging are achieved to not 
only improve the technology and systems available, but also to develop novel 
imaging modalities and preclinical imaging systems that can be used to image un-
engineered bacteria in vivo. Interest in the development of targeted or activatable 
probes in recent years has strongly contributed to many of the main advancements in 
preclinical imaging [13]. Since 2008, bacterial probes based on bis-dipicolylamine-
Zinc(II) binding to bacterial anionic surfaces have been described, but these probes 
have not entered widespread use [14-16]. A novel fluorescent bacterial-specific 
probe has recently been described [17]. This strategy utilises a fluorescently-labelled 
sugar, maltodextrin, which specifically accumulates within bacteria, enabling 
focusing of the fluorescent signal following systemic administration of probe. It was 
hypothesised that exploitation of enzymatic activity unique to bacteria would permit 
identification of suitable substrate chemistry and therefore the downstream 
development of a wider range of probes. Endogenous bacterial enzymes that catalyse 
potentially suitable reactions have been described as evidenced by in vitro terminal 
assays [18], but to date, very few have been exploited with substrates for in vivo 
imaging. Kong et. al [19] have elegantly demonstrated the potential for use of 
endogenous bacterial enzymes for in vivo imaging of Mycobacterium tuberculosis 
infection with a system that exploits the intrinsic β-lactamase activity of  M. 
tuberculosis to activate a β-lactam ring-containing fluorescent probe. However, 
expression of β-lactamases is confined to certain bacteria and the variety of β-
lactamases found in Gram-positive and Gram-negative bacteria (reviewed in [20]) 
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could make the production of a universally applicable probe for imaging of β-
lactamase activity a difficult task. Therefore, the need to develop an imaging system 
based on probe activation by a widely expressed, endogenous bacterial enzyme that 
is not produced by mammalian cells still exists. 
Nitroreductases are a family of bacterial enzymes that share the ability to 
reduce nitro functional groups and may be categorised as oxygen insensitive (type I) 
or oxygen sensitive (type II), and are widespread across the bacterial kingdom[21]. 
Nitroreductases are generally regarded as being unique to bacteria, (although have 
been described in species such as certain parasites), and therefore, their use for 
explicit reduction of NTR activatable drugs and imaging probes presents a highly 
viable method for targeted in vivo drug or probe activation. Isolation of NTR genes 
(in particular the E. coli nfsB gene) and engineering of gene delivery vectors 
(viruses) has permitted highly specific cancer therapeutic strategies–Gene Directed 
Enzyme Prodrug Therapy (GDEPT) [22]. In this context, NTR-based imaging 
probes have been under investigation as eukaryotic reporters [23] [24]. The cell 
permeable, quenched fluorophore CytoCy5S is a red-shifted cyanine fluorophore that 
is reduced to its fluorescent form by nitroreductase (NTR) enzymes. Recently, 
CytoCy5S has been demonstrated to be an effective reporter in eukaryotic settings, 
in the context of cancer cell lines and a virus engineered to express nfsB, and has 
been shown to be non-toxic to mammalian cells [25, 26]. We hypothesised that 
endogenous production of nitroreductases by bacteria might permit imaging of viable 
bacteria through reduction of CytoCy5S. By harnessing the intrinsic ability of 
bacteria to activate this near infra-red probe, the localisation of bacteria in vivo can 
be quickly and easily visualised by non-invasive optical imaging, and represents a 
novel in vivo bacterial imaging strategy, for a wide range of bacteria.  
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Materials and methods 
 
Bacterial strains. Bacterial cultures used for each experiment were in the late log 
growth phase unless otherwise stated. E. coli K-12 MG1655 containing the 
integrated p16SluxABCDE was grown aerobically at 37
o
C in LB medium containing 
300 µg ml
-1
 erythromycin (Em). The NTR KO strain, E. coli K-12 AB502NemA[27] 
and its parent strain AB1157 were a kind gift from Dr Antonio Valle (University of 
Cádiz, Cádiz, Spain) and were cultured at 37
o
C in LB medium supplemented with 20 
µg ml
-1
 streptomycin (AB1157) or 50 µg ml
-1
 Kanamycin (AB502NemA). 
Salmonella enterica Typhimurium UK-1 containing the integrated p16SluxABCDE 
cassette was cultured aerobically at 37
o
C in LB medium supplemented with 300 µg 
ml
-1
 Em. For anaerobic growth of Bifidobacterium breve and infantis 35624 and 
Clostridium difficile TL176 ribotype R014[28], bacteria were grown in static culture 
conditions in RCM medium (Oxoid) and in an anaerobic culture incubator (Don 
Whitley Scientific). Lactococcus lactis subspec. cremoris MG1363 was grown  at 
30°C in M17 medium (Oxoid) supplemented with 1% (w/v) glucose. Listeria 
monocytogenes EGD-e was cultured at 37
o
C in Brain Heart Infusion medium 
(Oxoid). For in vitro experiments wells contained 10
7
 bacteria unless otherwise 
stated. 
 
Detection of NfsB by western blotting. Bacteria in log growth phase were pelleted 
by centrifugation (3,000g for 15 min) and the pellets were frozen at -70
o
C overnight. 
Pellets were resuspended in lysis buffer (25mM Tris-Cl, 2mM EDTA, 15mg/mL
-1 
lysozyme) at 37
o
C for 1 h before being briefly sonicated on ice. A Bradford assay 
standard curve was used to determine the protein concentration of total cell lysates. 
Equal levels of total protein were loaded in each lane of the gel. Proteins were 
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separated using the Novex NuPAGE SDS-PAGE Gel System (Invitrogen) and 
electroblotted onto PDVF membranes. Membranes were blocked using Odyssey 
blocking buffer (LI-COR) and probed with a polyclonal antibody to NfsB diluted 
1:1000. Immune complexes were detected using an Odyssey infrared scanner (LI-
COR).  
 
Animals and tumour induction. 6-8 week old female BALB/c mice weighing 
approximately 18-20 grams were kept as previously described [29]. For tumour 
induction, a 200 µl suspension of 5 x 10
4
 4T1 cells in serum free Dulbecco‘s 
Modified Eagle‘s Medium (DMEM) culture medium or 2 x 105 CT26 cells were 
injected subcutaneously into the flank of BALB/c mice. The viability of inoculated 
cells was determined using the Nucleocounter system (ChemoMetec). Tumour 
growth was monitored twice weekly and mice were randomly assigned to groups 
when the tumours reached approximately 100 mm
3
 in volume as determined by 
caliper measurement. 
  
Ethics statement. All murine experiments were approved by the animal ethics 
committee of University College Cork (AERR #2010/003 and #2012/015). 
 
Bacterial administration to mice. Bacteria were grown overnight as described 
above. These bacteria were used to inoculate fresh growth medium containing the 
relevant antibiotic and allowed to grow until reaching OD600 0.6. Cultures were 
harvested by centrifugation (4000 x g for 10 min) and washed three times in 
phosphate buffered saline (PBS) before resuspension in one-tenth volume PBS. For 
tumour colonisation studies 10
6
 bacteria were injected via the lateral tail vein (E. 
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coli) 1 week before imaging [30] or intratumouraly (B.breve) 3 days before imaging . 
Mice used for intramuscular bacteria studies received a 50 µl injection of bacteria 
directly into the rear right or left quadriceps. These mice received 10
7
 bacteria via 
intramuscular injection unless otherwise stated. For infection studies with S. 
Typhimurium UK-1, mice were injected via the tail vein with 10
4
 bacteria and were 
monitored for progression of infection and localisation of bacteria within the liver 
and spleen before CytoCy5S administration. 
 
Bacterial recovery from mice. Following in vivo fluorescence imaging, tumours 
were resected aseptically and the tissue was homogenised by pushing through a 70 
µm pore nylon filter into sterile PBS. The resultant cell suspension was then plated 
on selective agar following serial dilution in sterile PBS. 
 
Preparation of CytoCy5S. The fluorogenic, red-shifted substrate CytoCy5S (GE 
Healthcare) (excitation 628 nm/emission 638 nm) was dissolved in dimethyl 
sulfoxide to prepare a 1 mg/ml stock solution that was further diluted in PBS to a 
final working concentration of 10 µg/ml. Mice were injected with 100 ng CytoCy5S 
in a volume of 200 μl before in vivo imaging unless otherwise stated. 
 
Image acquisition and formation. In vivo bioluminescence and fluorescence 
imaging was carried out using the IVIS100 or IVIS Lumina II system (Perkin 
Elmer). At defined timepoints following injection of CytoCy5S mice were imaged 
for bioluminescence and regions of interest were quantified using LivingImage 3.2 
or 4.3.1 software. For fluorescent image acquisition, mice were imaged for 
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excitation/emission 640 nm/660 nm. Representative images of mice show a 
randomly selected mouse from each group (minimum of n=3 in all cases). 
 
Effect of CytoCy5S on bacterial viability assay. E. coli K-12 MG1655 and E. coli 
K-12 AB502NemA were cultured aerobically and anaerobically overnight as 
described. Bacteria were then subcultured and divided into three groups (untreated, 
CytoCy5S treated and DMSO/PBS treated) in triplicate in fresh medium and grown 
until cultures reached OD600 of 0.2. At this point, the CytoCy5S treated group was 
administered 100 ng CytoCy5S in an injection volume of 200 μl. The DMSO/PBS 
group received equal quantities of the diluent without CytoCy5S. At hourly 
timepoints, all cultures were subjected to serial dilution before plating on selective 
agar to determine cfu/ml values. Cultures were also tested for changes in OD600 
readings as well as bioluminescence and fluorescence. 
 
Conversion of CytoCy5S by intracellular L. welshimeri. RAW 264.7 cells were 
grown in 6 well plates until a monolayer of cells was formed. Cells were washed 
twice in DMEM before incubation with L. welshimeri (suspended in DMEM) at a 
multiplicity of infection of 1000:1 for 2 hours. Cells and bacteria were coincubated 
at 37
o
C. Following coincubation, the media was removed and the monolayer was 
washed twice with DMEM. Media containing 1% pen/strep antibiotics was then 
added to each well to kill extracellular bacteria. This incubation step was allowed to 
proceed for 1.5 h before the cell monolayer was washed and trypsinised. The 
resultant cell suspension was transferred to 1.5 ml tubes before imaging for 
fluorescence. 
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Imaging of intramuscular bacteria using CytoCy5S as a fluorescent probe. 
BALB/c mice were anaesthetised and the fur on the rear limbs was removed. Mice 
were injected directly into the right quadriceps muscles at a depth of approximately 5 
mm with 50 µl of bacteria suspended in PBS. The number of bacteria injected ranged 
from 5 x 10
2
 to 5 x 10
7
. Mice also received an intramuscular injection of 50 µl sterile 
PBS in the left rear quadriceps. 1 h after bacterial injection, mice received an IP 
injection of 100 ng CytoCy5S. Mice were imaged for bioluminescence and 
fluorescence a regular intervals beginning immediately after probe injection. 
 
In vivo tracking of S. Typhimurium infection. BALB/c mice received an IV 
injection of 10
4
 luminescent Salmonella enterica Typhimurium UK-1 suspended in 
PBS. Progression of infection was tracked by BLI until bacteria were localised to the 
liver and spleen approximately 3 days post bacteria injection. Mice then received an 
IP injection of CytoCy5S followed by fluorescence imaging 90 min post probe 
injection. Mice were culled and the livers and spleens removed for ex vivo 
luminescence and fluorescence imaging before homogenisation of the tissue to allow 
for creation of a single cell suspension and plating on selective agar to determine the 
presence and number of bacteria in each of the resected organs. 
 
Non-invasive imaging of tumour colonising bacteria. BALB/c mice bearing 
subcutaneous 4T1 or CT26 flank tumours were injected with bacteria intravenously 
(E. coli) or intratumouraly (B. breve). Following tumour colonisation by bacteria (1 
week post injection for E. coli or 3 days post injection for B.breve) mice received an 
intraperitoneal injection of CytoCy5S and were imaged for fluorescence at regular 
timepoints thereafter. 
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Statistical analysis. All statistical analysis was carried out using GraphPad Prism® 
5.0. Statistical differences were determined using a Two-tailed Student‘s t-test, 
Mann Whitney test or Two-way ANOVA with Bonferroni post-test where 
applicable. Statistical significance was defined at the 5% level. 
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Results 
 
In vitro monitoring of CytoCy5S activation by bacteria 
 
Bacteria were incubated with 50 ng of CytoCy5S (per well) in vitro and were IVIS 
imaged for fluorescence. A fluorescent signal that exceeded autofluorescence was 
evident in wells containing E. coli MG1655 (MG1655), Salmonella enterica 
Typhimurium UK-1, Lactococcus lactis MG1363 and Listeria monocytogenes EGD-
e, Clostridium difficile and Bifidobacterium infantis 35624 immediately after probe 
addition (Figure 2). The signal increased over time and was maintained for over 2.5 
h.  
As can be seen in Figures 3a and 3b, the level of fluorescent signal obtained 
following probe incubation with bacteria is dependent on the number of bacteria per 
well as well as the concentration of CytoCy5S. CytoCy5S activation by MG1655 
bacteria reaches saturation at 50 ng/ml of the probe (Figure 3b). Macrophage 
engulfed L. welshimeri have also been shown (Figure 4) to be capable of probe 
activation in vitro. Fluorescence from CytoCy5S activated by RAW 264.7 engulfed 
L. welshimeri was seen to be significantly (Student‘s t-test, p<0.05) greater than 
autofluorescence from probe alone or from RAW 264.7 cells coincubated with 
CytoCy5S in the absence of bacteria. 
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Figure 1. Schematic representation of CytoCy5S reduction by bacterial 
nitroreductases. The cell permeable, quenched fluorophore, CytoCy5S, enters bacteria cells 
where nitroreductase enzymes reduce the probe. Reduction leads to unquenching and a 
fluorescent signal is emitted from the probe upon excitation with an appropriate laser. The 
fluorescent probe is cell trapped and accumulates within bacteria.  
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Figure 2. In vitro analysis of CytoCy5S activation by bacteria. Bar graph showing the 
change in fluorescence for a panel of bacteria 1 h post incubation with 50 ng/well 
CytoCy5S. Although a robust fluorescent signal is obtained following probe activation by all 
strains tested the level of activation varies between strains. No significant difference in 
fluorescence was observed between strains (p>0.05). The dotted red line represents 
fluorescence from probe in PBS and the dotted black line shows fluorescence from bacteria 
alone. n=3 in all cases. Error bars represent SD. 
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Figure 3. Determination of the effect of bacterial cell numbers and CytoCy5S 
concentration on in vitro fluorescence. a) Fluorescence from activated CytoCy5S increases 
with the number of E. coli MG1655 per well. The dotted line represents fluorescence from 
probe alone. b) Incubation of representative Gram-positive and Gram-negative bacteria with 
concentrations of CytoCy5S ranging from 10 ng/ml to 2 µg/ml. E. coli = MG1655, 
Lactococcus = lactis and Listeria = welshimeri. The dotted line represents fluorescence from 
probe alone. Error bars represent SD. n=3 in all cases. 
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Figure 4. In vitro CytoCy5S activation in by RAW 264.7 engulfed bacteria. RAW 264.7 
cell engulfed L.welshimeri are capable of activating CytoCy5S. Probe activation as 
determined by fluorescence is significantly greater than that seen when RAW 264.7 cells are 
coincubated with CytoCy5S in the absence of bacteria (p<0.05). n=3 in all cases. The dotted 
black line represents fluorescence from probe in PBS. Error bars represent standard 
deviation (SD).  
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NfsB nitroreductase activity is primarily responsible for CytoCy5S activation. 
 
Western blot analysis of NfsB expression levels in E. coli revealed that the protein is 
differentially expressed between strains (Figure 5a) . High levels of NfsB expression 
were observed in the E. coli AB1157 strain when compared with the NTR KO strain 
E. coli AB502NemA which is a derivative of AB1157 that has had nfsB knocked out 
as well as two of the other most enzymatically active E. coli nitroreductases (nfsA, 
nemA) [31, 32]. NfsB expression was rescued following transformation of bacteria 
with a plasmid expressing nfsB (Figure 5a). An increase in NfsB expression 
following pNfsB transformation was seen to correlate with an increase in 
fluorescence from bacteria incubated with CytoCy5S (Figure 5b). Although the 
fluorescent signal at 1 h from AB502NemA is significantly (P<0.001) less than 
AB1157 expressing the full NTR complement, a signal is still evident, indicating 
that multiple NTRs (other than NfsA, NfsB and NemA) are capable of CytoCy5S 
activation. 
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Figure 5. Analysis of NfsB expression levels in E. coli and the effect of nitroreductase 
gene knockout on CytoCy5S activation. a) Western blot of protein extracts from E. coli 
AB1157 and AB502NemA +/- pTrc NfsB probed with an anti-NfsB antibody. The band 
representing the NfsB protein is seen at 23.9 kDa. b) Graph showing the integrated 
intensities of bands from a western blot of protein extracts from E. coli AB1157 and 
AB502NemA +/- pTrc NfsB, probed with an anti-NfsB antibody (primary Y axis/bars). 
Fluorescence from live bacteria 1 h post incubation with CytoCy5S is represented on the 
secondary Y axis (red dots). Although the fluorescent signal from AB502NemA is 
significantly (P<0.0001, Student‘s t-test) less than AB1157 expressing the full NTR 
complement, a signal is still evident, indicating that multiple NTRs (other than NfsA, NfsB 
and NemA) are capable of CytoCy5S activation. Error bars represent SEM. 
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The effect of CytoCy5S on bacterial cell viability in vitro and in vivo. 
 
As can be seen in Figure 6, coincubation of the probe with bacteria in vitro for a 
period of 7.5 h did not significantly affect the viability of bacterial cells. Similarly, 
no significant toxicity to bacteria was observed in vivo (Figure 6b) where 
bioluminescence from muscle localised lux tagged bacteria was used as a readout for 
bacterial cell viability. The decrease in luminescence that occurred over 72 hours in 
the untreated group was mirrored by the CytoCy5S treated group. 
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Figure 6. Analysis of the effect of CytoCy5S on bacterial viability in vitro and in vivo. a) 
E. coli MG1655 bacterial cultures were coincubated with 500 ng ml
-1
 CytoCy5S at 37
o
C. At 
hourly timepoints aliquots from cultures (+/- CytoCy5S) were plated on selective agar and 
the resultant colony forming unit (cfu) counts were compared with untreated bacterial 
cultures. b) The effect of CytoCy5S on bacteria in vivo was assessed via correlation with 
luminescence from muscle bearing luminescent E. coli MG1655. Luminescence from 
infected muscle before injection of the fluorescent probe is represented as 100% (of bacteria 
in muscle) and changes in luminescence following probe injection are represented as a 
change in percentage. No significant difference (Student‘s t-test) in luminescence between 
mice that received CytoCy5S and mice that received PBS was observed at any timepoint 
tested. n=3 mice per group. Error bars represent SD for panel a and SEM for panel b.  
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Route of CytoCy5S administration for in vivo experiments. 
 
In order to determine the optimal route of probe administration, fluorescence from E. 
coli colonised 4T1 flank tumours was quantified following either intravenous (IV) or 
intraperitoneal (IP) injection of 100 ng CytoCy5S (Figure 7). Regions of interest 
(ROI) drawn around the tumours were used to determine the level of fluorescence 
from the tumour at various timepoints following CytoCy5S administration. Over the 
duration of the experiment there was no significant difference (p>0.05) between the 
IV and IP groups. With this in mind it was determined that IP probe administration, 
which resulted in the highest level of fluorescence at each timepoint tested, is the 
optimal route of administration. IP injection is not only technically much easier than 
IV but also allows for repeated injections on a single day as opposed to IV where 
repeated injection in the tail vein would prove extremely difficult. 
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Figure 7. Evaluation of intravenous versus intraperitoneal routes of administration of 
CytoCy5S for fluorescent imaging of tumour localised E. coli. BALB/c mice bearing 
subcutaneous 4T1 flank tumours were colonised by luminescent E. coli MG1655. Following 
tumour colonisation mice received a 100 ng injection of CytoCy5S either via IP or IV 
administration. Mice were imaged for fluorescence at regular intervals post probe 
administration. No significant difference in fluorescence was observed between IV and IP 
groups (p>0.05). n=3 for both groups. Pictures of mice shown below the graphs are 
randomly selected representative images for each group. Error bars represent SEM. The 
dotted blue line represents the average luminescence value from mice across the course of 
the experiment.  
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In vivo fluorescence from bacterial activated CytoCy5S reflects bacterial 
numbers 
 
The utility of CytoCy5S for in vivo bacterial imaging was examined in various 
mouse models. BALB/c mice were directly injected in the quadriceps with escalating 
numbers of E. coli MG1655 or PBS. Mice received 5x10
2 
,5x10
4
, 5x10
6
 or 5x10
7
 
bacteria before IP injection of 100 ng CytoCy5S. Use of lux-tagged bacterial cells 
permitted correlation with bacterial location, quantity and viability [29]. 
Luminescence imaging of mice showed that viable bacteria remained within the 
muscle tissue over time. The location of the fluorescent signal (corresponding to 
CytoCy5S) overlapped with the location of bacteria within the tissue as determined 
by luminescence (corresponding to lux luminescence from the same bacteria) (Figure 
8a). A bacterial dose response was evident, and while the level of fluorescence from 
muscle bearing 5x10
2
 and 5x10
4
 bacteria was below the detection limit, strong and 
sustained fluorescence was observed from muscle bearing 5x10
6
 and 5x10
7
 bacteria 
(Figure 8a). IP injection of CytoCy5S showed no significant improvement on 
bacteria mediated fluorescence over IV (Figure 7), and hence IP administration was 
utilised in subsequent experiments for logistical reasons.  
A probe dose response was also observed (Figure 8b). Fluorescence saturation in 
vivo was achieved at a probe dose of 100 ng and was maintained at equal levels to 
that measured from mice that received 150 ng of the probe at 24 h post probe 
injection. The fluorescent signal was maintained for over 72 h in mice that received 
5x10
7
 bacteria plus CytoCy5S, with a peak fluorescent signal at 1 h post probe 
injection (Figure 8c). Mice that received an intramuscular injection of PBS instead of 
bacteria showed no fluorescence or bioluminescence from the hind limbs. 
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Figure 8. E. coli-related CytoCy5S fluorescence in vivo. a) An increase in fluorescence 
from quadriceps muscle injected with E. coli MG1655 was seen to correlate with increasing 
numbers of luminescent bacteria injected into the muscle. BALB/c mice were injected with 
5x10
2
, 5x10
4
, 5x10
6
 or 5x10
7 
E. coli MG1655 in the right quadriceps and PBS in the left. 1 h 
post bacterial injection, mice received 100 ng CytoCy5S IP and were imaged for 
bioluminescence and for fluorescence. The dotted line represents autofluorescence from PBS 
injected limbs. Pictures of mice shown below the graphs are randomly selected 
representative images for each group. b) In vivo CytoCy5S dose escalation study showing 
the effect of CytoCy5S concentration on fluorescence from intramuscular bacteria. Mice 
received IP injections of 25 ng, 50 ng, 100 ng or 150 ng CytoCy5S. Fluorescence saturation 
from BALB/c mice bearing 5x10
6 
bacteria in the quadriceps was achieved at 100 ng 
CytoCy5S. The dotted line represents autofluorescence. c) Change in fluorescence from 
activated CytoCy5S within muscle localised E. coli MG1655 over time. A robust fluorescent 
signal exceeding autofluorescence was still evident at 72 h post probe injection. n=3 in all 
cases. Error bars represent SEM. 
98 
 
In vivo imaging of S. Typhimurium infection in mice 
 
BALB/c mice were infected with 1 x 10
4
 bioluminescent S. Typhimurium UK-1 by 
tail vein injection and progression of infection to a chronic stage was monitored 
using BLI. Mice were deemed to have established infection once BLI showed 
bacterial luminescence concentrated to the liver and spleen (approximately four days 
post IV bacterial administration). When mice reached this peak state of infection 
CytoCy5S was administered. Fluorescence imaging 90 min post probe injection 
showed a strong signal from livers (2.38 x 10
5
 p/sec/cm
2
/sr +/- 1.34 x 10
4
) and 
spleens (3.08 x 10
5
 p/sec/cm
2
/sr +/- 3.7 x 10
4
) which correlated with the location of 
bacteria within the mice as determined by BLI (Figure 9b). Following imaging, mice 
were culled and the livers, spleens and kidneys were removed (Figure 9c). Ex vivo 
luminescence and fluorescence imaging of the organs confirmed that infection was 
confined to the liver and spleen with no luminescence or fluorescence apparent from 
other organs. 
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Figure 9. In vivo imaging of Salmonella Typhimurium UK-1 infection. a) Metabolically 
active S. Typhimurium UK-1 cells are capable of reducing CytoCy5S to its fluorescent form 
in vitro. A significant (P<0.0001) increase in fluorescence signal from S. Typhimurium UK-
1 incubated in vitro with 50 ng CytoCy5S over autofluorescence from S. Typhimurium UK-
1 alone was observed. b) BALB/c mice were infected with 10
4
 S. Typhimurium UK-1 by tail 
vein injection. Use of lux-tagged bacteria permitted determination of the specific location of 
these bacteria within the host using BLI. Once established infection with S. Typhimurium 
UK-1 was confirmed by BLI, bacteria were tracked by fluorescence imaging of activated 
CytoCy5S 120 min post probe injection. The fluorescent signal produced following 
administration of 100 ng CytoCy5S colocalised with the luminescent signal from the 
bacteria. The pictures of mice in this panel are randomly selected representative images of 
infected mice. n=3 mice per group. c) Ex vivo BLI and FLI of the liver, spleen and kidneys 
(uninfected) of UK-1 infected mice shows that luminescence and fluorescence were 
localised to bacteria infected organs. 
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In vivo imaging of tumour targeting E. coli 
 
We have previously demonstrated high-level, specific bacterial growth within mouse 
tumour xenografts [29]. BALB/c mice bearing subcutaneous 4T1 xenograft tumours 
were IV administered 1 x 10
5
 E. coli MG1655 and allowed one week to permit 
colonisation of the tumours and clearing of bacteria from the rest of the body. 
Following tumour colonisation as evidenced by BLI, CytoCy5S was IP administered 
and mice imaged for fluorescence at a range of time-points. A strong tumour-specific 
fluorescent signal was maintained in probe-administered mice for up to 4 h (Figure 
10). Upon excision and dissection of tumours 8 h post probe injection, robust 
fluorescence from the tumour was still evident. Colocalisation of luminescence and 
fluorescence from the tumour confirmed that CytoCy5S activation was occurring 
specifically in the presence of bacteria. MG1655 colonisation of the tumour was 
further confirmed and quantified by plating of single cell suspensions from tumours 
on selective agar (data not shown). Mice bearing subcutaneous tumours that did not 
receive bacteria showed no fluorescence following IP injection of CytoCy5S. 
Similarly, mice that bore bacteria colonised tumours and did not receive any 
CytoCy5S showed no fluorescence. CytoCy5S can also be used to detect Gram-
positive bacteria in vivo. BALB/c mice bearing subcutaneous CT26 flank tumours 
received an intratumoural injection of B. breve. Three days post injection of bacteria, 
mice received an IP injection of CytoCy5S and were imaged for fluorescence 1.5 h 
later. As was seen with E. coli colonised tumours, probe activation was confined to 
the tumour site and no off target activation of the probe was observed. The 
fluorescent signal from the tumour following bacteria mediated probe activation was 
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significantly (p<0.01) greater than that seen in mice that did not have bacteria 
colonised tumours.  
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Figure 10 (part 1). In vivo imaging of E. coli colonised tumours. a) BALB/c mice bearing 
subcutaneous 4T1 flank tumours colonised with E. coli MG1655 or PBS show a tumour 
localised bioluminescent signal. Following IP injection of CytoCy5S, mice were imaged at 
various timepoints for fluorescence. A peak fluorescent signal was reached 45 min post 
CytoCy5S injection. Fluorescence from E. coli bearing mice that received CytoCy5S was 
maintained for over 120 min while no signal exceeding autofluorescence was evident in the 
PBS group. n=3 mice per group. Autoluminescence is represented as a dotted blue line on 
the graph and autofluorescence is shown as a dotted red line.  
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Figure 10 (part 2). In vivo imaging of E. coli colonised tumours. b) Ex vivo imaging of an 
E. coli colonised tumour from a mouse that received CytoCy5S. The dissected tumour 
maintained a strong fluorescent signal at 8 h post CytoCy5S injection c) BALB/c mice 
bearing subcutaneous CT26 flank tumours colonised with IT administered B. breve show a 
tumour localised fluorescent signal 1.5 h following IP administration of CytoCy5S. The 
level of fluorescence is significantly higher (p<0.01) than in mice that did not have bacteria 
colonised tumours (PBS group). n=3 mice per group. Pictures of mice shown below the 
graphs are randomly selected representative images for each group. Error bars represent 
SEM in (a) and (c).  
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Discussion. 
 
In this chapter, we describe a novel in vivo optical imaging system based on the 
exclusive activation of a fluorophore specific for bacterial nitroreductase enzymatic 
activity, to provide a highly targeted strategy for preclinical imaging of in vivo 
bacterial localisation is described. Natural levels of bacterial nitroreductases were 
shown to be capable of reducing the quenched fluorophore CytoCy5S to its 
fluorescent form in vitro in a range of bacteria, thereby demonstrating the versatility 
of the system for the non-invasive detection of metabolically active bacteria.  
Beyond the strategies necessitating genetic engineering of bacteria, only a 
small number of other strategies have been reported. In addition to studies by Kong 
et. al. and Leevy et. al., the maltodextrin-based system mentioned earlier and an ex 
vivo–labelling approach involving quantum dots (QD) have been described [33]. 
However, transiently labelled bacteria do not offer much by way of longitudinal 
monitoring due to dilution of the reporter. Furthermore, the QD system was 
restricted to certain Gram-negative species as a result of probe uptake issues. The 
probe-enzyme strategy outlined here is applicable to a broad range of Gram-negative 
and Gram-positive species, even traditionally poorly genetically tractable genera 
such as Clostridium and Bifidobacterium, while repeat in situ probe administration 
overcomes probe dilution, providing real-time read-out with a degree of quantitation. 
Fluorescence from activated CytoCy5S strongly correlated with the number of 
bacteria within the muscle and was seen to reduce over time in line with the 
reduction in luminescence observed from infected quadriceps. The considerable 
longevity of the fluorescent signal (72 h following IP injection of the probe) is most 
likely due to saturation of cells with CytoCy5S leading to steady and continual probe 
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activation as NTRs perpetually reduce single CytoCy5S molecules before becoming 
available for the activation of subsequent probe molecules. 
Two studies involving CytoCy5S have been published by other groups. The 
first report of this probe, by Bhaumik and colleagues [25], exploited CytoCy5S as a 
reporting system for cancer gene therapy based on NTR activation of a prodrug 
(GDEPT), with CytoCy5S facilitating imaging of the NTR-engineered viral vector in 
mouse xenograft experiments. A subsequent publication described the utility of 
CytoCy5S for imaging of mouse xenograft growth using cancer cells engineered to 
stably express NTR [26]. Both papers demonstrated the utility of this probe in mice 
in terms of high sensitivity, low background and lack of toxicity to mammalian cells, 
and were entirely focused on reporting transfected cancer cells. Of interest, Bhaumik 
et al. observed that when a 10 x dose of probe was administered, fluorescence was 
evident from the abdominal region after 48 h. The authors proposed that this may be 
due to non-specific background signal due to NTR activity from E. coli and some 
other gut species, which might interfere with their desired imaging of transduced 
tumour cells, but that could be reduced by antibiotic administration.  
The work described in this chapter is the first to demonstrate the potential for 
this probe as a specific bacterial imaging agent. This strategy proved to be 
exquisitely specific to bacterial cells, with no increase in organ fluorescence upon 
administration of probe to untreated mice. For example, in tumour experiments, 
tumours that did not harbour bacteria did not show a fluorescent signal, while 
activated CytoCy5S within infected mouse liver and spleen was readily observed 
with no off-site probe activation in uninfected organs. The reduction in fluorescence 
that resulted from the co-incubation of the NTR KO strain with CytoCy5S validates 
the specificity of this probe to nitroreductase activity, while demonstrating that a 
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broad range of relevant enzymes capable of its activation are present within a single 
strain. In the presence of the full complement of bacterial nitroreductases a robust 
and sustained fluorescent signal can be obtained and longitudinal fluorescence 
imaging can be carried out for up to 7.5 h post single administration. 
 The pursuit of highly targeted in vivo imaging strategies is an aim that unites 
a number of research fields. The application of this imaging strategy to the non-
invasive detection of Salmonella infection in vivo represents an important addition to 
the current state of the art imaging systems. In vitro validation of functionality with 
other infectious disease-related agents such as L. monocytogenes, E. coli and C. 
difficile indicates applicability to in vivo monitoring of a wide range of infectious 
diseases in internal organs. Since common GIT commensal genera such as 
Bifidobacterium and E. coli also proved to activate the probe, this strategy can add 
value to other research fields involving microbiome research, probiotics etc. The 
ability of systemically circulating bacteria to specifically home to and grow within 
solid tumours to high numbers provided for the tumour localised production of NTR. 
Through the utilisation of this tumour-targeting phenomenon, it was possible to 
achieve highly targeted CytoCy5S activation specifically within the tumour site. 
Activation of CytoCy5S within the tumours also permitted non-invasive 
visualisation of the tumour. All current tumour imaging and therapy strategies strive 
to achieve high levels of specificity for tumours while avoiding healthy tissue. The 
tumour specific replication of systemically administered bacteria is a phenomenon 
common to all bacteria tested to date [34-40]. This capacity for tumour targeting 
makes bacteria ideal vectors for the delivery of genes, proteins or therapeutic 
payloads to the tumour microenvironment and the ability to image ‗bacterial 
therapeutics‘ is of high value. Furthermore, this system could also be used as a 
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reporter for tracking conversion of NTR activated prodrugs such as CB1954 to 
analyse the therapeutic efficacy of treatment with these prodrugs [41]. 
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Chapter 3: Development of a novel, 
nitroreductase activated, luminescent 
probe 
 
Sections from this chapter have been published as 
Vorobyeva, A. G., Stanton, M., Godinat, A., Lund, K. B., Karateev, G. G., Francis, 
K. P., ... & Dubikovskaya, E. A. (2015). Development of a bioluminescent 
nitroreductase probe for preclinical imaging. PloS one, 10(6). 
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Abstract 
 
Bacterial nitroreductases (NTRs) have been widely utilised in the development of 
novel antibiotics, degradation of pollutants, and gene-directed enzyme prodrug 
therapy (GDEPT) of cancer that reached clinical trials. In the case of GDEPT, since 
NTR is not naturally present in mammalian cells, the prodrug is activated selectively 
in NTR-transformed cancer cells, allowing high efficiency treatment of tumours. 
Currently, no bioluminescent probes exist for sensitive, non-invasive imaging of 
NTR expression. We therefore developed a "NTR caged luciferin" (NCL) probe that 
is selectively reduced by NTR, producing light proportional to the NTR activity. 
Here we report successful application of this probe for imaging of NTR in vitro, in 
bacteria and cancer cells, as well as in vivo in mouse models of bacterial infection 
and cancer. This novel tool should significantly accelerate the development of cancer 
therapy approaches based on GDEPT and other fields where NTR expression is 
important. 
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Study Aim 
 
The aim of this chapter was to characterise and develop a novel caged luciferin probe 
(NCL) for use in the in vivo detection of nitroreductase expressing bacteria. The 
probe was synthesised and designed by a collaborating lab in the EPFL at our 
request. This probe differs from CytoCy5S (Chapter 2) in that it is a luminescent 
probe, and while requiring genetic modification of the bacterium, bioluminescence 
typically offers increased sensitivity over fluorescence. This work aimed to 
determine the suitability of the probe for application to detection of bacterial 
infection and the localisation of bacteria in a live host.  
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Introduction. 
 
The nitroreductase (NTR) family of enzymes are widespread amongst bacteria and 
are known to metabolize nitrosubstituted compounds and quinones using NADH or 
NADPH as reducing agents [1-4]. They are important for the development of novel 
antibiotics being the main target for the treatment of infections caused by bacteria, 
e.g. Mycobacterium tuberculosis [5], Helicobacter pylori [6] and by parasites, e.g. 
Trypanosoma [7], Giardia and Entamoeba [8]. Their enzymatic activity in gut 
microbiota is linked to carcinogen production and etiology of colorectal cancer [9, 
10]. In addition, they are used in biotechnology for degradation of environmental 
contaminants [1]. Due to their absence in mammalian cells they are also utilized as 
activating enzymes in gene-directed enzyme prodrug therapy (GDEPT) approaches 
for cancer chemotherapy [11] where the NTR gene is used to selectively transform 
cancer cells, providing unique targeted therapy of tumours over normal tissues [12]. 
The nitroaromatic prodrug CB1954, in conjunction with bacterial NTR, is promising 
for GDEPT and has reached clinical trials for prostate cancer [13]. Following the 
recent first approval in Europe of a gene therapy medicine, the potential for clinical 
application of GDEPT is increasing [14]. However, both preclinical and clinical 
development of NTR-based GDEPT systems has been severely hampered by the lack 
of imaging tools that allow sensitive in vivo evaluation of transgene expression in 
living subjects. Quantification of the level of transgene expression is extremely 
important because it is directly linked to the effectiveness of the therapy. 
Bioluminescence (BL) is currently the most sensitive optical in vivo imaging 
modality available, and has been applied to visualize multiple biological processes in 
small animals [15, 16]. It obviates most of the limitations of in vivo fluorescent 
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imaging [17], such as high tissue-derived autofluorescence, photobleaching, limited 
tissue penetration and lack of quantification. Several activatable fluorescent probes 
for NTR imaging in vitro have been previously described [18-22]. However, the only 
reported probe (CytoCy5S) for imaging of NTR in vivo relies on fluorescence 
(CytoCy5S) [23-25] and therefore possesses the limitations mentioned above. 
Similar to bioluminescent imaging, in vivo chemiluminescent imaging offers the 
advantages of high sensitivity due to low background and high signal-to-noise ratios. 
Prior studies have elegantly demonstrated the application of chemiluminescence for 
imaging of myeloperoxidase activity [26] and beta-galactosidase activity [27] in 
vivo. However, although chemiluminescence has the additional advantage of not 
requiring luciferase transfected cells for the generation of light, expression of this 
enzyme allows more elaborate disease models to be developed due to the 
researcher‘s ability to define its spatial localization and regulation. Moreover, most 
chemiluminescent agents suffer from low quantum yield, short maximal photon 
wavelength emission and high instability. For example, the quantum yield of 
aqueous luminol chemiluminescence is 1.23 ± 0.20% [28] with a maximal emission 
of 424 nm [29], while the reported quantum yield of firefly BL is 41.0 ± 7.4% [30], 
that is about 40 times higher, with D-hydroxyluciferin and D-aminoluciferin having 
wavelength at 560 nm and 603 nm respectively [31]. Recently, Zhang et al. [32] 
showed the advantage of using both near-infrared fluorescent and chemiluminescent 
imaging in combination, while addressing the wavelength issue associated with 
luminol chemiluminescence in vivo by shifting it into the near-infrared region 
utilising quantum dots. BL is based on the interaction of a small molecule D-
luciferin with firefly luciferase that results in the generation of photons of light. The 
system can be "tuned" through "caging" of the luciferin scaffold to image and 
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quantify activities of biological molecules. Target-mediated selective removal of the 
caging moiety leads to production of free D-luciferin and subsequent generation of 
photons by luciferase, that can be quantified [33]. While this strategy was previously 
used by us and others to study biological processes (delivery and biodistribution of 
cell penetrating peptide conjugates [34], cell surface glycosylation [35], hydrogen 
peroxide fluxes [36], fatty acids uptake [37]) and image enzyme activity (beta-
galactosidase [38], caspases [39-41], furin [42] and beta-lactamase [43], no 
bioluminescent probes have been previously reported for imaging of NTR. Here, we 
describe the development of novel NTR-specific bioluminescent probe, termed 
Nitroreductase Caged Luciferin (NCL). Our results demonstrate that this probe can 
be used for non-invasive real-time imaging of NTR activity in vitro, in live bacteria 
and mammalian cells, as well as in preclinical models of cancer and bacterial 
infection. 
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Materials and Methods  
 
Chemical materials and synthesis. The synthetic procedures and characterisation are 
detailed in [44] 
Kinetics of NCL reaction with NTR by fluorescence. Fluorescence was measured 
using a Tecan Infinite M1000 (Tecan Austria GmbH) plate reader. Kinetic 
measurements of NCL (5–50 μM) uncaging by NTR (0.25 μg ml-1) were performed 
in the presence of NADH (500 μM) at 37°C in PBS buffer (pH 7.4). The kinetics rate 
of luciferin release from NCL was measured by fluorescence at 330 nm excitation 
and 530 nm emission wavelengths. The fluorescence calibration curve for luciferin 
was used to calculate the rate. Kinetic parameters Km and Vmax were determined 
from Michaelis-Menten model and Lineweaver-Burk plot was used to display the 
data. The kcat value was calculated by dividing the Vmax value, obtained from the 
data acquired for the determination of the corresponding Km values for the probe, by 
the concentration of the nitroreductase in the assay. 
Bioluminescent imaging of NTR with NCL in enzyme assay. In vitro imaging 
studies were performed in clear bottom black 96 well plates from Becton Dickinson 
and Company. An IVIS Spectrum (PerkinElmer) was used to measure the amount of 
bioluminescent imaging (BLI) signal production. The data are presented as 
pseudocolour images indicating light intensity (red being the most intense and blue 
the least intense), which are superimposed over the grayscale reference photographs. 
Bioluminescence was quantified using region of interest (ROI) analysis of individual 
wells and the average signal expressed as the total number of photons emitted per 
second per cm
2
 per steradian (p/sec/cm
2
/sr) from each of the three wells was 
calculated by using the Living Image software. Total luminescence was calculated 
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by integrating the area under corresponding kinetic curves. Luciferase buffer was 
prepared as following: 2 mM ATP, 5 mM MgSO4 in PBS (pH 7.4). Stock solutions 
of luciferase in luciferase buffer, NADH, NCL, luciferin and NTR in PBS (pH 7.4), 
were freshly prepared and aliquoted in a 96-well plate to give the following final 
concentrations in the total volume of 100 μl/well: luciferase (60 μg ml-1), NADH 
(100 μM), NTR (10 μg ml-1), luciferin or NCL (0.25–5 μM); luciferin and NCL were 
added at the last step with a multichannel pipette from the additional 96-well plate. 
Bioluminescence signal from the plate was acquired immediately every 1 min with 
0.5 s integration time for 30 min. 
Bacterial strains, plasmids and culture conditions. E. coli K-12 MG1655 (- luc 
gene) and E. coli K-12 AB1157, containing the luciferase expressing pUC57 Click 
beetle red (CBR) plasmid (+ luc gene) was a kind gift from Daniel Ansaldi (Perkin 
Elmer). The NTR triple mutant, E. coli K-12 AB502NemA, was a kind gift from Dr 
Antonio Valle (University of Cádiz, Cádiz, Spain) and was transformed with the 
pUC57 CBR plasmid for production of luciferase. E. coli MG1655 lux, expressing 
lux luciferase, was generated as previously described [45]. All strains were grown 
aerobically at 37°C in Luria Bertani (LB) medium supplemented with 100 μg ml-1 
ampicillin (Amp). 
Bioluminescent imaging of NTR activity by NCL in E. coli. An IVIS-100 
(PerkinElmer) was used to measure the amount of BLI signal production. Stock 
solutions of luciferin and NCL in PBS (pH 7.4) were freshly prepared and aliquoted 
in a 96-well plate to give the final concentrations (1–250 μM) in the total volume of 
200 μl/well. The volume of bacterial suspension was 150 μl/well. Bioluminescence 
signal from the plate was acquired immediately every 2 min with 10 s integration 
time for 1 h. 
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Bioluminescent imaging of bacteria reduced NCL in a luciferase producing 
cancer cell line. 4T1 or 4T1 rluc cells were plated at a density 5 × 10
4
 cells/well in 
two 6-well plates for 24 h. A culture of E. coli AB1157 that contained 100 µM NCL 
was incubated at 37
o
C for 1 h to allow sufficient time for reduction of the probe to 
occur before centrifugation and removal of the supernatant. The bacterial supernatant 
was then filter sterilised before addition of 500 µl to appropriate wells containing 
either 4T1 or 4T1 rluc cells. Control wells were treated with supernatant from an E. 
coli culture that did not contain NCL. Plates were imaged using the IVIS Lumina at 
regular timepoints for a total of 2 h. The observed BLI signal was quantified using 
ROI analysis with Living Image software. 
Ethics statement. All animal procedures were performed in accordance with the 
national ethical guidelines prescribed by the Health Products Regulatory Authority 
(HPRA). Protocols were approved by the animal ethics committee of University 
College Cork (AERR #2010/003 and #2012/015). All efforts were made to minimise 
suffering. 
Bacterial administration and imaging of bacterial nitroreductase in mice. Bacteria 
were grown at 37°C in a shaking incubator until reaching OD600 of 0.6 in LB 
medium, containing 100 μg/ml Amp. Cultures were harvested by centrifugation 
(4000 × g for 10 min) and washed three times in PBS. After washing, bacteria were 
resuspended in one tenth volume of PBS. Mice were kept at a constant room 
temperature (22°C) in a conventional animal colony. Standard laboratory food and 
water were provided ad libitum. Mice were afforded an adaptation period of at least 
4 days before the beginning of experiments. Female BALB/c mice (Harlan, 
Oxfordshire, UK) in good condition, without infections, weighing 18–22 g and 6–8 
weeks old, were kept as previously described [46] and were included in experiments. 
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BALB/c mice were anaesthetized and the fur on the rear legs was removed. Mice 
were injected directly into the right quadriceps muscle at a depth of approximately 5 
mm with 50 μl of bacteria suspended in PBS. The concentration of bacterial 
suspensions used for injection ranged from 10
6
 to 10
9
 bacteria/ml. Mice also 
received an intramuscular injection of 50 μl sterile PBS in the left rear quadriceps 
(control) and E. coli lux MG1655 (positive control). 1 h post bacterial injection, mice 
received an IP injection of 200 μl of 10 mM NCL probe (0.8 mg) or 200 μl of 10 
mM D-luciferin potassium salt (0.63 mg) in PBS. For in vivo experiments involving 
varying concentrations of the probe, the concentration of NCL probe injected was 
200 μl of 1, 10 or 20 mM solutions in PBS (0.08, 0.8 or 1.6 mg of NCL probe). Mice 
were imaged for bioluminescence at regular intervals beginning immediately after 
probe injection using IVIS 100. Mice that were infected with bacteria for 
experimental purposes were monitored for signs of illness for the duration of the 
experiment. No adverse symptoms were reported. Following bioluminescence 
imaging, or at experiment end, animals were euthanized by cervical dislocation. 
Mice and tumour induction. As described in Chapter 2. 
Imaging of nitroreductase in a mouse model of subcutaneous cancer. 6-8 week old 
BALB/c mice bearing subcutaneous 4T1luc+/- flank tumours were IV injected with 
E. coli MG1655 (lux +/-). Once tumour colonisation had occurred (approx. 1 week 
post bacterial injection) as determined by luminescence imaging of mice that 
received luminescent E. coli, mice were injected IP with NCL or D-luciferin. Mice 
were imaged for luminescence 4 h post probe administration and the level of 
luminescence was quantified using ROI drawn around the tumour site. 
Statistical analysis. As detailed in Chapter 2.  
122 
 
Results 
Probe design 
 
The reduction of nitroaromatic compounds can occur through one- or two-electron 
mechanism [1]. Two types of bacterial NTRs have been described and they are 
classified according to the oxygen dependence. The NTRs used in our study (NfsA, 
NfsB) are type I oxygen-insensitive NTRs, they catalyse the reduction of the nitro 
group by addition of a pair of electrons, and their activity does not depend on the 
level of oxygen. However, the oxygen-sensitive NTRs (type II) catalyse the 
reduction of the nitro group by the addition of one electron, forming the nitro anion 
radical, which is oxidized back to the nitro group by oxygen. Bacteria contain both 
types of nitroreductases with type I being the most characterized among other NTRs. 
The independence of reduction from the level of oxygen in E. coli had been 
previously demonstrated for an NTR-sensitive coumarin probe (7-nitrocoumarin-3-
carboxylic acid) suggesting the prevalent involvement of type I NfsA and NfsB 
possibly along with other uncharacterized NTRs [47]. The design and synthesis of 
the NCL probe was carried out by Anzhelika Vorobyeva at the Ecole Polytechnique 
Federale de Lausanne. 
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Figure 1. General strategy for imaging of NTR activity with Nitroreductase Caged 
Luciferin (NCL) probe. NCL is a luminescent probe composed of D-luciferin attached to a 
nitrofuryl moiety that acts as a chemical ―cage‖. Reduction of the nitrofuryl nitro group by 
NTR promotes the cleavage of the C-O bond (uncaging) leading to the subsequent release of 
luciferin. This free luciferin is oxidised by luciferase to emit a photon of light.  
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The suitability of exploiting NTR activity as a means to selectively distinguish 
bacterial cells from host background has previously been demonstrated [48]. Several 
NTR-related enzymes have been identified in mammalian cells and they functionally 
relate to type I NTRs (NAD(P)H-quinone oxidoreductase (DT-diaphorase EC 
1.6.99.2) and xanthine dehydrogenase EC 1.17.1.4). They can potentially contribute 
to reduction of nitroaromatics, although they are not phylogenetically related and do 
not exhibit the typical domain characteristic of NTR family. These properties were 
investigated in the study on FMISO imaging reagent, a derivative of nitroimidazole 
used as a hypoxia PET tracer [49]. It was reported that under hypoxic conditions 
xanthine dehydrogenase is converted to xanthine oxidase that reduces FMISO and 
other nitroimidazole-containing compounds. Similarly, eukaryotic NTRs that are 
functionally related to type II (aldehyde oxidase EC 1.2.3.1, cytochrome c oxidase 
EC 1.9.3.1, and NADPH cytochrome P450 reductase EC 1.6.2.4) can potentially 
reduce nitroaromatics anaerobically and are generally used as targets for hypoxia-
activated prodrugs and imaging agents [50]. Therefore, several important factors 
need to be taken into account when designing the compounds activated selectively 
by bacterial or mammalian enzymes. For bacterial NTRs the activation is largely 
dependent on the redox potential of the nitroaromatics. For example, nitrofurans 
display relatively high redox potentials (reported from -250 to -270 mV) and are 
reductively activated by NAD(P)H nitroreductases of enteric bacteria. At the same 
time metronidazole (nitroimidazole) is only activated by anaerobic enzymes showing 
low redox potentials (-480 mV) in some bacteria and protozoa, making it well 
tolerated in humans when used as an antibiotic [51]. Substrate specificity of the 
designed compounds is also important, for example CB1954 prodrug is efficiently 
reduced by bacterial NTRs and a human DT-diaphorase (NQO2) while being a poor 
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substrate for a human paralogue NQO1 enzyme [52]. These and other important 
aspects of selectivity of bioreductive prodrugs are discussed in more details in a 
recent review by Wilson and Hay [53]. The overall probe design is based on caging 
of D-luciferin with nitrofuryl moiety resulting in "Nitroreductase Caged Luciferin" 
(NCL) probe (Figure 1). 5-Nitrofuryl was selected as a cage as its derivatives 
(nitrofurazone, nitrofurantoin) were shown to be efficiently activated by NTR in 
bacteria [51]. Upon the reduction of the nitro group by NTR the resulting electron-
donating amino group promotes the cleavage of the C-O bond (uncaging), leading to 
the subsequent release of luciferin which is oxidized by luciferase and a photon of 
light is emitted. Therefore, release of free luciferin followed by light production is 
only possible in the presence of NTR. 
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Bioreductive activation of NCL in cell-free assays 
 
The specificity of probe uncaging by incubating NCL with a recombinant NTR 
enzyme from E. coli (NfsA) in the presence of NADH as a cofactor was investigated. 
The resulting data demonstrate rapid conversion of NCL into free luciferin under 
these conditions, the calculated values of rate constant and NCL half-life, were 5.8 × 
10
-3
 s and 119.5 s respectively (data not shown). Next, the Michaelis-Menten kinetic 
parameters for the NTR-specific cleavage of NCL probe was determined using 
fluorescence to monitor release of luciferin (λex/em = 330/530 nm) as the caged probe 
is not fluorescent. Both Vmax and Km values were found to be comparable to those 
previously reported for a NTR fluorescent substrate [20] and were determined to be 
0.057 μM s-1 and 24.7 μM respectively. Catalytic efficiency of probe reduction by 
NTR (kcat/ Km) was determined to be 2.25 × 10
7
 M
-1
 s, which is two orders higher 
than that of luciferin-luciferase reaction (1.07 × 10
5
 M
-1
 s) [54]. To evaluate if the 
probe can be used as a reporter of NTR activity, the effect of the NTR inhibitor 
dicoumarol (competitive with NADH) on the efficiency of NCL uncaging was 
investigated. A gradual concentration-dependent decrease in signal was observed 
(Figure 2a) indicating that the uncaging of NCL depends on the activity of NTR. The 
quantitative capability of the probe against the amount of NTR was assayed by 
fluorescence (λ330/530) and it was found that the detection limit was 0.15 μg/ml. To 
determine the utility of NCL as a bioluminescent reporter, the light emission from 
increasing concentrations of NCL (0.25–5 μM) in the presence or absence of NTR 
and firefly luciferase was measured (Figure 2b). The resulting signal was 
concentration-dependent and no significant light was produced in the absence of 
NTR, resulting in high signal to background noise ratios even at relatively low 
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concentrations of the probe in comparison to that previously reported [36,42]. In 
addition, NCL demonstrated an average 70% conversion into luciferin, the highest 
uncaging efficiency among existing caged luciferin substrates reported to date 
[36,42].  
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Figure 2. Evaluation of NTR-specific uncaging of NCL probe. a) NCL (20 µM) uncaging 
by NTR (0.5 µg/ml) in the presence of NADH (100 µM) was inhibited by dicoumarol (0 to 
200 µM). b) Total luminescence over 30 min from luciferin or NCL (0.25-5 µM) with 
NADH, luciferase, and NTR, compared with the control (no NTR), *p < 0.001.  
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Imaging of NTR activity in E. coli 
 
The validation of NCL in a live biological system was initially approached by 
utilising bacteria as a source of both NTR and luciferase and comparing the level of 
luminescence obtained using this novel system with the luminescent signal acquired 
when the established D-luciferin system was used as a positive control (Figure 3). 
The potential of NCL probe for imaging NTR in E. coli naturally expressing NTR 
[2–4] and engineered to express luciferase was also investigated. The resulting signal 
from NCL or luciferin control was compared between several E. coli strains: E. coli 
engineered to stably express luciferase (E. coli CBR) and a strain of E. coli (NTR 
KO luc+) with three well-described NTR genes knocked out (NfsA, NfsB and 
NemA). Addition of NCL to E. coli CBR (E. coli luc+) resulted in probe reduction 
and the subsequent production of an imageable luminescent signal that exceeded 
background luminescence from E. coli CBR in the absence of NCL. When compared 
with luminescence from NCL treated, NTR KO E. coli a significant (p<0.05) 
decrease in luminescence was observed. This demonstrates that E. coli NTRs are 
responsible for probe uncaging as the reduced NTR activity of the NTR triple KO 
strain was less capable of probe reduction to liberate free luciferin. As was expected 
based on the in vitro data shown in Figure 3, probe uncaging by E. coli did not result 
in the production of a signal commensurate with that seen with E. coli CBR + D-
luciferin.  
The data presented in Figure 4a show a significant signal above background 
was detected from E. coli luc+ in comparison with E. coli wt, indicating the need for 
luciferase presence for light production. Both wt and NTR KO luc+ strains showed 
similar levels of luciferase expression when treated with luciferin. However, with 
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NCL the signal from the parent strain was significantly higher than from the NTR 
mutant strain (NTR KO luc+), demonstrating probe selectivity for detection of NTR 
activity in bacteria. The presence of a signal in wells with NTR KO luc+ strain 
indicates that reduction of the nitrofuryl cage is not exclusive or specific to any of 
the three major E. coli NTRs (NfsA, NfsB and NemA) and that cage reduction can 
be achieved at detectable levels in the presence of the remaining NTRs in E. coli. In 
E. coli, several nitroreductases (NfsA [2], NfsB [3], YdjA [4]) and reductases 
(NemA [55]) are characterized, while the exact functions of other reductase proteins 
remain unclear. Recent studies [4] indicate that E. coli reductases could also have 
additional nitroreductase activity. The signal dependence on different numbers of 
bacteria was also investigated and significant signals were evident at concentrations 
of bacteria as low as 10
4
 cells/ml (1.5 × 10
3
 cells/well) (Figure 4c). The average 
efficiency of probe uncaging in bacteria was calculated to be 35% (Figure 4d). 
  
131 
 
 
Figure 3. Comparison of total luminescence from E. coli CBR incubated with D-
luciferin or NCL. Total luminescence acquired over 4 h was compared between E. coli 
incubated with either D-luciferin or NCL. A high level of luminescence was recorded from 
wells containing E. coli + NCL (8.8 x 10
5
 (p/sec/cm2/sr)) which is comparable with that 
recorded from wells containing E. coli + D-luciferin (4.7 x 10
6
 (p/sec/cm2/sr)). 
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Figure 4. Light production in E. coli by NTR-mediated uncaging of NCL. a) Light 
output from NCL (300 μM) after 2 h incubation in luciferase-expressing E. coli (+ luc gene) 
is significantly higher than in NTR mutant (NTR KO luc+) (*p < 0.001) and in wild type (- 
luc gene). The dashed line indicates the background. b) Overlay of a photographic image 
and bioluminescence from the assay described. c) Bioluminescence from 100 μM NCL 
probe and luciferin incubated with various concentrations of luciferase expressing E. coli 
AB1157 (10
2
 –108 bacteria/ml) for 10 min before imaging. d) Bioluminescence from 
luciferase expressing E. coli luc+ (10
8
 bacteria/ml) incubated with various concentrations of 
NCL or luciferin (1–250 μM) for 10 min before imaging. Error bars represent SD in all 
cases.  
133 
 
Effect of NCL on bacteria cell viability 
 
The effect of the NCL probe on the growth and the viability of bacteria in vitro was 
tested by comparing CFU from cultures that were grown in the presence of NCL 
with cultures grown in the absence of the probe. A fresh E. coli culture grown with 
100 µM NCL did not show any significant difference in the number of CFU over a 4 
h time-course when compared with bacteria grown in the absence of the probe 
(Figure 5). This result demonstrates that NCL does not affect the growth or viability 
of E. coli in vitro at the concentration tested. 
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Figure 5. NCL does not affect the viability of E. coli in vitro. E. coli AB1157 CBR were 
incubated with 100 uM NCL and cultured at 37
o
C for 4 h. Aliquots of the bacterial culture 
were taken every hour and plated on selective agar overnight. No significant difference 
(p>0.05) in CFU counts between NCL treated and untreated bacteria was observed. Error 
bars represent SD. n=3. 
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In vitro light production from bacteria activated NCL with 4T1 cells as the 
source of luciferase 
 
In vitro incubation of NCL in the presence of wt E. coli AB1157 and luciferase 
producing 4T1 murine breast cancer cells (4T1 luc) resulted in the production of 
light. Following NCL reduction by bacterial nitroreductases, free luciferin entered 
4T1 cells where cell produced luciferase was available for completion of the 
luciferase-luciferin reaction and production of light. Luminescence from wells 
containing NCL, bacteria and 4T1 luc cells was detected using the IVIS Lumina and 
the intensity of light produced was quantified. Luminescence was measured 2 h post 
incubation with NCL (or PBS) and was determined to be significantly greater 
(p=0.048) than luminescence from wells that contained wild type 4T1 cells and 
luciferase producing (CBR+) E. coli in the presence of NCL. The luminescence 
signal from samples that contained the luc+ cancer cells, bacteria and NCL was 
determined to be 220% greater than wild type 4T1 cancer cells plus CBR+ bacteria 
and NCL 2 h post probe incubation (3.06 x 10
6
 vs 1.39 x 10
6
 p/sec/cm
2
/sr) (Figure 
6). 
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Figure 6. In vitro light production from bacteria activated NCL with cancer cells as the 
source of luciferase. a) An increase in luminescence was observed in vitro when luc+ 
cancer cells were incubated with bacteria activated NCL. 10 min post NCL incubation, 
luminescence from these wells was observed to be significantly greater (p<0.05) than from 
wells containing wild type 4T1 cells. b) Light production from uncaged NCL with either 
cancer cells or bacterial cells as the source of luciferase. Luminescence readings taken from 
wells containing NCL and 4T1 cells +/- luc and E coli +/- CBR 2 h post incubation with 
NCL. 
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Route of NCL administration for in vivo experiments 
 
In order to determine the optimal route of NCL administration to BALB/c mice, 
luminescence from E. coli infected quadriceps muscles was quantified following 
either intravenous (IV) or intraperitoneal (IP) injection of 20 mM NCL (Figure 7). 
Regions of interest drawn around the mouse hind legs were used to determine the 
level of luminescence from the infected muscle at various timepoints following NCL 
administration. Over the duration of the experiment there was no significant 
difference (p>0.05) between the IV and IP groups. With consideration to this result it 
was decided to proceed with IP probe administration. IP injection presents a 
technically more simple method of probe injection than IV and also facilitates 
repeated probe injection in a single day, if necessary, which is in contrast to IV 
injection where repeated injection into the lateral tail vein is unfeasible. 
Luminescence from NCL outlasts D-luciferin in vivo. 
 
BALB/c were injected with 5 x 10
7
 E. coli CBR and IP injected with either NCl or 
D-luciferin. Mice were imaged from luminescence from infected muscle for 48 h and 
the level of signal acquired was compared between the two groups. In keeping with 
the in vitro data, luminescence from D-luciferin injected mice exceeded NCL over 
the first 4 h. However, the difference in luminescence was not significant. When the 
luminescent signal was tracked over the course of 48 h, mice that received NCL 
were shown to maintain a luminescent signal that exceeded background (uninfected 
muscle) while luminescence from limbs containing bacteria and D-luciferin returned 
to background levels after less than 18 h (Figure 8). 
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Figure 7. Evaluation of intravenous versus intraperitoneal routes of administration of 
NCL for luminescent imaging of E. coli infected quadriceps. BALB/c mice were injected 
with 10
7
 E. coli in the quadriceps. Following muscle infection mice received a 20 mM 
injection of NCL either via IP or IV administration. Mice were imaged for luminescence at 
regular intervals post probe administration. No significant difference in fluorescence was 
observed between IV and IP groups (p>0.05). n=4 for both groups. Pictures of mice shown 
below the graphs are randomly selected representative images for each group. Error bars 
represent SEM. The dotted black line represents the average luminescence value from 
uninfected limbs. 
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Figure 8. Duration of luminescence from NCL and D-luciferin. Luminescence from 
infected muscle is maintained for longer following NCL injection than following D-
luciferin. BALB/c mice with E. coli infected quadriceps were injected with either NCL or 
D-luciferin and tracked for changes in luminescence over 48 h. Luminescence from mice 
that received D-luciferin was initially higher than NCL but had returned to background 
levels after approximately 18 h post probe injection. Luminescence from mice that received 
NCL was maintained for over 48 h. n=3. Error bars represent SEM. Images shown below the 
graph are representative of mice in that group.  
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In vivo comparison of NCL with CytoCy5S 
 
As a further characterisation of the NCL probe a direct comparison with CytoCy5S 
(Chapter 2) was made in vivo in an intramuscular infection model. BALB/c mice 
with E. coli infected (5 X 10
6
) quadriceps were imaged for fluorescence or 
luminescence to establish the level of background signal. Mice were then injected 
with either CytoCy5S or NCL and imaged accordingly 1 h post probe administration. 
The relative increase in signal compared to the previously established background 
level was calculated by dividing the ROI reading at 1 h by the background reading. 
The fold increase in signal for both probes is shown in Figure 9. A 4.47 fold increase 
in fluorescence from infected muscle was observed in mice that received CytoCy5S 
while a slightly higher, and non-significant (p>0.05), increase was observed in mice 
that received NCL (4.76 fold increase). 
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Figure 9. Direct comparison of the increase in in vivo signal from E. coli between 
CytoCy5S and NCL treated mice.  BALB/c mice with E. coli infected quadriceps received 
an IP injection of either CytoCy5S or NCL. Mice were imaged for fluorescence (CytoCy5S) 
or luminescence (NCL) 1 h post probe administration and the relative increase in signal 
compared to pre-probe background signal was determined. Mice that received NCL showed 
a slightly higher increase in signal compared to mice that received CytoCy5S (4.76 fold vs 
4.47 fold). Error bars represent SEM. n=3.  
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Imaging of bacterial NTR in vivo in a mouse model of intramuscular infection 
 
The utility, and importantly, the specificity, of the probe in vivo was examined in a 
mouse model of thigh muscle infection, again utilising bacteria as the source of both 
NTR and luciferase. BALB/c mice were injected in quadriceps with various numbers 
of E. coli luc+ (5 × 10
4
 – 5 × 107), followed by IP injection of NCL 30 min later 
(Figure 10a). Animals were imaged at various time points over 24 h (Figure 10c). 
Signal from the probe was detected 20 min post injection lasting for as long as 24 h 
and correlated with the amount of probe injected. The intensity increased over the 
first 4 h reaching plateau afterwards. The total photon flux produced during this time 
was approximately 1/3 of the total flux detected from the mice injected with 
luciferin, demonstrating high efficiency of uncaging by bacterial NTR in vivo 
(Figure 10b). 
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Figure 10. In vivo activation of NCL probe by luciferase and nitroreductase 
expressing E. coli in a mouse model of thigh infection. a). Luminescence over 4 h 
from E. coli luc+ infected quadriceps (5 × 10
4–5 × 107 bacteria) after IP injection of 0.8 mg 
NCL probe (200 μl of 10 mM solution in PBS). b). Luminescence over 4 h from E. coli luc+ 
infected quadriceps (5 × 10
7
 bacteria) following IP injection of 0.8 mg of probe or 0.63 mg 
of luciferin (200 μl of 10 mM solution in PBS). c). Luminescence imaging of mice over 24 h 
bearing 5 × 10
7
 bacteria treated with various (0.08, 0.8 and 1.6 mg) NCL probe 
concentrations (200 μl of 1, 10 and 20 mM solutions of NCL in PBS). As a positive control, 
mice were injected with equal amounts of E. coli MG1655 expressing lux luciferase that 
doesn't require exogenous substrate for light production [45]. The signal was collected over 
24 h, n = 3. Images of mice shown below the graph are randomly selected representative 
images of mice in the group. 
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Imaging of bacterial NTR activity in a mouse model of Salmonella infection 
 
As a means for testing the ability of NCL to act as a probe for the non-invasive 
detection of infectious bacteria, BALB/c mice were intravenously injected with luc+ 
Salmonella enterica Typhimurium UK-1 (Salmonella CBR). A subset of mice 
received lux tagged Salmonella to facilitate luminescence imaging of bacterial 
localisation in vivo and thereby allow for the determination of when a chronic 
infection had been established in the liver and spleen of the mice. Once this group of 
mice showed signs of chronic infection by BL imaging (4 days post bacteria 
injection), the remaining mice received an IP injection of 10 mM NCL. Mice were 
then imaged for the presence of a luminescent emanating from within infected 
organs where NCL had been reduced by NTR expressing Salmonella CBR. 
However, the low level of BL detected in mice that received lux tagged Salmonella 
strongly indicates that the level of infection of the liver or spleen was low. As a 
result of this, the NCL was most likely not reduced in adequate amounts to produce 
sufficient light for in vivo detection using the IVIS. No luminescent signal above 
background (obtained from uninfected mice) was detected in mice that received 
Salmonella CBR + NCL (Figure 11).  
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Figure 11. In vivo detection of infection from NTR expressing Salmonella CBR using 
NCL. BALB/c mice received an IV injection of Salmonella enterica Typhimurium UK1 wt, 
CBR or lux. Mice that received lux tagged Salmonella were then tracked by BLI for the 
onset of chronic infection in the liver and spleen. Once infection was determined to have 
occurred four days post bacteria injection, mice that had been infected with Salmonella CBR 
received an IP injection of 10 mM NCL and were imaged for luminescence from Salmonella 
colonised organs. No luminescent signal that exceeded control luminescence from wt 
Salmonella infected mice (dotted black line) was observed. Images were collected 45 min 
post probe injection. n=3. Pictures are of representative mice from each group.  
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Imaging of NTR activity in subcutaneous xenograft model of cancer 
 
In order to further determine the utility of NCL the probe was investigated as a tool 
for imaging tumours in a cancer xenograft model in mice (Figure 12). BALB/c mice 
bearing subcutaneous 4T1luc tumours were injected via the lateral tail vein with 5 X 
10
5
 E. coli MG1655. One week post bacterial injection, mice that received lux 
tagged bacteria were imaged for luminescence to confirm that tumour colonisation 
had occurred. Following this, the remainder of mice (that had received wild type E. 
coli or PBS) were IP injected with NCL. Mice were imaged for luminescence 4 h 
post probe injection, and bacteria-containing 4T1luc tumour bearing mice showed a 
strong, tumour localised luminescent signal (1.69 x 10
8
) and no luminescence from 
any organs of the body indicating that probe activation had been confined to the 
bacteria colonised tumour site. Luminescence from these tumours was significantly 
greater (p<0.05) than luminescence from mice bearing bacteria colonised tumours 
that did not receive NCL, mice bearing tumours + bacteria and mice with 4T1 wt 
(luc-) tumours colonised with E. coli and injected with NCL. Low level 
luminescence was observed in tumours of mice bearing luc+ tumours that did not 
receive bacteria but were injected with NCL, (1.69 x 10
7
) which was a log fold lower 
than the bacteria + NCL group, and not significantly greater than control groups.  
This experiment demonstrated the utility of NCL for use in a murine model 
of cancer where the tumour is the source of luciferase and the tumour colonising 
bacteria were the source of NTR. 
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Figure 12. Bacterial mediated in vivo imaging of NCL in a murine model of cancer. 
BALB/c mice bearing subcutaneous 4T1luc tumours were colonised with E. coli. Following 
IP injection of NCL, mice were imaged for luminescence. Active NCL luminescence from 
bacteria colonised tumours was observed to be a log fold higher than from uncolonised 
tumours and significantly greater (p<0.05) than in mice that did not receive probe or bore 
luc- 4T1 tumours and received bacteria + NCL. Error bars represent SEM. n=3-5. The dotted 
line represents autoluminescence and the images of mice below the graph are randomly 
chosen images representative of the group.  
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Discussion 
 
In this chapter, a novel caged luciferin probe was tested and evaluated in multiple in 
vitro and in vivo models. NCL was demonstrated to be effective for real-time 
imaging of NTR activity in vitro in live bacteria and mammalian cells, as well as in 
vivo where NCL was utilised for the non-invasive detection of bacteria in models of 
thigh infection and a preclinical model of cancer. This novel reagent has the potential 
to significantly simplify screening of prodrugs in vivo and accelerate the preclinical 
development of enzyme-activatable therapeutics for translation into the clinic.  
 Cell free assays demonstrated 70% conversion of caged NCL to free luciferin 
which is higher than all other caged luciferins currently available. In the presence of 
luc+ E. coli, NCL reduction was achieved and the role of the major E. coli NTRs 
was evaluated. Comparison of probe uncaging between NTR competent bacteria and 
NTR KO strains showed that while the three main E. coli NTRs play a major role in 
NCL uncaging, the remainder of the reductases are also capable of uncaging the 
probe at detectable levels. Bacterial cell viability assays were used to determine the 
effect of NCL on the viability of cells in vitro and the results demonstrated that the 
probe does not affect bacterial viability. When cancer cells were used as the source 
of luciferase and bacteria provided NTR, NCL activation was seen to be significantly 
greater (p<0.05) than probe free controls and also exceeded the luminescent signal 
from wells that contained cancer cells in co-culture with luc+ NTR producing 
bacteria at 2 h post NCL incubation. 
In vivo testing of NCL revealed that 10
7
 bacteria localised to the thigh muscle 
are required for the production of light on a level sufficient for detection using the 
IVIS Lumina. The level of luminescence observed was also shown to be dependent 
149 
 
on the concentration of probe administered to mice bearing muscle localised E. coli. 
Direct comparison of NCL with the fluorescent probe CytoCy5S (discussed in 
Chapter 2) showed that the observed increase in signal 1 h post probe incubation in a 
model of thigh infection was higher in mice that received NCL. This further 
highlights the utility of this luminescent probe. However, in a model of Salmonella 
infection, no luminescence was observed from the liver or spleen of infected mice. 
Analysis of images obtained from mice that were infected with luminescent 
Salmonella indicated that the degree of infection (as determined by the number of 
bacteria in the liver or spleen) may not have been sufficient to allow for NCL 
uncaging at an imageable level. 
When NCL was applied to a murine cancer model for tumour imaging, it was shown 
that a strong, tumour localised luminescent signal can be acquired when the 4T1 
tumour acts as the source of luc and tumour colonising E. coli express NTRs 
specifically within the tumour site following colonisation. In the absence of injected 
E. coli, a high level of probe uncaging was still observed. This may be due to the 
presence of other bacteria within the tumour following natural colonisation. 
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Chapter 4: Exploitation of endogenous 
bacterial enzymes for cancer therapy. 
 
Sections from this chapter have been published as 
Stanton M., Lehouritis P., McCarthy F.O., Jeavons M. and Tangney M. Activation 
of multiple chemotherapeutic prodrugs by the natural enzymolome of tumour-
localised probiotic bacteria. Journal of Controlled Release. Under review 
& 
Lehouritis, P., Cummins, J., Stanton, M., Murphy, C. T., McCarthy, F. O., Reid, G., 
... & Tangney, M. (2015). Local bacteria affect the efficacy of chemotherapeutic 
drugs. Scientific reports, 5. 
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Abstract 
 
Some chemotherapeutic drugs (prodrugs) require activation by an enzyme for 
efficacy. We and others have demonstrated the ability of probiotic bacteria to grow 
specifically within solid tumours following systemic administration, and we 
hypothesised that the natural enzymatic activity of these tumour-localised bacteria 
may be suitable for activation of certain such chemotherapeutic drugs.  
Wild type probiotic bacteria such as E. coli Nissle and Bifidobacterium breve 
were screened against a panel of popular prodrugs. All strains were capable of 
activating at least one prodrug. E. coli Nissle 1917 was selected for further studies 
because of its ability to activate numerous prodrugs and its robust nature. HPLC data 
confirmed biochemical transformation of prodrugs to their toxic counterparts. 
Further analysis demonstrated that multiple enzymes can complement prodrug 
activation, while simultaneous activation of multiple prodrugs (CB1954, 5-FC and 
Fludarabine Phosphate) by E. coli was confirmed, resulting in significant efficacy 
improvement over single drugs. Experiments in mice harbouring murine tumours 
validated in vitro findings, with significant reduction in tumour growth and increase 
in survival of mice treated with probiotic bacteria and a combination of prodrugs. 
These findings demonstrate the ability of probiotic bacteria, without the 
requirement for genetic modification, to enable high-level activation of multiple 
prodrugs specifically at the site of action. 
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Study Aim 
 
The aim of the work presented in this chapter was to develop a Bacterial Directed 
Enzyme Prodrug Therapy (BDEPT) based on the activation of multiple prodrugs by 
endogenously produced bacterial enzymes. It was hypothesised that native bacterial 
enzymes could be used to specifically activate prodrugs within a tumour site to elicit 
a therapeutic response while minimising off-target effects. 
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Introduction 
 
One of the primary limitations of classical chemotherapy is insufficient tumour 
selectivity because the therapeutic drug concentration required at the tumour is not 
achievable without inducing systemic toxicity. Emerging technologies have thus 
focused on increasing the specificity of the therapeutic agent to the tumour site. 
Bacteria have the capacity to preferentially proliferate within tumours [1]. The 
mechanism for this phenomenon is believed to be a function of the nature of the 
tumour and involves a number of physical characteristics, including leaky tumour 
vasculature; the tumour microenvironment offering protection from the immune 
system; as well as a low oxygen and rich nutrient environment derived from dying 
tumour cells on which bacteria thrive [2]. Tumour targeting by bacteria has been 
repeatedly demonstrated by several groups over the years with a broad range of 
genera (e.g. bifidobacteria, salmonellae, clostridia) [3-9]. The use of non-pathogenic 
strains is preferable for safety reasons, which traditionally necessitates genetic 
modification in order to provide expression of heterologous therapeutic agents, either 
by the bacterium itself, or via plasmid transfer to host cells (bactofection) [3]. 
Enzyme-directed prodrug therapy is a broad term used to describe two-step 
strategies which aim to localise chemotherapeutic activity to the site of the tumour, 
thereby limiting adverse side effects and permitting administration of higher drug 
doses. Traditionally, a gene coding for an enzyme that has the ability to convert a 
non-toxic prodrug to a toxic drug is used to arm a cancer gene therapy vector (e.g. 
virus [10] ligand [11], antibody [12], bacterium [13]). Firstly, the vector is 
administered to the patient in order to deliver the gene to the tumour cells. There, the 
gene becomes expressed and sensitises the cells to a specific prodrug. In the second 
step, the relevant prodrug is administered to the patient and is converted to a toxic 
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drug specifically by enzyme-expressing tumour cells resulting in localized toxicity 
while sparing distant healthy tissue. Various species of bacteria have been examined 
as tumour-specific gene delivery vehicles in this context at clinical and pre-clinical 
levels [14, 15] and to date, bacteria have been genetically engineered to over-express 
genes coding for therapeutic enzymes [14, 16] (Figure 1). 
It was hypothesised that; i) since bacteria grow specifically within solid tumours 
following systemic administration, tumour-localised bacteria may be conceived as a 
tumour-specific enzymatic reservoir capable of local activation of prodrugs; ii) since 
bacterial genes are employed in gene therapy strategies to activate prodrugs, native 
expression of such therapeutic genes by a bacterium may be sufficient to mediate 
prodrug activation; iii) a given bacterium contains multiple enzymes capable of 
activation of various prodrugs, so it may be possible to use multiple prodrugs in 
conjunction with bacteria to treat cancer. 
Previously, the Tangney lab has shown that various probiotic bacteria can 
specifically colonise tumours in murine models [3, 17-19]. In this chapter it is 
reported that probiotic bacterial species can activate multiple prodrugs, without the 
need for genetic modification. 
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Figure 1. Schematic representation of bacterial directed enzyme prodrug therapy 
(BDEPT). Systemically administered bacteria are capable of selectively colonising solid 
tumours in vivo. These tumour localised bacteria produce a range of unique bacterial 
enzymes within the tumour site, some of which may be exploited for the tumour targeted 
activation of administered prodrugs resulting in highly localised toxicity and tumour 
regression. 
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Materials and methods 
 
Bacteria and cell lines. Bacteria were cultured as described in Chapter 2.  Lewis 
Lung Carcinoma (LLC), 4T1 (mouse mammary carcinoma) and CT26 (mouse 
colorectal carcinoma) cells were purchased from ATCC and were propagated 
according to the supplier‘s instructions. The murine recycled prostate cancer cell line 
TRAMPC1 was kindly provided by Ciavarra RP [20] of Eastern Virginia Medical 
School, Norfolk USA, and propagated as described in [21].  
Drugs. All drugs and enzymes were purchased from Sigma except: Etoposide 
Phosphate (Santa Cruz), Capecitabine (Santa Cruz), AQ4N (R&D), Nelarabine 
(A&B), and Vidarabine (Santa Cruz). Drugs were resuspended in H2O or DMSO, 
with appropriate control vehicle utilised accordingly in all experiments. 
Cell cytotoxicity assay. Microtitre plates (96-well) were pre-seeded with 4000 
cells/well in appropriate medium for each cell line and allowed to attach overnight. 
On the day of the assay, bacteria were cultured to log-phase and a subculture ratio, 
corresponding to an OD600nm of 0.2 determined for each strain, was exposed for 2 h 
(4 h in the case of IC50s) to drug in falcon tubes containing DMEM in a tissue 
culture incubator. Falcon content was filter-sterilized to remove presence of bacteria 
(using 0.2 µm pore filters (Sarstedt) before adding 200 µl per well. Plates were 
incubated until cells in control (untreated) had achieved confluent growth. 
Cytotoxicity was quantified using an MTS staining with the Cell Titre 96 AQueous 
One solution Cell Proliferation Assay (Promega). The plates were incubated with 
normal media (80 µl) and MTS solution (20 µl) in a 37°C incubator for 
approximately 2 h (until distinct change of colour occurred). 
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Bacterial plating assay. Bacteria were grown to log phase and plated directly on to 
agar plates containing the appropriate growth medium with 200 µM CB1954 or 
without. Colonies were counted and scored after an overnight incubation at 37°C. 
Survival of bacteria in the presence of CB1954 was expressed in relation to untreated 
controls. 
 
Bacterial lysis and heat inactivation. Bacteria were heat inactivated at 95 °C for 40 
min. Lysis was facilitated by sonication using three 10 sec pulses (at 20 Kz, 50 W). 
Between each pulse, samples were incubated on ice for 30 sec. A 20-fold drop in 
optical density was considered sufficient lysis. 
Bacterial prodrug susceptibility assay. Overnight bacterial cultures were used to 
inoculate fresh LB medium +/-  prodrugs and transferred into 96 well format 
(300l/well) for automated tracking in a plate reader. The change in optical density 
at 600 nm (37C) of each individual well was monitored over several hours (in a 
Spectra max M2 device) in the presence of drugs. 
 
HPLC and Mass spectrometry analysis: The results described were obtained using a 
Waters Micromass LCT Premier mass spectrometer (Instrument number KD160). 
Analysis was performed in ESI + mode using a gradient elution method to identify 
unknowns in the sample. An external reference standard of Leucine enkephalin was 
infused in order to confirm mass accuracy of the Mass Spectrometer (MS) data 
acquired. The samples were run in triplicate to ensure consistency and data were 
analysed by Masslynx 4.1 software. HPLC conditions: A waters Alliance 2695 with 
a 2996 Photodiode Array detector and Waters Xbridge C18 5 µm 150 x 4.6 mm was 
used for the chromatographic separation with mobile phase: Acetonitrile (containing 
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0.1 % formic acid) and Water (containing 0.1 % formic acid) using the following 
gradient: 0 min (10:90); 0.5 min (10:90); 5 min (90:10); 10 min (100:0); 11 min 
(100:0); 11.1 min (10:90); 14 min (10:90). A flow rate of 0.5 ml/min, sample run 
time of 14 min and injection volume of 1 – 30 µl was used. For CB1954 the 
following gradient was used: 0 min (10:90); 0.5 min (10:90); 26 min (30:70); 27 min 
(10:90); 30 min (10:90). A flow rate of 1 ml/min, sample run time of 30 min and 
injection volume of 10 µl was used. The MS conditions were as follows: the samples 
were subjected to ESI + ionisation and acquired from 90 to 1250 m/z at a capillary 
voltage of 3.00 kV, sample cone of 30V and a source temperature of 140C. An 
external Enkephalin in Water/Acetonitrile (ESI + m/z= 556.2771) for exact mass 
correction using Lockspray was used. The UV conditions were set at a sampling rate 
of 1 spectrum/second, scanning wavelengths from 195-400 nm at a resolution of 1.2 
nm. 
Murine experiments. As described in Chapter 2 
Animals and Tumour Induction: All murine experiments were carried out 
according to the methods described in Chapter 2. 
Bacterial and drug administration: Overnight cultures of E. coli were re-inoculated 
into fresh LB (1/50 dilution) and incubated shaking at 37 
o
C until they reached an 
OD600 of 0.7. Cells were then washed twice in PBS. Tumours were administered 10
6 
E. coli in an injection volume of 50 μl by intratumoral (IT) injection. The viable 
count of each inoculum was determined by retrospective plating onto LB agar. Two 
h post bacterial administration, drug (CB1954 20 mg/kg) was administered by intra-
peritoneal (IP) injection in an injection volume of 50 µl. The drug was subsequently 
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administered on days 3, 6, 9, and 11 and animals not receiving drug were 
administered an equal volume of PBS vehicle. 
Image acquisition and formation. As described in Chapter 2 and 3. 
Cytospins. Exudate from drug treated tumours was collected post culling in a 1.5 ml 
tube and centrifuged at 1000 rpm for 5 minutes to pellet any tissue or debris in the 
sample. The supernatant was removed and was cytospun and stained using pro-diff I 
and II (Braidwood Laboratories BAPROD1). Cytospin images are representative of 
at least two independent samples. Images were captured using a DP70 digital 
microscope camera and Olympus DP-Soft823 version 3.2 software (Mason 
Technologies Dublin, Ireland). 
Statistical analysis. All statistical analysis was carried out in accordance with the 
methods outlined in Chapter 2. 
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Results 
Effect of prodrugs on bacterial cell survival in vitro 
 
While activated prodrugs have been shown to be highly effective at killing 
mammalian cells, we determined to investigate the effect these drugs would have on 
bacterial cell viability following drug activation by endogenous bacterial enzymes. A 
panel of bacteria were analysed for changes in viability in the presence or absence of 
the prodrug CB1954 (200 µM) by growing bacterial cultures on LB agar +/- 
CB1954. While the plating efficiency of the E. coli Nissle strain did not change 
between CB1954 treated and untreated cultures, E. coli MG1655 was seen to be 
almost entirely ablated in the presence of CB1954 (Figure 2). A similar result was 
seen when B. breve was grown with 200 µM CB1954 while L. lactis showed no 
change in plating efficiency between treated and untreated cultures. These data 
indicate that prodrug activation by bacteria can have serious effects on the viability 
of a bacteria population following drug activation (Figure 2a). With this in mind, E. 
coli Nissle was chosen as the ideal candidate for further studies as it exhibits a high 
level of prodrug activation and, importantly, is itself not killed by the activated 
prodrug. In order to demonstrate this, the effect of a range of prodrugs on E. coli 
Nissle growth over time in liquid culture was also analysed (Figure 2b). No 
significant effect (p>0.05) on bacterial cell growth was observed with any prodrug 
tested, even when prodrug concentrations exceeded those that are effective at cancer 
cell killing (Figure 2b). 
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Figure 2: In vitro evaluation of effects of CB1954 on probiotic bacterial survival. a) 
Bacterial survival in the presence of CB1954. E. coli Nissle cells in logarithmic phase were 
plated directly on to LB plates containing CB1954 (200M) and grown overnight. The 
plating efficiency shown is normalised to cfu counts from plain LB plates (+: prodrug 
efficacy on cancer cells). b) Prodrug influence on bacterial growth. Prodrugs were incubated 
with bacteria in LB medium and the change in optical density at 600 nM was monitored over 
time at 37C. Data represent the average and standard error of four technical replicates. 
These data are representative of 2 independent experiments. 
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Figure 3. Schematic of in vitro cell kill assay. Bacteria and Drug are mixed in DMEM 
medium, and co-incubated for 3h at 37C. The drug is separated from bacteria using 
centrifugation and microfiltration. The filter sterilised DMEM containing the transformed 
drug is applied to tumour cells in a 96 well plate. Tumour cell viability is evaluated via MTS 
assay for end-point measurements.  
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Validation of prodrug co-activation by High Performance Liquid 
Chromatography (HPLC) 
 
In order to validate prodrug activation at the molecular level, a sample of two 
prodrugs (CB1954 and 5-FC) was examined by HPLC. The chromatogram shown in 
Figure 4 displays the analysis of drugs pre- and post-incubation with E. coli Nissle. 
The data confirmed prodrug activation and metabolites related to CB1954 and 5-FC 
activation by E. coli Nissle were identified by peaks at 10.08 (CB1954) and 3.88 (5-
FC). As a positive control and a reference, purified nitroreductase B enzyme + 
CB1954 was used and the HPLC chromatogram of each strain alone was used as a 
negative control (not shown). By comparison, when CB1954 was co-incubated with 
bacteria, similar retention time peaks are formed to the reference, confirming that a 
biochemical transformation has taken place.  
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Figure 4. Validation of prodrug co-activation by (HPLC). HPLC chromatogram of 
supernatants of E. coli previously co-incubated with prodrugs in PBS at 37C. Top; drugs 
alone (purified 5-FU is run as a control), bottom: Single drug-bacterial incubations.  
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E. coli is capable of activating a range of prodrugs and inducing cancer cell 
killing. 
 
Various cell lines were cultured and incubated with supernatant from E. coli Nissle 
+/- a range of prodrugs. The percentage of cells that survived in the presence of E. 
coli Nissle activated prodrug was determined by comparison with cell numbers from 
wells that were not treated with prodrug. A high level of cell killing (ranging from 80 
to 98%) was observed across all cell lines tested and in the presence of all prodrugs 
tested (Figure 5).  
Given the focus of this study on exploiting the natural enzymolome of 
bacteria, the ability of multiple endogenous enzymes from E. coli to contribute to the 
activation of a range of prodrugs was examined (Figure 5). Five prodrugs (Tegafur, 
Fludarabine, AQ4N, CB1954 and 5-FC) were co-incubated with E. coli Nissle and 
the cytotoxic effects on cancer cells examined. A very high level of cell killing was 
observed across the full range of prodrugs tested following activation by bacteria. 
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Figure 5. Various prodrugs can be activated by E. coli and elicit cancer cell killing in 
vitro. Therapeutic efficacy of E. coli in conjunction with prodrugs on multiple cell lines. 
Survival was measured by the MTS assay and is expressed relative to untreated cells. Data 
represent the average and standard error of four technical replicates. These data are 
representative of 2 independent experiments.  
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Tumour colonising E. coli Nissle activates CB1954 an elicits a therapeutic effect 
in vivo. 
 
BALB/c mice bearing subcutaneous CT26 flank tumours were IT injected with E. 
coli Nissle or PBS, and IP injected with CB1954 (20 mg/kg) or PBS every 3 days 
and monitored over time (Figure 6). As expected, the PBS:PBS and PBS:CB1954 
groups showed the greatest increases in tumour volumes over time. Considerably 
decreased tumour volume was observed in the Bacteria:CB1954 group compared 
with the drug alone group at all time-points analysed. A significant increase in 
median survival (26 days vs. 8 days. p=0.028) was observed in the Bacteria:CB1954 
group compared with the CB1954 alone group (Figure 6b), indicating drug 
activation by the intratumoural bacteria. These data indicate increased anti-tumour 
activity in tumours containing bacteria and CB1954. Bacteria alone did not 
significantly affect tumour volume relative to PBS administration although some 
reduction is evident in bacteria administered tumours, suggesting that bacteria alone 
may have a mild anti-tumour effect. 
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Figure 6. Tumour colonising E. coli Nissle activates CB1954 to elicit a therapeutic 
response. a) Subcutaneous flank CT26 tumours growing in BALB/c mice were injected IT 
with E. coli Nissle or PBS vehicle alone. CB1954 (20 mg/kg) was injected IP for the 
duration of the experiment at 3 day intervals. a) Tumour volume (%) relative to the first day 
of CB1954 injection (day 0) is shown. b) The median survival post Day 0 of the CB1954 + 
bacteria group was significantly greater than that of the CB1954 alone group (26 days vs. 8 
days. P = 0.0374). Data are expressed as mean ± SEM of 3-5 individual mice per group. 
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In vivo optical imaging of NTR activity during CB1954 tumour therapy using 
CytoCy5S. 
 
The ability to monitor therapeutic effect using optical imaging provides researchers 
with a valuable tool for pre-clinical research. Having demonstrated the utility of 
CytoCy5S as a bacterial activated fluorescent reporter system in Chapter 2 [22], we 
aimed to develop a system whereby native bacterial NTRs could be used for both 
therapy and imaging in the same experiment. Since CB1954 is an NTR activated 
prodrug, it stood to reason to use CytoCy5S in conjunction with CB1954 to 
longitudinally monitor the response of BALB/c mice to CB1954 therapy. Mice 
bearing subcutaneous CT26 flank tumours were IT injected with E. coli Nissle or 
PBS and then received an IP injection of CB1954 or vehicle control. Mice were 
treated and imaged 3 times per week and changes in tumour volume were recorder 
following caliper measurement. No noticeable correlation between tumour localised 
fluorescence and tumour volume was detected. However, the strong fluorescent 
signal (> 10
9
 p/sec/cm
2
/sr) evident at day 17 (post first drug/probe injection) and the 
steady increase in fluorescence over time shows that bacterial numbers within the 
tumour increased over the course of the experiment. 
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Figure 7. In vivo optical imaging of nitroreductase activity during CB1954 tumour 
therapy using CytoCy5S. BALB/c mice bearing subcutaneous CT26 flank tumours 
colonised with E. coli Nissle (via IT injection) were injected with CytoCy5S and CB1954 
every 3 days. Mice were imaged for fluorescence on each treatment day. Fluorescence from 
tumours increased over time but no significant difference (p>0.05) was observed between 
mice that received CB1954 and mice that just received bacteria and CytoCy5S. 
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A cocktail of prodrugs can be activated by bacteria in vitro. 
 
Although the activation of individual prodrugs in the presence of bacteria was 
demonstrated by HPLC in Figure 4, it was important to determine whether or not a 
cocktail of prodrugs could be activated by a single bacterium. The effect of a 
cocktail of 3 prodrugs, Fludarabine phosphate, 5-FC and CB1954, on cancer cell 
survival was evaluated and it was shown that the combination of all 3 prodrugs, in 
the presence of E. coli, elicited the most effective level of cancer cell killing (Figure 
8). Having established that E. coli are capable of activating multiple prodrugs in 
combination to achieve cancer cell killing, the cocktail of CB1954 and 5-FC was 
chosen for future cocktail experiments as they proved to be the most cytotoxic 
prodrugs in in vitro screens. The cocktail (CB1954 and 5-FC) did not have any effect 
on bacterial viability (Figure 8b). The supernatant from CB1954 and 5-FC in 
combination with E. coli was subjected to HPLC analysis and the chromatogram 
peaks formed by the cocktail of drugs when the prodrugs were pre-incubated with 
bacteria showed that metabolites were formed, as evidenced by peaks at 10.08 
(CB1954) and 3.88 (5-FC) showing that both prodrugs were metabolised.  
177 
 
 
Figure 8. E. coli Nissle can activate a prodrug cocktail consisting of CB1954 and 
5-FC in vitro. a) Cancer cell survival in the presence of multiple prodrugs. Bacteria were 
incubated with prodrugs for 1h. Fludarabine phosphate (5M), 5-FC (2M), CB1954 
(25M). b) Prodrug influence on bacterial growth. Prodrugs were incubated with bacteria in 
LB medium and the change in optical density at 600 nM was monitored over time at 37C. 
(CB1954: 200M, 5-FC: 500M, FP (Fludarabine phosphate): 20M). c) HPLC 
chromatogram of supernatants of E. coli previously co-incubated with a cocktail of CB1954 
and 5-FC at 37C. Red rectangle: Magnification of 5-FC profile in this reaction. 
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In vivo tumour therapy utilising a cocktail of CB1954 and 5-FC prodrugs 
 
In order to replicate in vitro observations, the efficacy of E. coli as a tumour-specific 
drug-activating agent was examined in tumour bearing mice in conjunction with 
CB1954 and 5-FC (Figure 9). BALB/c mice bearing subcutaneous CT26 flank 
tumours were colonised with E. coli Nissle via IT injection of bacteria. On the same 
day as bacterial injection, mice received an intraperitoneal (IP) injection of CB1954 
or 5-FC or both drugs. Drug injections were repeated 3 times per week for the 
duration of the experiment. Therapeutic efficacy was determined by tracking 
changes in tumour volume (caliper measurement) and by calculating the median 
survival of mice (Figure 9c). Mice that received bacteria and either CB1954 or 5-FC 
alone showed increased median survival compared with control groups (PBS, 5-FC, 
CB1954, 5-FC/CB1954) (p<0.05) while the combination of both drugs in the 
presence of tumour localised bacteria was shown to increase median survival more 
than bacteria with either drug alone. Mice that received bacteria and a cocktail of 
CB1954 and 5-FC showed significantly greater median survival (p<0.01) than mice 
that received PBS or drugs without bacteria. While the increase in median survival of 
the bacteria plus cocktail group was not statistically significantly greater than the 
bacteria + 5-FC or CB1954 groups (p > 0.16), the increase in survival does indicate 
that the drugs had a complimentary effect and represent a viable treatment option.  
While CB1954 and 5-FC were not seen to be significantly toxic to bacteria in 
vivo, it was important to determine whether or not these drugs would have an effect 
on the viability of bacteria in vivo within the tumour site. Therefore, a subset of mice 
received an intratumoural injection of luminescent E. coli encoding the bacterial lux 
operon allowing for non-invasive in vivo imaging of viable tumour colonising 
bacteria throughout the experiment. The ability to track live bacteria using 
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luminescence imaging allowed for protensive monitoring of the effect drug treatment 
was having on bacterial cell numbers within the tumour when compared with mice 
that did not receive drug. Longitudinal luminescence readings demonstrated that the 
drug cocktail did not have a negative impact on bacterial numbers and in some cases 
the number of bacteria within the tumour increased over time. The persistence of 
bacteria within the tumour for prolonged periods of time allows for repetition of drug 
administrations as the levels of bacterial enzymes within the tumour are not 
diminished following drug treatment. 
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Figure 9. Tumour therapy via in vivo activation of prodrugs. BALB/c mice bearing 
subcutaneous CT26 flank tumours colonised by E. coli Nissle 1917 received IP injections of 
CB1954 + PBS, 5-FC + PBS, CB1954 + 5-FC or PBS three times per week. Tumours were 
monitored for changes in volume and luminescence (where applicable) from live bacteria on 
each treatment day. a) The change in bacterial luminescence (relative to day 0) from tumour 
colonising luminescent E. coli is shown. Luminescence remains stable across the range of 
time-points indicating that bacterial levels within the tumour remained constant throughout 
the experiment. b) Changes in CT26 tumour volume were monitored until the first death in 
the group determined by a predefined endpoint. c) Survival plot of each group starting from 
the first day of bacteria/drug administration. Mice that received bacteria and both drugs 
showed significantly increased median survival (p<0.01) compared with groups that did not 
receive bacteria.  
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Immune cell recruitment to the tumour following drug activation by tumour 
localised bacteria. 
 
Following the culling of mice that had received bacteria and 5-FC or CB1954, 
tumours were resected and dissected for analysis. Some drug treated mice harboured 
tumours containing a yellow exudate. This was not observed in mice that did not 
receive drug and was deemed to be indicative of recruitment of immune cells to the 
tumour site following drug activation by bacteria. This exudate was collected and 
subjected to cytospinning and staining to facilitate further analysis of the cells 
present in the infiltrate. Microscopic analysis of the cytospun samples revealed the 
presence of immune cells only, of multiple types. While the vast majority of the cells 
were dead by the time of analysis, it was possible to distinguish macrophages, 
eosinophils and lymphocytes in samples from mice that had received either CB1954 
or 5-FC. However, as a result of the majority of cells in the samples being dead at 
the time of analysis, the clarity of cell morphology was compromised and some of 
the cell components appear diffuse while the cytoplasm and nuclei were not always 
intact as is common of apoptotic cells or cells. Lymphocytes were characterised by 
the appearance of large nuclei surrounded by a thin cytoplasm with a circular shape 
while macrophages were characterised by their large size and presence of a large, 
darkly stained nucleus surrounded by lightly stained cytoplasm and were more 
abundantly found in samples from mice that had received 5-FC prodrug. Eosinophils 
were identified by their large nuclei (appearing as a single nucleus in dead cells) and 
multiple granules present in the cytoplasm while neutrophils were characterised by 
the presence of a multi-lobed, crescent shaped nucleus that was darkly stained. 
Figure 10 shows representative images of each of these immune cell types as found 
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in the samples from drug treated mice. While no exudate sample was collected from 
mice that received the CB1954 and 5-FC cocktail treatment, it is thought that this 
was due to an absence of exudate in these tumours at the specific time of culling (= 
experiment end) and does not necessarily mean that these tumours never contained 
an exudate, but rather that it was absent due to increased life span of these treated  
mice. Exudate which may have been present in the tumours at earlier timepoints may 
have been cleared by the time of culling. Immune cells were clearly identifiable in 
all samples tested (from single drug groups) and interestingly, a distinct absence of 
non-immune or cancer cells was observed. No samples appeared to contain easily 
identifiable cancer cells. 
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Figure 10. Immune cell recruitment to the tumour following drug activation by tumour 
localised bacteria. Exudate collected from the tumours of mice that had received CB1954 
and/or 5-FC was cytospun and stained. The resultant samples were analysed by microscopy 
and multiple immune cells were detected in all samples analysed. Despite the fact that the 
cells were dead and displayed common signs of apoptosis such as fragmented nuclei, it is 
still possible to distinguish multiple forms of immune cell. The most abundant forms of 
immune cells found in samples were macrophages, lymphocytes and eosinophils. Images are 
representative of cells observed in each sample tested.  
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Discussion 
 
In this chapter, we investigated the use of wild type probiotic bacteria in conjunction 
with prodrugs for the treatment of solid tumours. Although traditionally prodrug 
research involves sophisticated drug design pegged to a specific gene followed by 
incorporation of that gene in a vector, our approach was in reverse. We decided to 
investigate the use of non-genetically engineered probiotic bacteria and exploit their 
natural enzymolome in order to activate multiple prodrugs even if their 
corresponding endogenous enzymes where unknown. Although most bacteria 
examined as anticancer agents are inherently toxic or attenuated, we have chosen to 
work with probiotic bacteria as they have a good safety profile. 
Since many of the enzymes used in existing prodrug activating strategies have a 
bacterial origin, we reasoned that the natural enzymolome of wild type bacteria 
would be capable of activating a broad class of prodrugs either alone or as cocktails. 
An ideal therapeutic strain would be free from the burden of genetic modification but 
still be capable of activating multiple drugs. This would broaden the options for a 
clinician, giving them the freedom to choose from a panel of prodrugs in order to 
treat patients on a case by case. In addition, it would allow them to change the 
prodrug depending on therapeutic response, but also permit the usage of multiple 
prodrugs simultaneously or consecutively in order to maximise efficacy. 
We began by screening several probiotic strains against popular prodrugs with 
different mechanisms of action of which some have unknown corresponding 
enzymes. Our aim was to find a strain that satisfies the criteria mentioned above. We 
discovered that the Gram-negative E. coli Nissle was able to increase the toxicity of 
all the examined prodrugs, while the Gram-positive bacteria could only influence a 
fraction of those. Currently, the molecular basis for this is unknown; however, this 
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observation prompted us to advance this study with E. coli. While CB1954 was 
activated by most strains, E. coli strains and B. breve could activate it to high levels 
and such an activation was confirmed biochemically. However, we found that B. 
breve and E. coli MG1655 were sensitive to CB1954 while E. coli Nissle was not 
(Figure 2). The aetiology for this sensitivity differential is unclear; however, it 
formed the basis to eliminate B. breve and MG1655 from further studies and focus 
on E. coli Nissle. By exploiting its enzymatic reservoir, it was possible to find a 
prodrug to treat any cancer cell line (Figure 5). Only the genes required for 
activation of CB1954, Fludarabine phosphate and 5-FC are known [23] [24] [25]; the 
enzymes that activate AQ4N and Tegafur in bacteria are unknown. In order to gain 
further insight into prodrug activation by multiple genes, we chose to use the 
prodrug CB1954 which is activated by nitroreductases described in earlier chapters.  
The concept of several enzymes acting in concert on a single drug is 
intriguing and suggests towards prodrug design around ubiquitous enzymes or 
enzyme families rather than relying on one gene. The ability to simultaneously 
activate prodrugs of different mechanistic classes is an important finding (which has 
never been described in this context, to our knowledge) that could potentially be 
used to treat resistant cancers. We show several different types of cocktails that can 
be activated, one of which was a combination of 3 prodrugs (Figure 8). To show 
proof of principle at the molecular level, we analysed one of the cocktail reactions 
(CB1954 and 5-FC) by HPLC (Figure 8). 
Finally, we replicated our in vitro data in vivo, by showing that wild type E. 
coli could enhance the cytotoxicity of CB1954 and 5-FC. The possibility of using 
one single organism to activate multiple prodrugs is very attractive in this field of 
research. However, fine-tuning a therapy using a cocktail of multiple drugs poses 
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technical challenges beyond the scope of this study, and we acknowledge that this is 
an artificial system. E. coli Nissle is a promising agent and further exploration of its 
enzymatic repertoire may lead to the discovery of new enzyme/prodrug 
combinations, thus expanding the existing prodrug arsenal and giving rise to new 
therapeutic strategies. The ability to non-invasively track the therapeutic response to 
a therapy through the use of optical imaging of unmodified bacteria (Figure 7) 
represents a novel development in the field. Although the data presented in Figure 7 
show little more than proof of concept, the potential applications of this system are 
clear to see. Combined imaging and therapy with CytoCy5S and a prodrug of choice 
could be used to detect the level of bacteria colonisation of the tumour to better 
inform the researcher with regard to optimal treatment timepoints. For example, had 
E. coli MG1655 been used as the tumour colonising strain in conjunction with 
CB1954 we would expect a proportion of the bacteria to be killed by CB1954 
following each treatment (if in vitro results from Figure 2 were recapitulated). In this 
scenario, CytoCy5S imaging could be carried out on a daily basis and when 
fluorescence levels showed that tumour colonisation was at an optimal level the next 
round of CB1954 could be administered, potentially leading to increased efficacy. 
Overall, these findings demonstrate the ability of probiotic bacteria, without 
the requirement for genetic modification, to enable high-level activation of multiple 
prodrugs specifically at the site of action, which may provide ‗old drugs‘ with a new 
lease of life, and/or improve the therapeutic window of new or existing drug 
regimes. 
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Discussion and future work 
 
The work outlined in this thesis provides proof-of-concept for the use of endogenous 
bacterial enzymes for activation of both fluorescent and luminescent imaging probes 
as well as the tumour-localised activation of one or more prodrugs. Genetic 
modification of bacteria, as is standard practice in almost all preclinical bacterial 
gene therapy and imaging studies, represents a major hurdle for clinical translation. 
As such, the data presented here describe the development of novel imaging and 
therapeutic strategies that rely solely on the use of the endogenous bacterial 
‗enzymolome‘. Native levels of unique bacterial enzymes were demonstrated to be 
sufficient for probe activation and prodrug conversion at levels adequate for the 
elicitation of imageable signal or therapeutic response in vitro and in vivo. This 
work, along with further studies in the use of non-engineered bacteria for imaging 
and disease treatment, contributes to the body of knowledge on progressing clinical 
use of bacteria as gene or protein delivery vehicles. 
Endogenous bacterial nitroreductases activate CytoCy5S: The hypothesis that native 
levels of bacterial NTRs would be sufficient for the reduction of the quenched probe 
CytoCy5S to its fluorescent form was tested. Proof of principle and assay 
optimisation were achieved in vitro with a range of unengineered bacterial species 
before the system was tested in vivo. Probe activation by tissue localised bacteria 
was demonstrated in models of local E. coli muscle infection and systemic 
Salmonella infection. CytoCy5S was also shown to be amenable to use as an 
imaging probe for in vivo tumour imaging where tumour localised bacteria 
specifically activated the probe within the tumour site to produce a tumour localised 
fluorescent signal.  
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This highly versatile system successfully demonstrates the concept of NTR 
enzymes as a reporting strategy for wild-type bacteria using optical imaging and a 
fluorescent probe, but the concept may also be extended to NTR-specific ‗caged‘ 
probes for use with other imaging modalities with more immediate clinical 
relevance, such as PET, MRI and SPECT [1, 2]. Overall, the ability to non-
invasively monitor bacterial infection in a pre-clinical setting using relatively cheap 
and accessible optical imaging methods provides infection researchers with a 
valuable tool, which has the potential for clinical translation for both diagnostic and 
clinical trial uses. 
 Future work would involve the development of an assay that compares total 
NTR activity in a given bacterial strain with CytoCy5S fluorescence. Another 
development of the work descrcibed in this chapter would be the testing and 
optimisation of a quenched fluorophore with similar properties to CytoCy5S that is 
amenable for use in both optical and other imaging strategies. A nitroreductase 
activated fluorescent probe with an excitation wavelength of approximately 800 nm 
could be used to recapitulate the preclinical in vitro and in vivo experiments outlined 
in the CytoCy5S study but would also be suitable for an imaging modality with more 
clinical potential such as photoacoustic imaging [3]. The optical characteristics of 
this fluorescent probe would make it idea for both preclinical and clinical use across 
imaging platforms and thus would represent an advancement of the work presented 
in this thesis. Future studies that utilise the CytoCy5S probe would focus on the in 
vivo detection of bacterial localisation in an extended number of models of infectious 
disease. 
Bacteria activate a novel caged luciferin probe: The work presented in Chapter 3 
builds on the data acquired from the CytoCy5S study and extends to demonstrate 
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bacterial-specific uncaging of a novel luminescent probe (NCL), thereby 
demonstrating the utility of bacterial enzymes as activating agents for 
bioluminescence imaging. Luminescence imaging of uncaged NCL was achieved in 
vitro and was successfully progressed to in vivo models of infection and cancer. 
Tumour localised BLI from bacterial colonised tumours was shown to be high. 
However, tumours that did not contain administered bacteria also showed relatively 
high levels of tumour localised luminescence. It is thought that this may be due to 
spontaneous colonisation of the tumour by naturally acquired bacteria. Other work in 
our lab has previously observed spontaneous colonisation of tumours by a range of 
bacteria [4] and could explain the activation of NCL in this murine model in the 
absence of administered bacteria. Although NCL was uncaged in untreated tumours, 
the level of probe uncaging was 10 X less than in mice that received IV E. coli. Of 
note is that the tumours examined in the NCL study were relativley large (~ 1.15 
mm
3
), and therefore more likely to feature spontaneously colonising bacteria [5]. We 
did not examine CytoC5S with tumours this large. 
Future work with the NCL probe could include the development of an in 
vitro screening assay for the accelerated detection of suitable prodrug activating 
agents. A screen based on quantification of light production following probe 
uncaging by NTR would facilitate large scale in vitro testing of an extended range of 
bacteria or NTR expressing viruses and engineered mammalian cells for the 
efficiency of probe uncaging and would thereby be used to identify the most efficient 
candidates for prodrug activation as the magnitude of the light signal produced 
would be directly proportional to the level of probe uncaging achieved. This novel 
reagent could significantly simplify screening of prodrugs in vivo and accelerate the 
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preclinical development of enzyme-activatable therapeutics for translation into the 
clinic. 
Endogenous bacterial enzymes can be exploited for tumour-targeted activation of 
prodrugs: The data presented in Chapter 4 represent a novel addition to established 
GDEPT strategies. The use of wild type probiotic bacteria as delivery vehicles for 
endogenously expressed genes to a tumour site side-steps one of the major regulatory 
hurdles associated with the use of bacteria in cancer therapy namely, genetic 
modification. This work provides evidence that native bacterial enzymes are 
sufficient for the activation of various prodrugs and that the level of prodrug 
activation is sufficient to achieve a therapeutic response in vivo. The idea that a 
single strain of wild type bacteria can essentially be viewed as an ―enzyme factory‖ 
capable of simultaneously activating a cocktail of prodrugs was also proffered. In 
vivo studies involving tumour colonising probiotic E. coli Nissle for the activation of 
individual prodrugs (CB1954 or 5-FC) were successful in significantly increasing 
the median survival of mice compared with drug free groups, while the combination 
of both prodrugs in a cocktail was observed to have an additive effect and also 
increased survival.  
Future work for this chapter would include further investigation of the 
enzymatic capabilities of E. coli Nissle by testing a broader range of prodrugs for 
increased (or decreased) efficacy following exposure to endogenous E. coli Nissle 
enzymes. This may lead to the identification of a more efficacious E.coli-prodrug 
therapy system. A deeper analysis of the effect of various prodrug cocktails could 
also be carried out. Further tweaking of the CB1954/5-FC system described in this 
study may yield increased efficacy or an entirely novel and more effective prodrug 
cocktail may be identified. While the theranostic study involving E. coli 
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Nissle/CytoCy5S tracking of CB1954 therapy demonstrated that fluorescence 
imaging could be used to monitor bacterial levels within the tumour throughout the 
course of the therapy, it may be more interesting in future studies to employ this 
strategy using E. coli MG1655 instead of Nissle. In vitro data demonstrated that 
MG1655 was killed following incubation with CB1954. With this in mind, it can be 
assumed that a population of tumour colonising MG1655 would be affected by 
CB1954 treatment. In this case, CytoCy5S could be administered to mice each day 
and the re-colonisation of the tumour by MG1655 following CB1954 could be 
tracked by changes in fluorescence from bacterial-activated CytoCy5S. This would 
allow the researcher to choose the optimal day for subsequent CB1954 treatment as 
fluorescence levels would be used to indicate when the level of MG1655 tumour 
colonisation had returned to pre-CB1954 treatment levels. 
 
Conclusion 
 
In conclusion, while modern research and treatments for cancer and infectious 
disease exclusively focus on the development of targeted therapies, it seems that 
wild type bacteria represent a highly novel and potentially useful tool for 
exploitation. Probiotic bacteria are currently an under-utilised source of native 
enzymatic activity, much of which is not found in mammalian cells. This fact, paired 
with their ability to target and grow within solid tumours, makes them highly 
attractive for improving the toxicity profile of therapeutic drug strategies, even 
beyond chemotherapy. Bacterial specific activation of imaging agents and drugs 
would also be of significant use in both the detection and treatment of bacterial 
infection. 
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At present, bacterial-mediated cancer therapy is under-developed but the 
versatility of bacteria as enzyme delivery agents, as well as the number of research 
fields to which this versatility could be applied makes it a certainty that the study and 
use of wild type bacteria as biological delivery vehicles will continue to grow and 
contribute significantly to a range of research areas. 
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